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Abstract 
Tracy L. Marion 
Role of Bile Acids and Compensatory Hepatic Transport Proteins in 
Troglitazone-Mediated Hepatotoxicity 
(Under the direction of Kim L. R. Brouwer, Pharm.D., Ph.D.) 
 
 
 Drug-induced hepatotoxicity is the most common reason pharmaceuticals are 
removed from clinical use. Understanding mechanisms of hepatotoxicity, and in vitro 
models to predict hepatotoxicity in humans, are essential for drug development and 
patient safety. The drug troglitazone (TRO) was removed from the market because 
of hepatotoxicity, but preclinical testing failed to predict toxicity in humans. One 
hypothesized mechanism for TRO’s hepatotoxicity is impairment of bile acid (BA) 
transport, causing cholestasis and subsequent hepatocellular apoptosis or necrosis. 
The goal of this research was to demonstrate that inhibition of BA transport and 
compensatory transport proteins contribute to the hepatotoxicity of TRO by causing 
intracellular accumulation of BAs and altering the BA pool composition. 
  In human sandwich-cultured hepatocytes (SCH) and suspended hepatocytes, 
TRO inhibited uptake and biliary efflux of [3H] taurocholic acid ([3H]TCA), consistent 
with published reports in rat SCH; however, intracellular accumulation of [3H]TCA 
was not observed in either species. Because BAs differ in affinity for transport 
proteins, it was hypothesized that TRO causes intracellular accumulation of more 
cytotoxic BAs, such as chenodeoxycholic acid (CDCA). Indeed, TRO caused 
significant intracellular accumulation of [14C]CDCA species in rat SCH. In suspended 
 iv
rat hepatocytes, TRO inhibited [3H]TCA uptake more potently than [14C]CDCA 
uptake. This differential effect on individual BA disposition was hypothesized to shift 
the intracellular BA pool toward more toxic species. However, 24-h exposure of rat 
and human SCH to TRO had no significant effect on the concentration or 
composition of BAs in medium, cell, or bile, although the SCH model reflected 
reasonably well the in vivo BA pool composition in rats and humans. TRO-sulfate 
(TS), the major TRO metabolite, inhibited TCA transport in plasma membrane 
vesicles overexpressing the efflux protein multidrug resistance-associated protein 4 
(MRP4). Accumulation of TS may inhibit BA efflux and increase intrahepatic 
accumulation of cytotoxic BAs in susceptible patients. This may explain, in part, the 
idiosyncratic nature of TRO hepatotoxicity. This research indicates that preclinical 
drug testing should include in vitro screens for drug-induced transport inhibition of 
multiple BAs, not just TCA, to fully characterize the effects of a compound on BA 
homeostasis.  
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CHAPTER 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter are reproduced with permission from: Use of Sandwich-
Cultured Hepatocytes To Evaluate Impaired Bile Acid Transport as a Mechanism of 
Drug-Induced Hepatotoxicity. Tracy L. Marion, Elaine M. Leslie, Kim L. R. Brouwer. 
Molecular Pharmaceutics 2007 4 (6), 911-918. Copyright 2007 American Chemical 
Society.  
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 Overview. Drug-induced hepatotoxicity is a significant problem in drug 
development and patient care. One manifestation of drug-induced hepatotoxicity is 
the development of cholestasis, or the inhibition of bile flow. One of the major 
functions of the liver is the synthesis from cholesterol of bile acids (BAs), which are 
the primary constituents of bile. BAs are remarkably conserved across species and 
are very similar between humans and other mammals, including the rat. The 
hepatobiliary architecture allows for continuous BA recirculation; BAs are 
transported from hepatocytes into bile canaliculi, are concentrated within the gall 
bladder, transit through the intestines, are taken back up into the portal venous 
circulation, and finally are extracted from the blood back into the liver. Because of 
this enterohepatic circulation, approximately 95% of the BA pool is conserved in 
humans. While BAs perform important functions in the body, they can be toxic to the 
liver if they accumulate to high concentrations, and some BAs are more cytotoxic 
than others. Although some differences exist, hepatic transport proteins that are 
responsible for the transport of BAs into and out of the liver also are conserved 
between species. Thus, the study of BA homeostasis in rats is highly relevant to 
humans. It is well established that inhibition of BA transport proteins by some drugs 
is a contributing factor to the development of cholestasis and liver injury in some 
patients. The diabetes drug troglitazone (TRO) (Figure 1.1) was removed from 
clinical use because it caused severe, idiosyncratic hepatotoxicity, requiring liver 
transplant or even causing death in some patients. In vitro and animal models have 
established that TRO inhibits BA transport, which is one proposed mechanism of 
TRO hepatotoxicity. This dissertation research examined the effects of TRO on the 
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hepatobiliary transport of individual BAs, the effect of TRO on BA composition, and 
the contribution of the basolateral efflux protein MRP4 in the hepatocellular response 
to accumulated BAs, parent TRO, and TRO metabolites. A number of model 
systems were employed to carry out this work, including primary human and rat 
SCH, suspended rat and human hepatocytes, and inside-out plasma membrane 
vesicles prepared from MRP4-overexpressing HEK293 cells.  
  
 Drug-induced Hepatotoxicity. Drug-induced hepatotoxicity can lead to 
acute liver failure and even death, and is the most common adverse event 
responsible for the removal of pharmaceuticals from clinical use (Kaplowitz 2001). In 
Western countries, >65% of acute liver failure cases may be attributed to drugs and 
toxins, with acetaminophen (APAP) toxicity accounting for the majority of cases 
(Polson and Lee 2007). Drug-induced hepatotoxicity falls into two categories: 
intrinsic and idiosyncratic. Intrinsic hepatotoxicity is generally dose-dependent, 
somewhat predictable, and characteristic for a particular drug, such as the 
hepatoxicity associated with APAP. In contrast, idiosyncratic toxicity is a rare 
hepatotoxic reaction of unknown etiology occurring in a small subset of patients; it is 
unpredictable, not dose-dependent, and displays no clear underlying mechanism. In 
most instances, there is no specific treatment for drug-induced liver injury except to 
remove the causative agent. Symptoms may resolve over time or progress to 
serious, and even life-threatening, disease. Clearly, drug-induced hepatotoxicity 
represents a critical problem for pharmaceutical companies, clinicians, and patients 
alike. Accordingly, an understanding of the possible mechanisms of drug-induced 
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hepatotoxicity is crucial to limit injury to patients and wasted resources in drug 
development. Much research into causes of drug-induced hepatotoxicity has 
focused on well-established mechanisms, including metabolism of compounds to 
reactive species, adduct formation and subsequent cellular damage, or perturbation 
of cellular energetics. However, recent research has led to the hypothesis that 
inhibition of BA transport is an important mechanism of drug-induced hepatotoxicity 
(Byrne et al. 2002; Fattinger et al. 2001; Stieger et al. 2000).  
 
 Cholestasis. While drug-induced hepatotoxicity can resemble all forms of 
liver injury (Kaplowitz 2003), it most often displays characteristics of hepatocellular, 
cholestatic, or mixed injury, depending on serum biochemical markers (Abboud and 
Kaplowitz 2007; Benichou 1990; FDA 2009; Pauli-Magnus and Meier 2006). 
Hepatocellular injury is marked by an initial elevation of alanine aminotransferase 
(ALT) levels, cholestatic injury is characterized by an increase in serum alkaline 
phosphatase (ALP) levels, and mixed injury displays features of both types of injury 
(Navarro and Senior 2006). Cholestasis is defined as the impairment of bile flow, 
and can be caused by intrahepatic or extrahepatic mechanisms. Intrahepatic 
cholestasis occurs at the cellular level and is caused by the perturbation of bile 
formation, while extrahepatic cholestasis occurs at the bile duct level as a result of 
mechanical obstruction or impairment of bile secretion and flow (Zollner and Trauner 
2008). Drugs or hormones can cause a type of noninflammatory cholestasis through 
the inhibition of BA transporters or the retrieval of transporters from the plasma 
membrane, whereas “cholestatic hepatitis” or inflammatory cholestasis, occurs as a 
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result of repression of transporter expression or function due to pro-inflammatory 
cytokine release in response to sepsis, viral hepatitis, alcohol, or drugs (Zollner and 
Trauner 2008). Clinically, symptoms of cholestasis include fatigue, nausea, jaundice, 
dark urine, pale stools, and pruritus. Cholestasis is diagnosed based on plasma 
concentrations of alkaline phosphatase (ALP), gamma-glutamyl transpeptidase 
(GGT), total serum BAs, and plasma conjugated bilirubin; ultrasound, computed 
tomography (CT) scans, and/or magnetic resonance imaging (MRI) also are used to 
diagnose extrahepatic cholestasis; liver biopsy also can aid in diagnosis (Pauli-
Magnus and Meier 2006). Acute cholestasis can progress to chronic vanishing bile 
duct syndrome (Altraif et al. 1994), and lead to chronic intrahepatic cholestasis. In 
adults, acute cholestasis is most commonly caused by prescription drugs, over-the-
counter drugs, and herbal remedies (Heathcote 2007).  
 
 Bile Constituents and Function. One of the many functions of the liver is 
the synthesis and secretion of bile, which plays an essential role in the digestion of 
lipids from the diet. Bile is a mixture of BAs, cholesterol, and phospholipids. Bile is 
formed in the liver and transported through the biliary tract to the gall bladder, where 
it is stored and concentrated up to ten-fold (Nathanson and Boyer 1991). The uptake 
of BAs from the blood, and BA efflux into the bile is the major driving force for BA-
dependent flow, which occurs as a result of electrical and ionic gradients generated 
by the Na+/K+ ATPase and diffusion of K+ ions through potassium channels (Bohan 
and Boyer 2002). Additionally, the canalicular secretion of bicarbonate and reduced 
glutathione contributes to BA-independent bile flow. Bile is secreted postprandially 
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from the gall bladder into the small intestine where it forms mixed micelles with lipids 
and cholesterol to aid in the digestion of dietary fats. Approximately 95-98% of the 
BAs secreted into the intestine are reabsorbed in the distal ileum, returned to the 
liver via the portal venous circulation, and re-extracted by hepatocytes in a process 
known as enterohepatic circulation (Wolkoff and Cohen 2003); because of this highly 
efficient process, the BA pool is constantly recycled (Hofmann 2007a). The small 
proportion of BAs that are not reabsorbed in each cycle are excreted in the feces 
and must be replaced through de novo synthesis (Hofmann 1999b). The size of the 
BA pool in humans is ~50-60 µmol/kg body weight, and totals ~3-4 g (Koopen et al. 
1999; Trauner and Boyer 2003). In addition to the important function of bile in the 
digestive process, bile also acts as an excretory fluid and is a major route of 
excretion for some endogenous products and xenobiotics that are not eliminated in 
the urine by the kidneys. Major constituents of bile in addition to BAs are conjugated 
bilirubin and/or biliverdin, phospholipids, organic molecules such as plant sterols and 
drug metabolites, and heavy metal cations (Hofmann 2007a).  
 
 Bile Acids: Synthesis, Structure, and Relative Cytotoxicity. BAs are the 
major products of cholesterol catabolism; ~500 mg cholesterol are converted to BAs 
per day in the adult human liver (reviewed in Thomas et al. 2008). BAs are 
amphipathic detergent-like molecules consisting of a rigid steroidal nucleus of three 
six-membered rings and one five-membered ring, with a short aliphatic side chain of 
variable length (Figure 1.2). There are two major classes of BAs, depending on the 
length of the aliphatic side chain (either 24 carbons [C24] or 27 carbons [C27]); C24 
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BAs are the major form in the bile of higher vertebrates (Mukhopadhyay and Maitra 
2004). BAs are synthesized in the hepatocyte through a number of enzymatic 
modifications of cholesterol, which begins with the hydroxylation of the cholesterol 
moiety at the 7α position by cholesterol 7α-hydroxylase (CYP7A1) (Bertolotti et al. 
2001; Higuchi and Gores 2003). The resulting 7α-hydroxycholesterol is again 
hydroxylated at the 12β position by CYP8B1, and ultimately, the aliphatic side chain 
is hydroxylated by mitochondrial CYP27A (reviewed in Thomas et al. 2008).  
 BAs share a common structure because they are all synthesized from 
cholesterol. The number and location of hydroxyl groups on the steroid nucleus 
determine the individual BA species and its physicochemical properties. 
Hepatocytes of humans and most other mammals synthesize two primary BAs—
cholic acid (CA) and chenodeoxycholic acid (CDCA). CA has two hydroxyl groups, 
whereas CDCA has a single hydroxyl group. In rodents, but not humans, CDCA can 
be further hydroxylated to form α-, β-, or ω-muricholic acid (MCA) (Botham and Boyd 
1983). During enterohepatic circulation, a small percentage of the primary BAs 
undergo 7α-dehydroxylation by bacterial enzymes in the intestines to form two major 
secondary BAs: deoxycholic acid (DCA), which has a single hydroxyl group, and 
lithocholic acid (LCA), which has no hydroxyl groups (reviewed in Thomas et al. 
2008).  
 In humans, virtually all BAs within the hepatocyte are conjugated to glycine 
(~75%) or taurine (~25%) at the terminal carboxyl group of the aliphatic side chain 
by the enzyme bile acid–coenzyme A:amino acid N-acyltransferase (BAAT) (Byrne 
et al. 2002; Falany et al. 1994; Solaas et al. 2000); in rats, ~95-98% of BAs are 
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conjugated to taurine, also by the rat homologue of BAAT (Alvaro et al. 1986; Mizuta 
et al. 1999; Pellicoro et al. 2007). This conjugation of BAs to glycine or taurine 
confers a negative charge, lowers the pKa, and increases aqueous solubility, 
facilitating excretion into bile (Kullak-Ublick et al. 2004). Conjugation of BAs with 
glycine or taurine is highly efficient, and only a tiny fraction of BAs (<1%) remains 
unconjugated in the bile in humans (Fracchia et al. 1996). However, BAs can be 
conjugated, deconjugated, hydroxylated, and dehydroxylated multiple times by 
bacterial enzymes as they circulate through the intestines during enterohepatic 
circulation. Analysis of plasma from healthy human subjects revealed that about 
30% of the BAs in the blood returning from the intestines are not conjugated to 
taurine or glycine (Tagliacozzi et al. 2003). Sulfation or glucuronidation of BAs also 
occurs, but these are generally considered minor pathways of BA conjugation in 
humans (Hofmann 1990, 2007b). BA concentrations in plasma vary over time and 
reflect the fed or fasted state (Angelin and Bjorkhem 1977). BA concentrations in 
hepatocytes can range from 1-2 µM (Hofmann 1999a) up to ~200 µM (Blitzer and 
Boyer 1982), and up to 1 mM in bile (Hofmann 1999a).  
 BAs perform important physiological roles, but they are cytotoxic when they 
accumulate to high intracellular concentrations, and cause mitochondrial dysfunction 
and trigger apoptosis or necrosis (Roberts et al. 1997). Each BA has different 
physicochemical properties and can have distinct biological activities. The 
hydrophobicity of BAs, which is predictive of their toxicity, is inversely proportional to 
the number of hydroxyl groups on the steroid nucleus and their orientation, as well 
as the conjugation state of the BA (Figure 1.2). The order of toxicity of BAs, from 
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most toxic to least toxic, is: LCA > DCA > CDCA > CA; taurine conjugates are less 
toxic than glycine conjugates (Thomas et al. 2008). BAs have different affinities for 
BA transporters (Byrne et al. 2002; Gerloff et al. 1998; Noe et al. 2001); therefore, 
perturbation of BA transport that causes an increase in intracellular BAs may cause 
the accumulation of some BAs that are more cytotoxic than others through 
competition for efflux.  
 
 Hepatic Bile Acid Transport Proteins.  BA uptake into hepatocytes from 
sinusoidal blood, and excretion of BAs from hepatocytes into the bile canaliculi, is 
dependent on a number of transport proteins (Figure 1.3). The Na+-taurocholate co-
transporting polypeptide NTCP (SLC10A1) is the only Na+-dependent basolateral 
(sinusoidal) BA transport protein in the human hepatocyte; NTCP transports 
conjugated and unconjugated BAs from the blood into the hepatocyte (Geyer et al. 
2006; Mita et al. 2006; Pauli-Magnus and Meier 2006). The basolateral organic 
anion transporting polypeptides (OATPs/SLCOs) are generally considered hepatic 
uptake transporters, and translocate BAs and a variety of organic anions and select 
organic cations in a Na+-independent manner into the hepatocyte (Pauli-Magnus and 
Meier 2006). The multidrug resistance-associated proteins MRP3 (ABCC3) and 
MRP4 (ABCC4) are involved in the basolateral excretion of BAs from the hepatocyte 
back into the blood (Rius et al. 2006; Rius et al. 2003; Zelcer et al. 2003a; Zelcer et 
al. 2003b). Apical (canalicular) BA transport proteins include the bile salt export 
pump BSEP (ABCB11), which transports conjugated and unconjugated BAs into the 
bile canaliculi (Gerloff et al. 1998; Suchy and Ananthanarayanan 2006) and MRP2 
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(ABCC2), which transports glucuronidated and sulfated BAs, tauroursodeoxycholic 
acid (TUDCA), and reduced glutathione (GSH) (Gerk et al. 2006; Jedlitschky et al. 
2006; Nies and Keppler 2006; Pauli-Magnus and Meier 2006). The heteromeric 
organic solute transporter OSTα/β is a more recently identified facilitative transporter 
that transports substrates bidirectionally based on the concentration gradient; it may 
play a role in the basolateral efflux of bile acids during conditions of impaired 
canalicular bile acid efflux (reviewed in Soroka et al. 2010).  
 
 Sandwich-Cultured Hepatocyte Model. Sandwich-cultured hepatocytes 
(SCH) are a promising tool for elucidating the mechanisms of drug-induced toxicity. 
Unlike hepatocytes cultured using conventional techniques which lose polarity and 
metabolic function (Jauregui et al. 1986; Niemann et al. 1991), hepatocytes cultured 
between two layers of gelled collagen or extracellular matrix such as Matrigel® in a 
sandwich configuration maintain polarity, morphology, and liver-specific metabolic 
activity (Liu et al. 1998; Liu et al. 1999a; Liu et al. 1999b; Liu et al. 1999c). Over time 
in sandwich culture, hepatocytes develop functional bile canalicular networks sealed 
by tight junctions, and hepatic transport proteins are expressed and localized to the 
correct membrane domains allowing for assessment of transport function (LeCluyse 
et al. 1994; Liu et al. 1998; Liu et al. 1999a; Liu et al. 1999b; Liu et al. 1999c). In 
contrast to in vivo studies in which the bile canaliculi are inaccessible, the 
hepatocytes and canalicular networks of cells in a sandwich-cultured configuration 
are directly accessible, making it possible to measure substrates excreted into bile. 
Cryopreserved sandwich-cultured human hepatocytes also form bile canalicular 
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networks, and the function of multiple uptake and excretory transport proteins is 
similar to that of fresh hepatocytes (Bi et al. 2006). This technology is applicable to 
hepatocytes from species commonly used in toxicological testing including rats, 
dogs, and monkeys (Rose et al. 2006), as well as from humans, and therefore 
represents an effective in vitro approach to study drug-induced hepatotoxicity.  
 Transport studies in rat SCH reported by Liu et al (Liu et al. 1999a; Liu et al. 
1999b; Liu et al. 1999c) first utilized these polarized cells to measure both the 
uptake of substrate across the basolateral membrane of the hepatocyte and 
excretion of substrate into the canalicular space. In Ca2+-containing standard buffer 
(Hanks’ balanced salts solution), the tight junctions that serve as a barrier between 
the canalicular lumen (intercellular junctions) and the extracellular space are 
maintained, and substrates are excreted into and contained within the bile canaliculi. 
The cumulative uptake of substrate across the basolateral surface of the hepatocyte 
is represented by the sum of substrate transported into the cytosol and that excreted 
into the bile canalicular networks. Depletion of Ca2+ results in disruption of the tight 
junctions and opens the canalicular spaces; thus, incubation of cells in Ca2+-free 
buffer (Hanks’ balanced salts solution without calcium chloride and magnesium 
sulfate, containing 1 mM EGTA) (Liu et al. 1999c) releases the contents of the bile 
canaliculi into the incubation medium within minutes. The amount of substrate 
excreted into the canalicular networks is calculated by subtracting the amount of 
substrate in cells preincubated in Ca2+-free buffer (cellular accumulation) from the 
accumulated amount of substrate in cells preincubated in Ca2+-containing buffer 
(cellular plus biliary accumulation). The biliary excretion of substrates can be 
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expressed as a biliary excretion index (BEI), which is the percentage of accumulated 
substrate residing within the bile canaliculi. The BEI is calculated from the following 
equation: BEI = [(Accumulationstandard buffer – AccumulationCa2+-free 
buffer)/Accumulationstandard buffer] * 100% (Liu et al. 1999a). The in vitro biliary clearance 
(Clbile) is calculated using the following equation: Clbile = (Accumulationstandard buffer – 
Accumulation
 Ca2+-free buffer) / (AUCmedium), where AUC represents the area under the 
substrate concentration-time profile in the incubation buffer.  
 A comparison of the Clbile of the model substrates inulin, salicylate, 
methotrexate, [D-pen2,5]enkephalin, and TCA measured in rat SCH revealed an 
excellent correlation (r2 = 0.99) with the Clbile of these substrates measured in vivo in 
rats (Liu et al. 1999a). More recently, Ghibellini et al. (2007) reported a good 
relationship between the human in vivo Clbile of three different compounds 
(piperacillin, 99m Tc-sestamibi and 99m Tc-mebrofenin, which exhibit low, intermediate, 
and high Clbile, respectively) with that predicted from in vitro studies with human SCH 
(Ghibellini et al. 2007). This study established the relevance of SCH for prediction of 
human in vivo Clbile. When the effects on BEI and in vitro Clbile of the P-gp inhibitors 
verapamil and progesterone, the P-gp activator quercetin, and the P-gp inducers 
dexamethasone and rifampin were assessed (Annaert and Brouwer 2005), 
comparisons of BEI and Clbile values in the absence and presence of the modulators 
were used to localize transport interactions to the basolateral or canalicular 
membrane, thus elucidating potential mechanisms of drug interactions in hepatic 
transport. For example, a change in BEI implies that canalicular transport is altered, 
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while an alteration in Clbile, with no change in BEI, suggests that the interaction is 
localized to the basolateral membrane.  
 
 Additional In Vitro Models to Identify Inhibitors of Bile Acid Transport. 
Freshly-isolated hepatocytes in suspension are a useful tool for the characterization 
of the mechanisms of hepatic uptake of substrates. During the isolation process, 
hepatocytes maintain proper localization and function of uptake transport proteins. In 
contrast, canalicular transporters are internalized from the membrane (Bow et al. 
2008); thus, suspended hepatocytes are not a suitable model system for studying 
hepatocyte efflux processes. By substituting choline for Na+ in the uptake buffer, 
Na+-dependent substrate uptake can be determined by subtracting total uptake in 
Na+ conditions from uptake in Na+-free conditions. A disadvantage of suspended 
hepatocytes is that metabolic capacity and transport protein function decrease 
rapidly, so cells should be used within 6-8 h of isolation.  
 The uptake of substrates into purified hepatic basolateral or canalicular 
plasma membrane vesicles is an established tool to determine the kinetics of 
substrate transport by membrane-bound proteins (Wolters et al. 1991). Although the 
preparation of highly enriched basolateral or canalicular membranes for vesicle 
transport studies is technically challenging, data from these vesicles can reveal 
information about transport mechanisms across a specific membrane that is not 
confounded by the presence of competing metabolic pathways or transport proteins 
on the opposite membrane. However, these vesicles theoretically include all 
transporters that reside together on the membrane, and thus may only differentiate 
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canalicular versus basolateral transport. The use of recombinant expression 
systems that overexpress a single transport protein in an immortalized parent cell 
(i.e., HEK293 cells) allows for the preparation of membrane vesicles that can be 
used to determine whether a compound is an inhibitor and/or substrate for that 
specific transport protein. These membrane vesicles can be used to directly 
measure the transport of a specific compound into the vesicles, or to measure the 
ability of a compound to inhibit the transport of a known substrate of the transporter 
(El-Sheikh et al. 2006; Leslie et al. 2003).  
 
 Inhibition of BA Transport is a Potential Mechanism of Hepatotoxicity 
for Numerous Drugs. Inhibition of BSEP, leading to the intracellular accumulation 
of cytotoxic BAs, has been hypothesized as one mechanism of drug-induced 
hepatotoxicity (Byrne et al. 2002; Fattinger et al. 2001; Stieger et al. 2000). Evidence 
for the importance of proper BSEP function is clear in progressive familial 
intrahepatic cholestasis type 2 (PFIC2), which is a rare genetic disease caused by 
mutations in BSEP; PFIC2 results in severe cholestasis from birth, with rapid 
progression to cirrhosis, and liver failure (Suchy and Ananthanarayanan 2006). In 
addition to BSEP, compounds that inhibit one or more of the proteins responsible for 
BA excretion also may cause the intracellular accumulation of BAs in hepatocytes, 
and subsequent toxicity due to detergent effects on cellular membranes, 
mitochondrial dysfunction, and cellular necrosis (Delzenne et al. 1992; Desmet 
1995; Gores et al. 1998; Pauli-Magnus et al. 2005). A number of drugs, including 
cyclosporin A, glibenclamide, rifampin, bosentan, and TRO, have been shown to 
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inhibit rat and human Bsep-mediated TCA biliary excretion in vitro (Fattinger et al. 
2001; Funk et al. 2001a; Kemp et al. 2005; Mano et al. 2007; Marion et al. 2007; 
Pauli-Magnus and Meier 2006; Stieger et al. 2000). Ritonavir, saquinavir, and 
efavirenz, three antiretroviral drugs associated frequently with hepatotoxicity in 
patients infected with human immunodeficiency virus, also inhibit hepatic BA 
transport (McRae et al. 2006).  
 Kostrubsky et al. studied the hepatotoxic potential of a group of compounds 
that are eliminated preferentially by biliary excretion, but were not predicted to show 
clinical hepatotoxicity based on results of testing in preclinical species (Kostrubsky et 
al. 2003). The effects of these compounds on TCA transport in hepatocytes cultured 
in conventional and collagen-sandwich configuration were evaluated. Cyclosporin A, 
bosentan, CI-1034, glyburide, erythromycin estolate, and troleandomycin inhibited 
BA excretion in a concentration-dependent manner in human SCH, and to a lesser 
extent in human hepatocytes cultured in conventional configuration, while the 
macrolide antibiotics were much less potent inhibitors of TCA excretion. Cyclosporin 
A, CI-1034, glyburide, and bosentan also inhibited uptake of TCA in a concentration-
dependent manner. As a result of these findings, Kostrubsky and coworkers 
suggested a strategy for using transport assays to rank compounds according to 
their hepatotoxic potential. Kostrubsky et al. also used data generated in SCH, in 
membrane vesicles isolated from Sf9 cells transfected with BSEP, and from in vivo 
studies in intact rats to compare the effects of the antidepressant nefazodone and 
the structural analogs buspirone and trazodone on hepatobiliary transport of TCA 
(Kostrubsky et al. 2006). Nefazodone potently inhibited BSEP in membrane vesicles 
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and inhibited TCA excretion in human SCH; in intact rats, nefazodone administration 
caused a transient increase in serum BAs. Buspirone and trazodone, in contrast, did 
not affect biliary transport in any of the models tested. These findings are consistent 
with clinical observations of hepatotoxicity and liver failure associated with 
nefazodone administration, and suggest that in vitro inhibition of BA transport may 
be predictive of hepatotoxicity in vivo.  
 
 Troglitazone (TRO). The peroxisome proliferator-activated receptor gamma 
(PPARγ) agonist TRO ((+/-)-5-[4-(6-hydroxy-2, 5, 7, 8-tetramethyl-chroman-2-yl-
methoxy)benzyl]-2,4-thiazolidinedione) was the first in a new class of 
thiazolidinedione antidiabetic agents. TRO was approved by the Food and Drug 
Administration in 1997 for the treatment of non-insulin-dependent diabetes mellitus 
(type II diabetes), but was subsequently withdrawn from the market in 2000 after 
numerous reports of hepatotoxicity and liver failure. For most patients who 
experienced hepatotoxicity, progression to acute liver failure was rapid and 
irreversible, occurred within a time period of less than one month, and occurred at 
any point during treatment (Graham et al. 2003b). Of the 94 cases of TRO-induced 
liver failure reported to the FDA, liver pathology data were available for 31 of these; 
hepatic necrosis was present in 71% of the cases, hepatitis was reported in 13%, 
and cholestasis with both acute and chronic inflammatory infiltrates was reported in 
7% (Graham et al. 2003b). Taking into account underreporting to the FDA of 
adverse events associated with TRO, the likely number of cases of liver failure 
among patients treated with TRO for 26 months was 1 to 2 per 1000 (Graham et al. 
 17 
2003a; Graham and Green 2000). Unfortunately, preclinical toxicological testing of 
TRO in animals failed to predict this hepatotoxicity, and subsequent research efforts 
have focused on elucidating the mechanism(s) of TRO-associated hepatotoxicity. 
While the precise mechanism(s) remain(s) unclear, several hypotheses have been 
suggested, including metabolism of TRO to electrophilic reactive intermediates, 
mitochondrial injury and induction of mitochondrial permeability transition, induction 
of apoptosis, PPARγ-mediated steatosis, and inhibition of BA transport (Masubuchi 
2006; Smith 2003).  
 In humans, TRO is metabolized extensively in the liver primarily by 
sulfotransferase (SULT) 1A3 to a sulfate conjugate (TS) (Honma et al. 2002; Kawai 
et al. 1997), and via UDP-glucuronosyltransferase (UGT) 1A1 to a glucuronide 
conjugate (TG) (Watanabe et al. 2002; Yoshigae et al. 2000); TRO also is oxidized 
by cytochrome P450 isozymes CYP3A4 and CYP2C8 to a quinone (TQ) (Yamazaki 
et al. 1999). The sulfate and quinone metabolites of TRO accounted for 70% and 
10%, respectively, of the metabolites detected in human plasma at steady-state after 
multiple oral dosing of TRO for 7 days (Loi et al. 1999a; Loi et al. 1997), while the 
glucuronide conjugate was a minor metabolite in plasma (Loi et al. 1999b; Parke-
Davis 1998). At a dose of 400 mg, the majority of [14C]TRO administered orally to 
humans (about 85%) was recovered in feces, with only 3% recovered in urine; the 
absolute bioavailability was 40-50% (Parke-Davis 1998). Metabolism of TRO in rats 
is similar to humans; TRO is primarily metabolized to TS and to a lesser extent to 
TG, while the formation of TQ is minor. In both plasma and bile of rats, TS is the 
predominant metabolite, and biliary excretion of TS is about 6-fold higher than of TG 
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(Izumi et al. 1997). Metabolism of TRO is extensive, and very little parent compound 
is excreted unchanged into urine or bile; TS and TG (68.0% and 11.6%, 
respectively, of a 5 mg/kg oral dose of TRO) were excreted into the bile in rats, 
indicating that the total body clearance of TRO is governed by its metabolic 
clearance (Izumi et al. 1996; Izumi et al. 1997; Kawai et al. 1997). Experiments by 
Lee et al. determined that the metabolism of TRO in rat and human SCH mimicked 
that in vivo in rats and humans; TRO was metabolized primarily to TS, and to a 
lesser extent to TG and TQ (Lee et al. 2009). Additionally, following a 2-h incubation 
with TRO, the accumulation of TS was extensive, with intracellular concentrations 
reaching an estimated 132-222 µM in rat SCH and 136-160 µM in human SCH, 
based on the reported volume of 6.2 × 10-6 µl/hepatocyte (Uhal and Roehrig 1982) 
and the accumulated mass of TS.  
 In vivo and in vitro experiments have demonstrated that TRO, and particularly 
TS, inhibit bile acid transport, which may lead to cholestasis and subsequent 
hepatocellular apoptosis or necrosis caused by the intracellular accumulation of BAs 
(Funk et al. 2001a; Funk et al. 2001b; Kemp et al. 2005; Preininger et al. 1999). 
Intravenous administration of TRO to rats increased plasma BA concentrations in a 
dose-dependent manner (Funk et al. 2001a). BA concentrations were greater in 
male rats than in females, and this effect was accompanied by accumulation of TS in 
liver tissue that was 5-fold greater in males than females (Funk et al. 2001a). In 
isolated perfused rat livers, TRO decreased bile secretion rates (Preininger et al. 
1999). In vitro, both TRO and TS competitively inhibited TCA transport in rat 
canalicular liver plasma membrane vesicles, and TS was 10-fold more potent a Bsep 
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inhibitor than TRO (Funk et al. 2001a; Funk et al. 2001b). Although TS is a more 
potent Bsep/BSEP inhibitor, Kostrubsky et al. reported that when treating human 
hepatocytes with TRO, increased cytotoxicity correlated with the amount of 
unsulfated TRO, suggesting that TRO is more directly cytotoxic than TS (Kostrubsky 
et al. 2000). Experiments also indicate that TRO inhibits basolateral uptake of BAs, 
in addition to inhibiting canalicular efflux. Acute, 10-min treatment with 10 µM TRO 
decreased both the cellular accumulation and biliary excretion of TCA in rat SCH, 
and decreased the initial uptake of TCA in rat suspended hepatocytes (Kemp et al. 
2005). In rat basolateral plasma membrane vesicles, 100 µM TRO also significantly 
inhibited Na+-dependent TCA uptake (Snow and Moseley 2006).  
 Like TRO, bosentan also has been shown to inhibit BA transport using 
multiple model systems. Inhibition of BSEP resulting in BA accumulation in the 
hepatocyte has been proposed as a mechanism of bosentan-induced hepatotoxicity. 
This mechanism is challenged by the observation that bosentan, like TRO, does not 
induce hepatotoxicity in rats. However, inhibition of both human and rat BSEP/Bsep 
by bosentan has been demonstrated in vitro using rat and human SCH and 
BSEP/Bsep enriched membrane vesicles (Fattinger et al. 2001; Kemp et al. 2005; 
Kostrubsky et al. 2003; Leslie et al. 2007; Mano et al. 2007). In both rat and human 
SCH, bosentan inhibited uptake, in addition to excretion, of TCA (Kemp et al. 2005; 
Leslie et al. 2007). These findings led to the hypothesis that the balance between 
inhibition of BA uptake and excretion processes could be very important for initiation 
of hepatotoxic events. Further analysis using rat and human suspended hepatocytes 
revealed that bosentan inhibited Na+-dependent TCA uptake, suggesting that 
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NTCP/Ntcp was inhibited (Kemp et al. 2005; Leslie et al. 2007). This observation 
was confirmed by examining the effect of bosentan on TCA uptake by HEK293 cells 
over-expressing rat Ntcp or human NTCP (Leslie et al. 2007). Interestingly, 
suspended hepatocytes and the HEK293 model system revealed that rat Ntcp was 
inhibited more potently by bosentan than human NTCP, suggesting that bosentan 
may cause toxicity in humans due to the combination of inhibition of BSEP and less 
potent inhibition of NTCP, resulting in accumulation of BAs in human hepatocytes; in 
rats, BAs may not accumulate in hepatocytes because both the uptake and 
excretion of BAs are inhibited, thus protecting the hepatocyte from toxicity.  
 With this observation regarding bosentan in mind, initial experiments in 
support of this dissertation research project were performed in order to determine 
the effect of TRO on TCA uptake and accumulation in human SCH compared to rat 
SCH (Appendix A). Results indicated that 10 µM TRO decreased cellular 
accumulation and biliary excretion of [3H]TCA in a concentration-dependent manner 
in both human and rat SCH similarly, although the BEI was decreased more in 
human than in rat (54.3% vs 71.0%, respectively) (Marion et al. 2007). Unlike the 
situation with bosentan, TRO was a more potent inhibitor of Na+-dependent [3H]TCA 
uptake in human suspended hepatocytes (IC50 = 0.33 µM) than in rat suspended 
hepatocytes (IC50 = 1.9 µM). This observation led to the following question: If TRO 
inhibits both basolateral uptake and canalicular efflux of TCA, then how could TRO 
cause the intracellular accumulation of BAs?  
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 Compensatory BA Transport. This question was addressed by considering 
the potential role of individual BA species and compensatory BA transport proteins in 
the hepatotoxicity of TRO. Because there is evidence that individual BAs have 
different affinities for BA transporters (Byrne et al. 2002; Gerloff et al. 1998; Noe et 
al. 2001), perturbations in BA transport may increase the intracellular accumulation 
of some BAs that are more cytotoxic than others through competition for efflux. The 
basolateral efflux transport protein MRP4 normally is expressed at low levels in 
hepatocytes, but is induced in cholestasis in humans (Gradhand et al. 2008), 
presumably as an adaptive response mechanism to compensate for increased 
intracellular concentrations of BAs; MRP4 induction may explain the increased 
excretion of BAs in the urine of patients with cholestasis (Assem et al. 2004; Schuetz 
et al. 2001; Zollner et al. 2003). Also, patients with PFIC2 have significantly 
increased liver expression of MRP4 mRNA and protein (Keitel et al. 2005).  
 The substrate specificity of MRP4 is broad, and includes the cyclic 
nucleotides cAMP and cGMP, prostaglandins, and BAs as well as sulfate-
conjugated BAs (Sampath et al. 2002; Zelcer et al. 2003a). If treatment with TRO 
causes an increase in intracellular BAs, MRP4/Mrp4 protein expression and/or 
membrane localization may increase in order to compensate, especially if TS 
accumulates within hepatocytes and continues to inhibit BSEP/Bsep function. 
Interestingly, Lee et al. found that pretreatment of rat SCH with buthionine 
sulfoximine (BSO), an inhibitor of glutathione synthesis, increased Mrp4 protein 
expression (Lee et al. 2008). This upregulation of Mrp4 may have been a direct 
effect of BSO, or a response to oxidative stress induced by GSH depletion. It has 
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been established that the canalicular transport proteins P-gp, BSEP, and MRP2 
reside inside intracellular compartments and traffic to the canalicular membrane 
under increased physiological demand for BA and organic anion efflux; this 
membrane trafficking can occur within minutes, and allows for more rapid 
upregulation of transport capability than would be possible through increased protein 
synthesis (reviewed in Kipp and Arias 2002). Similarly, Hoque and Cole reported 
that downregulation of the protein Na+/H+ exchanger regulatory factor 1 (NHERF1) 
by siRNA in MRP4-expressing HeLa cells increased MRP4 protein membrane 
localization, which was attributed to decreased internalization of this transport 
protein (Hoque and Cole 2008). Therefore, while basal MRP4 expression is 
considered low in liver, it is possible that increased mRNA and protein expression, 
as well as membrane trafficking, may play important roles in increasing MRP4 in 
cholestasis.  
 
 Goals and Specific Aims. The goal of this dissertation work was to examine 
the effect of TRO on the hepatobiliary disposition of individual BAs, to determine the 
effect of TRO on intracellular BA composition, and to elucidate the contribution of the 
basolateral efflux protein MRP4/Mrp4 to the hepatocellular response to accumulated 
BAs, parent TRO, and TRO metabolites. A number of model systems were 
employed to carry out this work, including primary rat and human SCH, suspended 
rat and human hepatocytes, and inside-out plasma membrane vesicles from MRP4 
overexpressing HEK293 cells. 
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SPECIFIC AIM 1: Demonstrate that TRO differentially affects the intracellular 
accumulation of BAs, leading to the accumulation of more cytotoxic BA species.  
Hypothesis 1: In contrast to TCA, acute TRO exposure causes the intracellular 
accumulation of more toxic BAs.  
Strategy:  
• Measure effect of TRO on acute (10-min) accumulation of [14C]CDCA species 
in medium, cells + bile, and cells in WT and TR- rat SCH  
• Compare accumulation of [14C]CDCA species to effects on acute [3H]TCA 
accumulation 
• Examine the effect of the pan-MRP/Mrp inhibitor MK571 to probe the effect of 
Mrp inhibition on disposition of both [14C]CDCA and [3H]TCA 
• Measure parent and metabolites of unlabeled CDCA following a 10-min 
incubation in rat SCH  
Hypothesis 2: TRO inhibits the accumulation of [14C]CDCA in WT and TR- rat SCH 
less than [3H]TCA because [14C]CDCA uptake is primarily Na+-independent, while 
TRO has a greater inhibitory effect on Na+-dependent Ntcp function.  
Strategy: 
• Measure the effect of TRO on initial uptake of [14C]CDCA and compare to 
effects on 1 µM [3H]TCA uptake in suspended rat hepatocytes 
• Examine the effect of MK571 on the inhibition of TCA uptake 
 
SPECIFIC AIM 2: Characterize the effects of TRO treatment on the endogenous BA 
pool, including composition and size, in medium, cells, and bile of rat and human 
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SCH. Hypothesis: TRO exerts differential effects on endogenous BAs, causing the 
intracellular accumulation of more toxic BAs, and shifts the intracellular BA pool 
composition toward more toxic species.  
Strategy: Compare longer-term (24-h) effects of TRO on endogenous BA 
disposition in cells + bile, cells, and medium in rat and human SCH  
• Measure and compare endogenous BAs common to both rat and human 
(TCA, GCA, TCDCA, GCDCA) in control SCH. Because of lack of 
enterohepatic cycling, secondary BAs and unconjugated BAs (LCA, DCA, CA, 
CDCA) were not included in the analysis. 
• Examine the effect of 24-h treatment with TRO on endogenous BA disposition 
in cells + bile, cells, and medium of rat and human SCH  
SPECIFIC AIM 3: Demonstrate that TS inhibits MRP4-mediated bile acid transport.  
Hypothesis: Intracellular accumulation of TS can inhibit compensatory MRP4-
mediated BA efflux.  
Strategy: Measure uptake of [3H]TCA by MRP4-expressing membrane vesicles 
from HEK293 cells in the presence of TS.  
• Measure uptake of TS in MRP4-expressing membrane vesicles 
• Measure MRP4-mediated uptake of the known MRP4 substrates 
methotrexate (MTX) and dehydroepiandrosterone (DHEAS) 
• Measure uptake of [3H]TCA in the presence of increasing concentrations of 
TS 
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Figure 1.1: Troglitazone ((+/-)-5-[4-(6-hydroxy-2, 5, 7, 8-tetramethyl-chroman-2-yl-
methoxy)benzyl]-2,4-thiazolidinedione).  
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Figure 1.2: Common structure of bile acids, and relative hydrophilicity or 
hydrophobicity. R1, R2, and R3 denote location of potential hydroxyl groups, X 
denotes location of taurine or glycine conjugation.  
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Figure 1.3: Human hepatic bile acid transport proteins.  
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CHAPTER 2 
 
Differential Disposition of Chenodeoxycholic Acid versus Taurocholic Acid in 
Response to Acute Troglitazone Exposure in Rat Sandwich-Cultured 
Hepatocytes 
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Abstract  
 Inhibition of bile acid (BA) transport may contribute to the hepatotoxicity of 
troglitazone (TRO), a peroxisome proliferator-activated receptor gamma (PPARγ) 
agonist. Typically, studies use taurocholic acid (TCA) as a model substrate to 
investigate the effects of xenobiotics on BA disposition; however, TRO may 
differentially affect the transport of individual BAs, potentially causing the 
accumulation of more cytotoxic BAs. The effects of TRO on the disposition of [14C]-
labeled chenodeoxycholic acid ([14C]CDCA), an unconjugated, cytotoxic BA, were 
determined in rat suspended hepatocytes and sandwich-cultured hepatocytes 
(SCH). MK571, a multidrug resistance-associated protein (MRP) inhibitor, was 
included to evaluate involvement of MRPs in CDCA disposition. Accumulation in 
cells + bile of total [14C]CDCA species in SCHs was 6-fold greater than for [3H]TCA, 
and was unaffected by 1 and 10 µM TRO. Both 100 µM TRO and 50 µM MK571 
ablated biliary excretion and significantly increased intracellular accumulation of total 
[14C]CDCA species. Results were similar in Mrp2-deficient TR- rat hepatocytes. LC-
MS/MS analysis revealed that taurine- and glycine-conjugated CDCA, in addition to 
unconjugated CDCA, were present in cells at the end of the 10-min incubation. In 
suspended rat hepatocytes, initial uptake of [3H]TCA was primarily Na+-dependent, 
whereas initial [14C]CDCA uptake was primarily Na+-independent. TRO and MK571 
decreased [14C]CDCA uptake to a lesser extent than [3H]TCA uptake. Differential 
effects on uptake and efflux of individual BAs may contribute to the hepatotoxic 
effect of TRO. Although TCA is the prototypic BA used to investigate the effect of 
xenobiotics on BA transport, it may not be reflective of other BAs.  
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Introduction 
 Troglitazone (TRO) is a peroxisome proliferator-activated receptor gamma 
(PPARγ) agonist used clinically to treat noninsulin-dependent type II diabetes until it 
was removed from the market following a number of cases of severe, idiosyncratic 
hepapotoxicity. Much research has focused on determining the mechanisms of 
TRO-mediated hepatotoxicity. One hypothesis is that TRO inhibits hepatic bile acid 
(BA) transport; inhibition of the bile salt export pump (BSEP) may cause intracellular 
accumulation of BAs (reviewed in Masubuchi, 2006) and subsequent toxicity due to 
detergent effects (Delzenne et al. 1992; Pauli-Magnus et al. 2005). Impaired BSEP 
function is a significant medical issue (reviewed in Pauli-Magnus et al. 2010); 
however, drug-mediated inhibition of hepatic BA transport as a mechanism of drug-
induced liver injury is poorly understood.  
 Normally, BA disposition is tightly controlled, and hepatic BA concentrations 
are governed by the rate of synthesis and by basolateral (sinusoidal) and apical 
(canalicular) transport proteins. On the basolateral membrane, the Na+-taurocholate 
cotransporting polypeptide (NTCP) mediates Na+-dependent uptake of BAs, while 
organic anion transporting polypeptide (OATP) isoforms mediate Na+-independent 
uptake of BAs, organic anions, some organic cations, and neutral species (Trauner 
and Boyer 2003). On the apical membrane, BSEP is the major canalicular transport 
protein that mediates biliary excretion of monomeric BAs, while multidrug resistance-
associated protein 2 (MRP2/Mrp2) transports divalent BAs into the bile canaliculi 
(Kullak-Ublick et al. 2000). Together, NTCP and BSEP represent the major transport 
proteins responsible for the vectorial transport of BAs from blood to bile. The 
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basolateral efflux transporters MRP3, MRP4, and the organic solute transporter, 
OSTα/β may also be involved in the excretion of BAs from hepatocytes back into the 
blood under cholestatic conditions (reviewed in Borst et al. 2007; Soroka et al. 
2010).  
 Taurocholic acid (TCA) is the taurine conjugate of the primary BA cholic acid 
(CA) that is present in both rats and humans. TCA is utilized commonly as a 
prototypic BA to study the effect of xenobiotics and drugs, including TRO, on BA 
transport both in vivo and in vitro. TRO caused the accumulation of [14C]TCA in rat 
liver tissue (Funk et al. 2001b), and inhibited Bsep–mediated TCA transport in rat 
canalicular membrane vesicles (Funk et al. 2001a) and in membrane vesicles from 
Sf9 cells overexpressing Bsep from different species (Kis et al. 2009). TRO inhibited 
TCA uptake and biliary excretion in primary rat SCH (Kemp et al. 2005), and 
inhibited TCA transport in both basolateral and canalicular rat liver membrane 
vesicles (Snow and Moseley 2006). Studies by our group in human SCH showed 
that TRO decreased TCA biliary excretion in a concentration-dependent manner, 
consistent with BSEP inhibition; Na+-dependent initial uptake of TCA also was 
inhibited in rat and human suspended hepatocytes (Marion et al. 2007). TRO also 
caused intracellular retention of preloaded [3H]TCA in human hepatocytes (Jemnitz 
et al. 2010).  
 BAs perform important physiological roles, but are cytotoxic and may cause 
mitochondrial dysfunction and trigger apoptosis or necrosis if they accumulate to 
high intracellular concentrations. The hydrophobicity of individual BAs is inversely 
proportional to the number and orientation of hydroxyl groups on the steroid nucleus, 
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and is predictive of toxicity (reviewed in Thomas et al. 2008). Individual BAs also 
have different affinities for some BA transporters (Byrne et al. 2002; Gerloff et al. 
1998; Noe et al. 2001); thus, perturbation of BA transport resulting in increased 
intracellular BAs may cause a disproportionate accumulation of more cytotoxic BAs 
through competition for transport.  
 The primary BA chenodeoxycholic acid (CDCA) comprises an estimated 
10.5% (Tagliacozzi et al. 2003) to 37% (McRae et al. 2010) of the BAs in human 
plasma, compared to 3% (Tagliacozzi et al. 2003) to 3.6% (McRae et al. 2010) for 
TCA. CDCA is more cytotoxic to hepatocytes than TCA (Miyazaki et al. 1984), and 
concentrations in human liver can reportedly increase 20-fold following extrahepatic 
biliary obstruction (Greim et al. 1973). Hepatic uptake of CDCA reportedly involves 
both Na+-dependent (NTCP-mediated) and -independent (i.e., OATP1B1 and 
OATP1B3) transport mechanisms (Maglova et al. 1995; Van Dyke et al. 1982); 
OATP1B1 and OATP1B3 also can transport a fluorescent CDCA analog (Yamaguchi 
et al. 2006). The present study compared the effects of TRO on the disposition of 
CDCA versus TCA in rat SCH and suspended hepatocytes. Experiments were 
designed to determine whether TRO differentially affects the hepatobiliary 
disposition of individual BAs resulting in greater intracellular accumulation of CDCA 
compared to TCA, and to examine the mechanism(s) of potential alterations. 
MK571, an MRP inhibitor, was included to investigate the potential involvement of 
MRPs in CDCA and TCA hepatobiliary disposition.  
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Materials and Methods 
 Chemicals. [14C]CDCA (50 mCi/mmol; purity > 97%) and [14C]inulin (2.8 
mCi/g, purity > 97%) were purchased from American Radiolabeled Chemicals, Inc. 
(St. Louis, MO), and [3H]TCA (5 Ci/mmol; purity > 97%) was purchased from Perkin 
Elmer (Waltham, MA). TRO was purchased from Biomol (Plymouth Meeting, PA). 
MK571 sodium salt was obtained from Cayman Chemical (Ann Arbor, MI). 
Dexamethasone, Hanks’ balanced salt solution (HBSS) premix, HBSS modified 
(without calcium chloride, magnesium sulfate, phenol red and sodium bicarbonate) 
premix, and collagenase (type IV) were purchased from Sigma-Aldrich (St. Louis, 
MO). Collagenase (type I, class I) was obtained from Worthington Biochemical 
(Freehold, NJ) and dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific 
(Fairlawn, NJ). GIBCO brand fetal bovine serum, recombinant human insulin, and 
Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Invitrogen 
(Carlsbad, CA). ITS (insulin, transferrin, selenium) Universal Culture Supplement 
Premix and Matrigel™ Basement Membrane Matrix were obtained from BD 
Biosciences (Palo Alto, CA). All other chemicals and reagents were of analytical 
grade and were readily available from commercial sources.  
 Hepatocyte Isolation and Culture. Hepatocytes were isolated from wild-type 
(WT) male Wistar rats (250-300 g; Charles River Laboratories, Inc., Raleigh, NC) or 
male Mrp2-deficient TR- rats (250-300 g; UNC colony) using a two-step collagenase 
perfusion method previously described (Liu et al., 1998; Annaert et al., 2001). Rats 
were maintained on a 12-h light/dark cycle with free access to water and standard 
rodent chow, and allowed to acclimate for at least 5 days before experimentation. 
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The Institutional Animal Care and Use Committee of the University of North Carolina 
at Chapel Hill approved all procedures.  
 Hepatocytes were seeded at a density of 1.75 x 106 cells per well on 6-well 
BioCoat™ plates with Collagen type I substratum in 1.5 ml DMEM supplemented 
with 5% (v/v) fetal bovine serum, 10 µM insulin, 1 µM dexamethasone, 2 mM L-
glutamine, 1% (v/v) MEM nonessential amino acids, 100 units penicillin G sodium 
and 100 µg streptomycin sulfate. Cells were incubated at 37°C in a humidified 
incubator and allowed to attach for 2 h, after which time the medium was aspirated 
to remove unattached cells, and replaced with fresh medium. Twenty-four hours 
later, on day 1 of culture, hepatocytes were overlaid with BD MatrigelTM basement 
membrane matrix at a concentration of 0.25 mg/ml in ice-cold DMEM supplemented 
with 1% (v/v) ITS+ Premix, 0.1 µM dexamethasone, 2 mM L-glutamine, 1% (v/v) 
MEM nonessential amino acids, 100 units penicillin G sodium and 100 µg 
streptomycin sulfate. Cells were cultured for 3 additional days to allow for the 
formation of canalicular networks between cells. Culture medium was replaced daily.  
 Accumulation of CDCA and TCA in WT and TR- Rat SCH. On day 4 of 
culture, hepatocytes were rinsed 3 times (20 s per each rinse) with 2 ml per well of 
warm standard HBSS with Ca2+ (three wells) or HBSS without Ca2+ (three wells). 
Following the washes, 2 ml of warm HBSS with or without Ca2+ were added, and 
cells were incubated at 37°C for 10 min. Incubation of  SCH with Ca2+-containing 
HBSS maintains the tight junctions between cells, and the bile canalicular structures 
formed between cells remain intact. Incubation of cells in Ca2+-free HBSS disrupts 
the tight junctions, allowing the contents of the canaliculi to be washed away. After 
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incubation, the HBSS was double-aspirated from each well and 1.5 ml of dosing 
solution consisting of HBSS with Ca2+, substrate (1 µM unlabeled CDCA plus 0.2 µM 
[14C]CDCA, or 1 µM TCA plus trace [3H]TCA), or inhibitor (specified concentrations 
of TRO or MK571, or vehicle [0.1% (v/v) DMSO]) were added. Cells were incubated 
at 37°C for 10 min. Following incubation, the dosing solution was aspirated from the 
cells and uptake was stopped by rinsing cells 3 times for 20 s each with 2 ml ice-cold 
HBSS with Ca2+ per wash. After washing, the HBSS was aspirated and 1 ml of lysis 
buffer (0.5% [v/v] Triton X-100 in phosphate-buffered saline) was added to each well 
and plates were shaken on a rotating plate shaker for 20 min. Aliquots (500 µl) of 
sample and 100 µl aliquots of dosing solution were collected for quantification of 
radioactivity by liquid scintillation counting; 500 µl aliquots were reserved for protein 
quantification using the Pierce BCA™ Protein Assay Kit (Thermo Scientific, 
Rockford, IL). Accumulation of [14C]CDCA and [3H]TCA in BioCoat™ plates without 
cells was subtracted to correct for nonspecific binding to the collagen substratum. 
 Temperature-dependent Accumulation of CDCA and TCA in WT Rat 
SCH. Accumulation in WT rat SCH of [14C]CDCA and [3H]TCA in the presence of 
vehicle was measured at 37°C using the above method. Accu mulation at 4°C was 
carried out using the same method, except that all reagents were kept at 4°C and all 
incubations were performed on ice.  
 Measurement of Taurine- and Glycine-conjugated CDCA Species in WT 
Rat SCH. In order to determine the extent of CDCA metabolism to taurine or glycine 
conjugates (TCDCA or GCDCA, respectively) during the 10-min incubation in the 
accumulation studies, WT rat SCH were treated using the above method for 
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measuring accumulation of CDCA at 37°C, except that th e dosing solution contained 
either vehicle (0.1% DMSO) or 1 µM unlabeled CDCA only. Following the final 
washes, wells were aspirated and plates were stored at -70°C until analysis by LC-
MS/MS for TCDCA and GCDCA, as well as for the rodent-specific BAs 
tauromuricholic acid (TMCA) and glycomuricholic acid (GMCA), which are 
metabolites of CDCA. CDCA, TCDCA, and GCDCA were measured using standard 
curves prepared with stable isotope equivalents; TMCA and GMCA were estimated 
from standard curves for TCA and glycocholic acid (GCA). Ten microliters of d4-
TCDCA, d4-GCDCA, d8-TCA, and d4-GCA solutions in methanol were added to 
previously frozen, untreated rat SCH plates to yield a final concentration of 0.5-100 
pmol/well (0.5-200 pmol/well for TCA) as standards. Lysis solution (750 µL; 70:30 
[v/v] methanol:water containing 19 pmol/well d8 TCA as an internal standard) was 
added to each well of study plates and to the plates containing standards. Plates 
were shaken on a rotating plate shaker at a speed of 500 rpm for 15 min. The total 
contact time of the lysis solution with cells, prior to filtration, was ~20-30 min. The 
cell lysates were transferred to a Whatman 96-well Unifilter Plate (Whatman, 
Florham Park, NJ) with 25 µm melt blown polypropylene over 0.45 µm polypropylene 
membrane. Lysate was filtered into a Greiner 96-well Deepwell Plate by 
centrifugation at 2000 x g for 5 min. Filtrate was evaporated to dryness under 
nitrogen gas, reconstituted in 200 µL of sample diluent (60:40 [v/v] methanol:10 mM 
ammonium acetate [native pH]), and mixed for 15 min on the plate shaker at 500 
rpm. The reconstituted samples were transferred to a Whatman 96-well Unifilter 
Plate with 0.45 µm PVDF (polyvinylidene fluoride) membrane and collected into a 
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Costar 3956 96-well plate (Corning, Corning NY) by centrifugation at 2000 x g for 5 
min. The 96-well plate was sealed with a silicone capmat prior to LC-MS/MS 
analysis. Liquid handling during these procedures was accomplished using a 
Hamilton Microlab® STAR liquid handling workstation and Tomtec Quadra 96® 320 
96-well simultaneous pipetting workstation.  
 LC-MS/MS Analysis. Chromatographic separation of a 10 µL sample 
injection volume was accomplished using a Shimadzu binary high-performance 
liquid chromatography system (Columbia, MD) incorporating LC-10ADvp pumps, a 
CTO-10Avp oven, a Shimadzu HTc 96-well autosampler, and a Thermo Scientific 
Hypersil GOLD C18 column (100 x 1.0 mm, 3 µm) with matching guard and pre-
column filter. The mobile phase was initially 70% [60% 0.5 mM ammonium acetate 
(native pH):40% methanol]:30% [20% 0.5 mM ammonium acetate (native pH):80% 
methanol]. From 2-15 min, the gradient was ramped to 100% [20% 0.5 mM 
ammonium acetate (native pH):80% methanol], then stepped back to initial 
conditions [60% 0.5 mM ammonium acetate (native pH):40% methanol] over 1 min. 
The flow rate through the column was 50 µL/min, and the column was maintained at 
35°C. The autosampler was maintained at 4°C and rins ed with 1500 µL of 50:50 
(v/v) methanol:water after aspiration. Methanol (100%; 10 µL/min) was added as a 
post-column solvent to the MS. A Thermo Electron TSQ Quantum Discovery MAX 
(Thermo Fisher Scientific) with an Ion Max ESI source in negative ion electrospray 
ionization mode was used for tandem mass spectrometry. The scan type was 
selected reaction monitoring (SRM). The transitions monitored at unit resolution are 
listed in Table 2.1.  
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 Initial Uptake of CDCA and TCA in WT Rat Suspended Hepatocytes. The 
initial uptake of substrate (0.5 µM unlabeled CDCA plus 0.5 µM [14C]CDCA, 25 
nCi/ml, or 1 µM TCA plus trace [3H]TCA, 60 nCi/ml) in WT rat suspended 
hepatocytes was measured in the presence of vehicle, 10 µM TRO, or 50 µM 
MK571 using standard methods (Leslie et al. 2007) with modifications. Uptake was 
performed in Na+-containing buffer to measure total uptake (Na+-dependent and -
independent), and in Na+-free, choline-containing buffer to measure Na+-
independent uptake. Na+-dependent uptake was calculated as the difference in 
uptake between the two conditions. The viability of freshly isolated hepatocytes was 
>90% as measured by trypan blue exclusion. Briefly, cells were washed 2 x in ice-
cold buffer containing sodium chloride, or in buffer in which choline chloride was 
substituted for sodium chloride (137 mM NaCl or choline chloride, 0.8 mM MgSO4, 
10 mM HEPES, 1.2 mM CaSO4, 0.86 mM K2HPO4, 0.14 mM KH2PO4, and 5 mM 
glucose, pH 7.4). Cells were resuspended at 1.0 x 106 cells/ml in the same buffer 
and kept on ice for immediate use. Aliquots of cells (4 ml) in bottom-inverted 
Erlenmeyer flasks were preincubated at 37°C in a shaking  water bath for 5 min. 
Vehicle (0.3% DMSO), 10 µM TRO, or 50 µM MK571 was added 15 s prior to the 
addition of [14C]CDCA or [3H]TCA. At 15, 30, and 45 s, 200 µL samples of the cell 
suspension were removed, placed in a 0.4 ml polyethylene tube over a top layer of 
silicone oil:mineral oil (82:18 [v/v], 100 µL) and a bottom layer of 3M KOH (50 µL), 
and immediately centrifuged. Radioactivity in the cell pellet and in the supernatant 
was measured by liquid scintillation counting. Adherent fluid volume was determined 
by incubating cells with [14C]inulin (60 nCi/ml) using the method of Baur et al. (Baur 
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et al. 1975). Uptake was normalized to protein concentrations in the incubation 
mixtures as measured at the end of each experiment using the BCA assay (Pierce 
Biotechnology, Inc., Rockford, IL).  
 Data Analysis. The biliary excretion index (BEI), which represents the 
percentage of accumulated substrate that is excreted into bile canaliculi, was 
calculated using B-CLEAR® technology (Qualyst, Inc., Durham, NC) from the 
following equation: BEI = [(Accumulationstandard buffer – AccumulationCa2+-free 
buffer)/Accumulation standard buffer] * 100% (Liu et al. 1999). Statistical analysis (one-way 
analysis of variance [ANOVA] and Dunnett’s multiple comparison test, or two-way 
ANOVA with Bonferroni’s multiple comparison test) was performed using GraphPad 
Prism 5.03. In all cases, a p value < 0.05 was considered statistically significant.  
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Results 
 Accumulation of CDCA Species in WT and TR- Rat SCH. Accumulation of 
[14C]CDCA species in cells + bile and cells was compared in WT and TR- rat SCH, 
respectively, following a 10-min co-incubation with 1.2 µM [14C]CDCA and vehicle 
control (CTL), increasing concentrations of TRO (1-100 µM), or 50 µM MK571. In 
WT rat SCH, 1 and 10 µM TRO had no significant effect on accumulation of 
[14C]CDCA species in cells + bile or cells compared to CTL, but 100 µM TRO 
significantly decreased cell + bile accumulation, increased cellular accumulation 
nearly two-fold compared to CTL, and markedly inhibited the biliary excretion of 
[14C]CDCA species; the BEI was reduced from ~60 to ~3% (Figure 2.1). MK571 
completely inhibited the biliary excretion and significantly increased cellular 
accumulation of [14C]CDCA species 2.8-fold over CTL.  
 Accumulation of [14C]CDCA species and [3H]TCA also was measured in TR- 
rat SCH (Figure 2.2) to determine whether loss of Mrp2 alters the biliary excretion of 
[14C]CDCA species. Figure 2.2A shows that accumulation of [14C]CDCA species in 
CTL TR- cells + bile and cells was similar to WT CTL values (Figure 2.1). TRO (10 
and 100 µM) significantly decreased cells + bile accumulation of [14C]CDCA species. 
Cellular accumulation of [14C]CDCA species was notably increased in the presence 
of 100 µM TRO and 50 µM MK571, consistent with inhibition of the biliary excretion 
of [14C]CDCA species (BEI values decreased from ~56 to 10%). For comparison, 
TCA accumulation was also measured in TR- SCH (Figure 2.2B). [3H]TCA 
accumulation in CTL cells + bile was ~8.5-fold lower than the accumulation of 
[14C]CDCA species in cells + bile of TR- rat SCH, similar to differences in CDCA and 
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TCA accumulation in WT rat SCH as shown in Figure 2.1 and published previously 
(Marion et al. 2007). Both 10 and 100 µM TRO, as well as 50 µM MK571, 
significantly decreased cells + bile accumulation of [3H]TCA; although there was a 
trend towards decreased cellular accumulation of TCA in TR- rat SCH, the 
differences were not statistically significant.  
 The BEI of [14C]CDCA species was similar between CTL WT and TR- rat 
SCH; TRO appeared to decrease the BEI of [14C]CDCA species and [3H]TCA in a 
concentration-dependent manner. While MK571 ablated the biliary excretion of 
[14C]CDCA in WT cells, the effect in TR- rat SCH was not as pronounced. BEI values 
for [3H]TCA in TR- rat SCH also were decreased by TRO and MK571, but the 
decreases in BEI observed with 100 µM TRO and MK571 for [3H]TCA were less 
than the decreases in BEI for [14C]CDCA species at the same concentrations.  
 MK571-Mediated Inhibition of TCA Accumulation is Concentration 
Dependent. Increasing MK571 concentrations (10, 20, and 50 µM) significantly 
inhibited [3H]TCA accumulation in cells + bile in WT rat SCH in a concentration-
dependent manner (Figure 2.3), and there was a clear trend towards increased 
cellular accumulation of [3H]TCA at higher MK571 concentrations. The BEI of 
[3H]TCA also was decreased in a concentration-dependent manner; 50 µM MK571 
completely ablated biliary excretion of [3H]TCA.  
 Accumulation of [14C]CDCA Species and [3H]TCA is Temperature 
Dependent. The accumulation of [14C]CDCA species and [3H]TCA was measured at 
4°C in WT rat SCH in order to rule out passive uptake.  As expected, the uptake of 
[14C]CDCA species and [3H]TCA into cells + bile and cells was almost entirely 
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ablated at 4°C, and biliary excretion was negligible , consistent with temperature-
dependent, active transport processes for both BAs (data not shown).  
 Unconjugated CDCA is Metabolized in WT Rat SCH. In order to determine 
the extent of CDCA metabolism during the 10-min incubation period in the 
accumulation studies, BAs were measured by LC-MS/MS in rat SCH incubated with 
vehicle (0.1% DMSO; CTL) or 1 µM unlabeled CDCA; results are shown in Figure 
2.4. Analysis revealed that endogenous unconjugated CDCA was below the limit of 
quantification in both cells + bile and cells in CTL SCH. In CTL cells, modest 
amounts of endogenous TCDCA (6% of total), and small amounts of GCDCA and 
GMCA (1% and 3% of total, respectively), were measured, while TMCA was the 
most abundant BA measured (90% of total) (Table 2.2). TMCA was extensively 
excreted into bile (86% of total), while TCDCA was excreted into bile to a lesser 
extent (11% of total); GCDCA and GMCA accounted for 1% and 2%, respectively, of 
the BAs in bile (Table 2.2).  
 Following a 10-min incubation of WT rat SCH with exogenously administered 
CDCA, unconjugated CDCA accumulated in cells; cellular TCDCA increased ~15-
fold, GCDCA increased ~14-fold, and GMCA increased ~3-fold compared to CTL 
values (Figure 2.4). Biliary excretion of CDCA and GMCA in the bile of cells 
exposed to exogenous CDCA was negligible, while TCDCA in bile increased ~4-fold. 
Interestingly, although cells + bile accumulation of TMCA did not change between 
CTL and treated cells, cellular accumulation increased ~2-fold and accumulation in 
bile decreased 21%. Overall, following the 10-min incubation, the accumulation in 
cells + bile exogenously administered unlabeled CDCA including its conjugates (the 
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difference in total BAs before and after exogenous CDCA exposure) was about 322 
pmols/mg protein, which is consistent with the accumulation of [14C]CDCA species in 
cells + bile in WT CTL SCH (~325 pmol/mg protein, Figure 2.1). This indicates that 
the CDCA species detected by LC-MS/MS represent the majority, if not all, of the 
parent and metabolites. As summarized in Table 2.2, following exogenous exposure 
to CDCA, the amount of TCDCA, GCDCA and unconjugated CDCA increased as a 
percentage of the total BAs measured in cells and bile, while the percentage of 
TMCA and GMCA within the cells and bile decreased as a percentage of the total.  
 Initial Uptake of [14C]CDCA is Primarily Na+-Independent, While [3H]TCA 
Uptake is Primarily Na+-Dependent. Initial uptake of [14C]CDCA and [3H]TCA was 
measured in WT rat suspended hepatocytes at 15, 30, and 45 s (Figure 2.5). Pilot 
studies indicated that uptake of both BAs was linear through 90 s (data not shown). 
TRO and MK571 significantly inhibited total [14C]CDCA uptake to a similar extent 
when compared to CTL (Figure 2.5A). Na+-independent uptake of [14C]CDCA at 45 
s in CTL cells (Figure 2.5B) was 65 ± 5% of total uptake in CTL cells (set at 100%), 
which was double the Na+-independent uptake of TCA in CTL cells (Figure 2.5E). 
Both TRO and MK571 significantly inhibited Na+-independent (Figure 2.5B) and 
Na+-dependent (Figure 2.5C) [14C]CDCA uptake. For comparison, initial uptake of 
[3H]TCA also was measured under the same conditions as [14C]CDCA. TRO and 
MK571 significantly inhibited total [3H]TCA uptake to a similar extent at all time 
points (Figure 2.5D). Na+-independent uptake of [3H]TCA in CTL cells (Figure 2.5E) 
was 34 ± 12% of total uptake in CTL cells at 45 s (set at 100%) (Figure 2.5D), 
consistent with previous reports demonstrating that TCA uptake in rat hepatocytes is 
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mediated primarily by a Na+-dependent process (Kemp et al. 2005; Van Dyke et al. 
1982). Both TRO and MK571 significantly inhibited Na+-independent (Figure 2.5E) 
and Na+-dependent (Figure 2.5F) [3H]TCA uptake.  
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Discussion 
 The intracellular disposition of a substrate is dependent upon both its uptake 
and efflux. In hepatocytes, inhibition of substrate uptake or increased basolateral 
efflux may lead to decreased intracellular concentrations, whereas impaired biliary or 
basolateral excretion may cause increased intracellular concentrations. Several 
studies have shown that 10 µM TRO inhibits the uptake, intracellular accumulation, 
and biliary excretion of TCA in rat hepatocytes (Ansede et al. 2010; Kemp et al. 
2005; Marion et al. 2007) and human SCH (Marion et al. 2007). Collectively, these 
data suggest that TRO-mediated inhibition of TCA uptake by NTCP/Ntcp prevents 
the intracellular accumulation of TCA in vitro.  
 The uptake of CDCA reportedly occurs partially by a nonsaturable Na+-
independent mechanism, hypothesized to be passive diffusion, and partially by a 
saturable process (Bartholomew and Billing 1983; Iga and Klaassen 1982; Van Dyke 
et al. 1982). In cultured rat hepatocytes, uptake of CDCA was significantly, but not 
completely, reduced by the removal of Na+, and also by ouabain, a Na+-K+-ATPase 
inhibitor (Van Dyke et al. 1982), suggesting a Na+-dependent component of uptake. 
The rate of uptake of CDCA in suspended rat hepatocytes was reportedly ~10-fold 
greater than the rate of TCA uptake (Iga and Klaassen 1982). In the present study, 
the accumulation of [14C]CDCA into cells + bile in WT rat SCH was ~6-fold higher 
than accumulation of [3H]TCA in cells + bile (historically ~40-70 pmol/mg protein) 
(Lee et al. 2010; McRae et al. 2006; Wolf et al. 2010). Unlike our previous reports 
using [3H]TCA as a substrate in SCH (Kemp et al. 2005; Marion et al. 2007), 10 µM 
TRO did not decrease accumulation of [14C]CDCA species in cells + bile or in cells. 
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However, treatment with 100 µM TRO caused significant intracellular accumulation 
and completely ablated the biliary efflux of [14C]CDCA species. These results are 
significant because, to the best of our knowledge, they are the first to show that TRO 
causes an increase in the in vitro intracellular accumulation of a BA without 
uncoupling uptake from efflux, as discussed below with TCA.  
 Additionally, MK571 inhibited biliary excretion and caused significant cellular 
accumulation of [14C]CDCA species. Hepatic MRP3/Mrp3 and MRP4/Mrp4 are 
upregulated under cholestatic conditions in both rat (Denk et al. 2004; Donner and 
Keppler 2001) and human (Gradhand et al. 2008; Scheffer et al. 2002) liver, and are 
postulated compensatory routes for basolateral BA efflux. MK571 was expected to 
increase intracellular CDCA accumulation by inhibiting basolateral efflux via Mrps; 
complete ablation of biliary efflux was not anticipated because BSEP/Bsep 
transports both conjugated and unconjugated BAs into bile, and MK571 has not 
been reported to inhibit BSEP/Bsep. In contrast to BSEP/Bsep, which transports 
monovalent BAs, Mrp2 transports sulfate- and glucuronide-conjugated (divalent) 
BAs (Konig et al. 1999). Initially, impaired biliary excretion of CDCA by MK571 
suggested that unconjugated CDCA was either completely metabolized to an Mrp2 
substrate (i.e., sulfated or glucuronidated) during the 10-min incubation, or that 
MK571 inhibited Bsep-mediated biliary excretion of [14C]CDCA species in rat SCH. 
Therefore, Mrp2-deficient TR- rat hepatocytes were utilized to elucidate a potential 
role for Mrp2 in the transport of [14C]CDCA species, and to compare the effect of 
MK571 on transport of [14C]CDCA species versus [3H]TCA. Accumulation of 
[14C]CDCA species in cells + bile and cells and BEI were similar in vehicle-treated 
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TR- compared to WT rat SCH, indicating that the lack of Mrp2 did not affect the 
disposition of [14C]CDCA species in rat SCH. Furthermore, MK571 and TRO had 
similar effects on intracellular accumulation of [14C]CDCA species in WT and TR- rat 
SCH. These data suggest that CDCA and/or CDCA metabolites are Bsep 
substrates, and that TRO and MK571 inhibited Bsep-mediated biliary excretion. In 
contrast to [14C]CDCA species, 10 µM and 100 µM TRO, as well as MK571, 
significantly and substantially decreased accumulation of [3H]TCA in cells + bile, but 
had no significant effect on cellular accumulation.  
 Recently, Jemnitz et al. (2010) used the method of Lengyel et al. (2008) to 
assess the effects of TRO on basolateral and canalicular efflux of TCA in SCH. In 
these studies, [3H]TCA was preloaded into rat and human SCH by incubating them 
with [3H]TCA in the absence of inhibitor; then, [3H]TCA was washed off, and cells 
were incubated with various inhibitors or vehicle in standard HBSS or in Ca2+- and 
Mg2+-free HBSS buffer. At the end of the 10-min incubation, effluxed [3H]TCA was 
measured in the buffer and in cells + bile or in cells. Using this method, 100 µM TRO 
decreased biliary excretion and increased intracellular accumulation of [3H]TCA in 
both rat and human SCH without affecting basolateral efflux of [3H]TCA into the 
medium. These results established that TRO can cause the intracellular 
accumulation of TCA, which had not been shown using other methods in SCH. 
Previous studies in rat and human SCH did not report this effect because TRO 
inhibits TCA uptake into hepatocytes. By preloading hepatocytes with TCA, any 
inhibitory effects of compounds on BA uptake are bypassed, as in the study by 
Jemnitz et al. (2010). However, this paradigm does not realistically represent the in 
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vivo situation. BAs are highly conserved through enterohepatic cycling; basolateral 
reuptake of BAs from the blood greatly exceeds BA synthesis, and intracellular BAs 
are excreted rapidly into the bile canaliculi. This vectorial transport of BAs from blood 
to bile represents the normal circulation of BAs. In our previous studies using TCA to 
examine the disposition of BAs following TRO exposure, it appears that TRO-
mediated inhibition of [3H]TCA uptake precluded any effects on intracellular [3H]TCA 
accumulation (Kemp et al. 2005; Marion et al. 2007).  
 In rats, ~95-98% of BAs are conjugated to taurine, and the remainder to 
glycine, whereas in humans, 75% of BAs are conjugated to glycine and 25% to 
taurine (Alvaro et al. 1986); conjugation confers a negative charge, lowers the pKa, 
and increases aqueous solubility, facilitating biliary excretion (Kullak-Ublick et al. 
2004). LC-MS/MS analysis revealed that when CDCA was administered 
exogenously to SCH, 88% of total biliary BAs were taurine conjugates with 4% as 
unconjugated CDCA and the remainder as glycine conjugates (Table 2.2). The 
present results are consistent with data from Hoffman et al. (1975), showing that 
when unconjugated CDCA was injected into rats, >90% was excreted into the bile as 
the taurine conjugate, <5% as unconjugated CDCA, and a small amount was 
excreted as the glycine conjugate (Hoffman et al. 1975). TRO- and MK571 
increased cellular accumulation of [14C]CDCA species in WT and TR- rat SCH. 
These results raise the possibility that in humans, TRO may cause intracellular 
accumulation of CDCA/CDCA species. GCDCA has been shown to induce 
apoptosis in primary rat hepatocytes (Kaplowitz 2003).  
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 Based on results in SCH, TRO and MK571 were expected to have little, if 
any, effect on initial uptake of CDCA in suspended rat hepatocytes. Results 
confirmed that the majority of [3H]TCA uptake was Na+-dependent, while [14C]CDCA 
uptake was primarily Na+-independent. Surprisingly, both TRO and MK571 
decreased Na+-dependent and -independent initial uptake of [14C]CDCA. TRO 
inhibits TCA uptake in suspended rat (Kemp et al. 2005) and human (Marion et al. 
2007) hepatocytes, and in basolateral membrane vesicles (Snow and Moseley 
2006). MK571 reportedly inhibits OATP1B3 (Letschert et al. 2005) and OATP2B1 
(Letschert et al. 2006), which would explain inhibition of the Na+-independent 
component of CDCA uptake. MK571 inhibited Na+-dependent TCA uptake into 
hepatocytes. To our knowledge, there are no prior reports of MK571-mediated 
inhibition of NTCP/Ntcp. Decreased initial uptake of [14C]CDCA in suspended rat 
hepatocytes is compatible with results in SCH. Given that total intracellular 
accumulation of BAs is dependent on uptake processes as well as canalicular and 
basolateral efflux processes, then total accumulation of [14C]CDCA species in cells 
in the presence of 10 µM TRO may be the result of decreased uptake coupled with 
decreased efflux, resulting in no change in net accumulation relative to CTL. 
However, the increased intracellular [14C]CDCA accumulation with 100 µM TRO may 
indicate that 100 µM TRO does not decrease[14C]CDCA uptake further, but further 
inhibits the biliary excretion of [14C]CDCA (decreased BEI) compared with 10 µM 
TRO. Thus, TRO may have different effects on uptake and efflux depending on the 
concentration at the site of transport. 
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 In conclusion, TRO differentially affects the uptake and accumulation of 
CDCA species compared to TCA in rat SCH, causing an intracellular increase in 
CDCA species but not TCA. In addition to the known inhibitory effect of MK571 on 
MRPs, our results suggest that MK571 also inhibits Ntcp and Bsep. Overall, these 
results demonstrate that inhibitors of BA transport proteins may have differential 
effects on the disposition of individual BAs, and suggest that use of a single BA 
substrate for transport studies (i.e., TCA) may yield an incomplete picture of a 
compound’s effects on overall BA disposition.  
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Analyte Molecular Weight Salt
Retention Time 
(min) Precursor m/z Product m/z Calibration Curve Range
TCA 515.7 none 5.7 514 124 n/a
d4-TCA 519.73 none 5.7 518 124 Internal Standard                          
d8-TCA 545.73 Na+ 5.7 522 128 0.5 – 200 pmol/well              
GCA 465.62 none 5.8 464 74 n/a
d4-GCA 469.65 none 5.8 468 74 0.5 – 100 pmol/well
TCDCA 499.73 none 8.1 498 80 n/a
d4-TCDCA  503.73 none 8.1 502 80 0.5 – 100 pmol/well
GCDCA 449.62 none 8.1 448 74 n/a
d4-GCDCA 453.65 none 8.1 452 74 0.5 – 100 pmol/well
CDCA 392.57 none 10.2 5 – 1000 pmol/well
 
Table 2.1: Transitions monitored at unit resolution for LC-MS/MS analysis of parent 
CDCA and taurine- and glycine-conjugated CDCA metabolites in cell lysates from 
WT rat SCH following a 10-min incubation with 1 µM CDCA. 
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cells bile cells bile
CDCA 0 0 22 4
TCDCA 6 11 21 34
GCDCA 1 1 5 6
TMCA 90 86 50 54
GMCA 3 2 2 2
CTL Treated% of total
 
 
Table 2.2: Accumulation (% total) of CDCA, TCDCA, GCDCA, TMCA, and GMCA in 
cells and bile in rat SCH following a 10-min incubation with vehicle (0.1% DMSO; 
CTL) or treated with 1 µM exogenous CDCA (Treated).   
 
 
 
 65 
 
 
Figure 2.1: Accumulation of [14C]CDCA species in cells+bile (black bars) or cells 
(white bars) in WT rat SCH following a 10-min incubation with 1 µM [14C]CDCA and 
vehicle control (0.1% DMSO; CTL), 1, 10, or 100 µM TRO, or 50 µM MK571. The 
biliary excretion index (BEI) was calculated as described in Materials and Methods. 
Data represent the mean ± SEM of triplicate determinations in at least n = 3 livers; * 
p < 0.05 vs CTL cells+bile; ** p < 0.05 vs CTL cells.   
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Figure 2.2: Accumulation of (A) [14C]CDCA species and (B) [3H]TCA in cells + bile 
(black bars) or cells (white bars) in TR- rat SCH following a 10-min incubation with 
1.2 µM [14C]CDCA or 1 µM [3H]TCA and vehicle control (0.1% DMSO; CTL), 1, 10, 
B 
A 
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or 100 µM TRO, or 50 µM MK571. The biliary excretion index (BEI) was calculated 
as described in Materials and Methods. Data represent the mean ± SEM of triplicate 
determinations in at least n = 3 livers; * p < 0.05 vs CTL cells+bile; ** p < 0.05 vs 
CTL cells. 
 68 
 
 
Figure 2.3: Accumulation of [3H]TCA in cells + bile (black bars) or cells (white bars) 
in WT rat SCH following a 10-min incubation with 1 µM [3H]TCA and vehicle control 
(0.1% DMSO; CTL), or 10, 20, or 50 µM MK571. The biliary excretion index (BEI) 
was calculated as described in Materials and Methods. Data represent the mean ± 
SEM of triplicate determinations in n = 3 livers; * p < 0.05 vs CTL.  
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Figure 2.4: Parent CDCA and formed CDCA species (taurine- and glycine-
conjugated CDCA); TMCA, and GMCA (pmol/mg protein) in cells + bile (solid bars) 
and cells (white bars) in WT rat SCH following a 10-min incubation with vehicle CTL 
(0.1% DMSO; CTL) or 1 µM unlabeled CDCA (Treated). Data represent the mean ± 
SD of triplicate determinations in n = 1 liver.  
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Figure 2.5: Accumulation of [14C]CDCA (A, B, C) or [3H]TCA (D, E, F) in suspended 
rat hepatocytes in the presence of 1 µM [14C]CDCA or 1 µM [3H]TCA, and vehicle (● 
0.3% DMSO; CTL), 10 µM TRO (■), or 50 µM MK571 (▲). Lines represent the linear 
regression of the data using GraphPad Prism 5.03. Total accumulation (Na+-
dependent and independent) was measured in Na+-containing buffer (A, D). Na+-
independent uptake was measured in choline-containing buffer (B, E). Na+-
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dependent uptake (dashed lines) was calculated by subtracting Na+-independent 
accumulation from total accumulation (C, F, open symbols, dashed line). Data 
represent the mean ± SEM of triplicate determinations in n = 3 experiments; † p < 
0.05 vs CTL for TRO, and ‡ p < 0.05 vs CTL for MK571.   
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CHAPTER 3 
 
Endogenous Bile Acid Disposition in Rat and Human Sandwich-Cultured 
Hepatocytes: Effect of Troglitazone 
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Abstract 
 Inhibition of hepatic transport proteins may mediate drug-induced liver injury 
by increasing the intracellular accumulation of potentially toxic compounds such as 
bile acids (BAs). Therefore, drug-induced changes in hepatic BA disposition may be 
potential indicators of hepatotoxicity. In this study, differences in the endogenous BA 
pool in primary rat and human sandwich-cultured hepatocytes (SCH) was compared, 
and the effects of troglitazone (TRO)-mediated inhibition of BA transport proteins on 
cellular BA accumulation and biliary excretion was determined in this in vitro model. 
Using the B-CLEAR® method, four BAs common to both rat and human—taurocholic 
acid (TCA), glycocholic acid (GCA), taurochenodeoxycholic acid (TCDCA), and 
glycochenodeoxycholic acid (GCDCA)—were measured in cells + bile canaliculi and 
cells of SCH by LC-MS/MS following 24-h treatment with vehicle or 10 µM TRO, an 
inhibitor of the bile salt export pump (BSEP) and the Na+-taurocholate cotransporting 
polypeptide (NTCP). Total BAs were ~12-fold greater in human SCH than in rat 
SCH. Similar to in vivo reports, ~90% of BAs in rat SCH were taurine-conjugated, 
while in human SCH, 99% of BAs were glycine-conjugated. There was a trend 
toward decreased cellular accumulation of BAs in human SCH treated with TRO, but 
because variability between donors was high, differences failed to reach statistical 
significance. In rat SCH, TRO decreased biliary excretion of TCA 3%, GCA 12%, 
TCDCA 15%, and GCDCA 27%. Interestingly, in human SCH, TRO had no effect on 
GCA but decreased biliary excretion of TCA 43%, TCDCA 67%, and GCDCA 48%; 
this differential effect may be attributable to differences in intracellular concentrations 
of TRO/metabolites. Total BAs in TRO-treated human SCH were decreased by 19% 
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compared to control, suggesting that TRO may affect BA synthesis pathways. 
Together, these data demonstrate that BA synthesis and secretion occurs in SCH 
similarly to in vivo, and suggest that TRO differentially affects BA disposition in rat 
and human SCH.  
 80 
Introduction 
 Drug-induced hepatotoxicity remains the most common reason for the 
withdrawal of drugs from the market (Kaplowitz 2001). Unfortunately, this toxicity is 
frequently indiosyncratic, occuring with no clear relationship to dose or duration of 
treatment (Roth and Ganey 2010). The difficulty in predicting idiosyncratic 
hepatotoxicity necessitates further study regarding mechanisms and identification of 
potential biomarkers of injury. Recent research suggests that interference with 
normal BA transport processes may be an important mechanism of drug- and 
xenobiotic-induced hepatotoxicity (Pauli-Magnus and Meier 2006). Drugs, 
xenobiotics, or hormones can cause noninflammatory cholestasis through the 
inhibition of BA transport proteins or the retrieval of transporters from the hepatocyte 
plasma membrane (Zollner and Trauner 2008). Inhibition of these transport proteins 
may mediate drug-induced liver injury by increasing the intracellular accumulation of 
potentially toxic compounds (parent drug/xenobiotic and/or metabolites), as well as 
endogenous BAs, which can cause toxicity through detergent effects on cellular 
membranes, mitochondrial dysfunction, and ultimately cellular apoptosis or necrosis 
(Delzenne et al. 1992; Desmet 1995; Gores et al. 1998; Pauli-Magnus et al. 2005). 
Clinically, diagnosis of cholestasis includes measuring levels of alkaline 
phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), conjugated bilirubin, 
and total BAs in the blood (Pauli-Magnus and Meier 2006). The measurement of 
serum BAs has long been considered a specific and sensitive indicator of liver 
function (Barnes et al. 1975; Kaplowitz et al. 1973; Korman et al. 1974). Altered BA 
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disposition also may be an indicator for impaired BA transport and potential toxicity 
in vitro.  
 Primary hepatocytes in a sandwich-culture configuration continue to 
synthesize and secrete BAs, as well as albumin, urea, transferrin and fibrinogen; 
however, when cultured using conventional methods (i.e., on a rigid substratum or 
on collagen-coated plates), cells de-differentiate and rapidly lose hepatocyte-specific 
functions (Dunn et al. 1991). The advantage of hepatocytes cultured in a sandwich 
configuration between layers of gelled collagen or extracellular matrix is that they 
begin to repolarize hours after plating, CYP450 enzymes are expressed, transport 
proteins traffic to their proper membrane domains and are functional over days in 
culture, and adjacent cells form intact, sealed bile-canaliculi-like structures over time 
into which BAs are secreted (LeCluyse et al. 1994; Liu et al. 1999a; Liu et al. 1999b; 
Liu et al. 1999c). BA synthesis and efflux into the culture medium in SCH has been 
shown to remain relatively steady for up to 42 days in culture (Shibukawa et al. 
1995). Modulation of the integrity of the tight junctions that seal the bile canaliculi by 
washing cells in buffer with or without Ca2+ and Mg2+ allows quantification of cellular 
and biliary BAs.  
 The vectorial, active uptake and efflux of hepatic BAs, as well as other 
endobiotics and xenobiotics, are mediated by a number of transport proteins which 
are expressed in polarized hepatocytes on the basolateral (sinusoidal) or apical 
(canalicular) membrane domains. On the basolateral membrane, Na+-taurocholate 
cotransporting polypeptide (NTCP) is a sodium-dependent transporter that is 
primarily responsible for the uptake of conjugated BAs from the blood, while 
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isoforms of the Na+-independent organic anion transporting polypeptide 
(OATP/Oatp) take up conjugated and unconjugated BAs and other organic anions; 
OATP/Oatp isoforms also may function as bi-directional transporters (Trauner and 
Boyer 2003). In humans, the efflux transporters multidrug resistance-assocated 
proteins 3 and 4 (MRP3, MRP4), as well as organic solute transporter OSTα/β also 
are localized to the basolateral membrane and may function as BA efflux 
transporters when intracellular BA concentrations are increased (Borst et al. 2007; 
Geier et al. 2007; Soroka et al. 2010). On the apical membrane, BSEP and multidrug 
resistance-associated protein 2 (MRP2/Mrp2) efflux monovalent and divalent BAs, 
respectively, into the bile canaliculi (Keppler et al. 1999; Keppler and Konig 2000).  
 A number of drugs inhibit rat and/or human Bsep/BSEP-mediated biliary 
secretion of TCA in vitro including cyclosporin, glibenclamide, rifampin, bosentan, 
ritonavir, saquinavir, efavirenz, and TRO (Fattinger et al. 2001; Funk et al. 2001a; 
Kemp et al. 2005; McRae et al. 2006; Pauli-Magnus and Meier 2006; Stieger et al. 
2000). The PPARγ agonist TRO, the first thiazolidinedione insulin-sensitizing drug 
introduced to treat type II diabetes, was removed from the market because of 
hepatotoxicity, but preclinical safety testing did not predict toxicity in humans. A 
number of studies have demonstrated that TRO, and particularly its major 
metabolite, troglitazone sulfate (TS), inhibit BA transport (Funk et al. 2001a; Funk et 
al. 2001b; Kemp et al. 2005; Preininger et al. 1999). The hepatotoxicity observed in 
humans following TRO treatment may not have been observed in rats during 
preclinical testing due to species differences in the composition of the BA pools, and 
differential effects on the hepatobiliary transport of BAs.  
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 Drug-induced changes in the intra- and/or extracellular disposition of 
individual BAs may be indicators of a the hepatotoxic potential of a compound. The 
goals of this study were to profile the endogenous BA pool in an in vitro model—
primary rat and human SCH—in which the medium, intracellular, and biliary 
compartments are accessible, in order to (1) compare species differences between 
rat and human in the disposition of hepatic BAs common to both, (2) determine 
whether TRO-mediated inhibition of transport proteins causes the intracellular 
accumulation of endogenous BAs, and (3) elucidate whether distinct changes in 
intra- and extracellular accumulation and biliary excretion of individual BA species 
occur such that a particular BA would be a marker for transport inhibition. In order to 
accomplish these goals, the mass of taurocholic acid (TCA), glycocholic acid (GCA), 
taurochenodeoxycholic acid (TCDCA), and glycochenodeoxycholic acid (GCDCA), 
accumulated in cells + bile canaliculi, cells, and medium of SCH following 24-h 
treatment with vehicle or 10 µM TRO were quantified by LC-MS/MS using the B-
CLEAR® method. Furthermore, intracellular and biliary concentrations of BAs were 
calculated using estimated cell volumes for human and rat hepatocytes.  
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Materials and Methods  
 Chemicals. Troglitazone was purchased from Biomol (Plymouth Meeting, 
PA). MK571 sodium salt was obtained from Cayman Chemical (Ann Arbor, MI). 
Dexamethasone, Hanks’ balanced salt solution (HBSS) premix, HBSS without 
calcium chloride, magnesium sulfate, phenol red and sodium bicarbonate premix, 
and collagenase (type IV) were purchased from Sigma-Aldrich (St. Louis, MO). 
Collagenase (type I, class I) was obtained from Worthington Biochemical (Freehold, 
NJ). DMSO was purchased from Fisher Scientific (Fairlawn, NJ). GIBCO brand Fetal 
bovine serum, insulin, and Dulbecco’s modified Eagle’s medium were obtained from 
Invitrogen (Carlsbad, CA). ITS+ Premix (insulin, transferrin, selenium) and BD 
MatrigelTM Basement Membrane Matrix were purchased from BD Biosciences (Palo 
Alto, CA). All other chemicals and reagents were of analytical grade and were 
readily available from commercial sources.  
 Hepatocyte Isolation and Culture. Hepatocytes were isolated from male 
Wistar rats (250-300 g; Charles River Laboratories, Inc., Raleigh, NC) using a two-
step collagenase perfusion method previously described (Liu et al., 1998; Annaert et 
al., 2001). Rats were maintained on a 12 h light/dark cycle with free access to water 
and standard rodent chow, and were allowed to acclimate for at least 5 days before 
experimentation. The Institutional Animal Care and Use Committee of the University 
of North Carolina at Chapel Hill approved all procedures. Human hepatocytes were 
obtained from CellzDirect (Durham, NC) pre-plated on 6-well BioCoat plates with 
collagen type I substratum (BD Biosciences, Bedford, MA). Donor information is 
listed in Table 3.1.  
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 Rat hepatocytes were seeded at a density of 1.75 x 106 cells per well on 6-
well BioCoat plates in 1.5 ml DMEM supplemented with 5% (v/v) fetal bovine serum, 
10 µM insulin, and 1 µM dexamethasone, 2 mM L-glutamine, 1% (v/v) MEM non-
essential amino acids, 100 units penicillin G sodium and 100 µg streptomycin 
sulfate. Cells were incubated at 37°C, 5% CO2 in a humidified incubator and allowed 
to attach for 2 h, after which time the medium was aspirated to remove unattached 
cells, and replaced with fresh medium. Twenty-four hours later, on day 1 of culture, 
rat and human hepatocytes were overlaid with BD MatrigelTM basement membrane 
matrix at a concentration of 0.25 mg/ml in ice-cold DMEM supplemented with 1% 
(v/v) ITS™+ Premix, 0.1 µM dexamethasone, 2 mM L-glutamine, 1% (v/v) MEM non-
essential amino acids, 100 units penicillin G sodium and 100 µg streptomycin 
sulfate. Rat and human hepatocytes were cultured for up to 3 and 6 more days, 
respectively, to allow for the formation of canalicular networks between cells. Culture 
medium was replaced daily.  
 Determination of BAs in Cells + Bile, Cells, and Culture Medium of 
Untreated Rat SCH over Days in Culture. At 24, 48, 72, and 96 h post-seeding, 1 
ml aliquots of culture medium were collected from each of 6 wells of rat SCH and 
stored at <-70°C until analysis. The remaining 0.5 ml of the culture medium was 
aspirated and duplicate wells were rinsed briefly with 1.5 ml/well of warmed HBSS 
containing Ca2+ (cells + bile condition), while two wells were rinsed with HBSS 
without Ca2+ (cells only condition), and the wash buffer was aspirated. Following the 
wash, 1.5 ml of HBSS with or without Ca2+ was added again to wells, and cells were 
incubated for 4 min at 37°C. Incubation of SCH with C a2+-containing buffer 
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maintained the tight junctions between cells so that the bile canalicular structures 
formed between cells remained intact. Incubation of cells in Ca2+-free buffer 
disrupted the tight juctions and opened the bile canalicular structures between cells, 
allowing the contents to be washed away. Following incubation, the HBSS was 
aspirated from each well and plates were sealed and stored at <-70°C until analysis.  
 Accumulation of BAs in Cells + Bile, Cells, and Culture Medium of Rat 
and Human SCH. On day 3 (rat) or 6 (human) of culture, medium was aspirated 
from each well of rat SCH and replaced with 1.5 ml medium containing vehicle (0.1% 
DMSO) or 10 µM TRO. Cells were incubated at 37°C for an additional 24 h. 
Following incubation, 1 ml aliquots of the culture medium were collected for analysis 
of BAs in the medium, and the remaining 0.5 ml was aspirated. Triplicate wells were 
briefly rinsed 2 times with 2 ml per well of warmed HBSS with or without Ca2+. After 
the washes, 2 ml of HBSS with or without Ca2+ was added, and cells were incubated 
at 37°C for 4 min. Following the 4-min incubation, the HBSS was aspirated, and 
plates were stored at <-70°C until analysis. Human and rat SCH were handled 
identically except that human SCH were treated on day 6 of culture, and samples 
were collected 24 h later on day 7.  
 Sample Preparation for LC-MS/MS Analysis of BAs in Cell Lysates. 
Endogenous BAs were measured using standard curves prepared with stable 
isotope equivalents. Ten microliters of deuterated BAs [d8-taurocholic acid (d8-TCA), 
d4-glycocholic acid (d4-GCA), d4-taurochenodeoxycholic acid (d4-TCDCA), and d4-
glycochenodeoxycholic acid (d4-GCDCA)] solutions in methanol were added to 
previously frozen, untreated rat and human SCH plates. The final concentration 
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range for rat cell lysate analysis was 0.5 - 100 pmol/well and for human cell lysate 
analysis was 0.5 – 50 pmol/well for taurine conjugates and 10 – 1000 pmol/well for 
glycine conjugates. Lysis solution (750 µl; 70:30 methanol:water [v/v] containing 25 
nM d4-TCA as an internal standard) were added to each well of study plates and to 
plates containing standards. Plates were shaken on a rotating plate shaker (Lab-
Line Instruments Model 4625) at a speed of 500 rpm for 15 min. The total contact 
time of the lysis solution with cells, prior to filtration, was ~20–30 min. The cell 
lysates were transferred to a Whatman 96-well Unifilter Plate (Whatman, Florham 
Park, NJ) with 25 µm melt blown polypropylene over 0.45 µm polypropylene 
membrane. Lysate was filtered into a Greiner 96-well Deepwell Plate by 
centrifugation at 2000 rcf for 5 min. Filtrate was evaporated to dryness under 
nitrogen gas and then reconstituted in 200 µl of sample diluent (60:40 methanol:10 
mM ammonium acetate [native pH]) and mixed for 15 min on the plate shaker at 500 
rpm. Reconstituted samples were transferred to a Whatman 96-well Unifilter Plate 
with 0.45 µm polyvinylidene fluoride (PVDF) membrane and collected into a Costar 
3956 96-well plate (Corning, Corning NY) by centrifugation at 2000 rcf for 5 min. The 
96-well plate was sealed with a silicone capmat prior to LC-MS/MS analysis. Liquid 
handling during these procedures was accomplished using a Hamilton Microlab® 
STAR 12-pipetting channel liquid handling workstation and Tomtec Quadra 96® 320 
96-well simultaneous pipetting workstation.  
 Sample Preparation for LC-MS/MS Analysis of BAs in Culture Medium. A 
volume of 300 µl of 100% methanol containing 25 nM d4-TCA as an internal 
standard was added to a well within a Millipore 96-well MultiScreen Deep Well 
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Solvinert filter plate. This was followed by the addition of 100 µl of medium study 
sample and mixing on the plate shaker at a speed of 500 rpm for 15 min. Following 
protein precipitation, the filter plate was stacked on a deep well plate and centrifuged 
at 2000 × rcf for 5 minutes. Filtrate was evaporated to dryness under nitrogen gas 
and reconstituted in 200 µl of sample diluent (60:40 [v/v] methanol:10 mM 
ammonium acetate [native pH]) and mixed for 15 min on the plate shaker at 500 
rpm. Reconstituted samples were transferred to a Whatman 96-well Unifilter Plate 
with 0.45 µm PVDF membrane and collected into a Costar 3956 96-well plate 
(Corning, Corning NY) by centrifugation at 2000 × rcf for 5 min. The 96-well plate 
was sealed with a silicone capmat prior to LC-MS/MS analysis. Liquid handling 
during these procedures was accomplished using a Hamilton Microlab® STAR 12-
pipetting channel liquid handling workstation and Tomtec Quadra 96® 320 96-well 
simultaneous pipetting workstation.  
Endogenous BAs were measured using standard curves prepared with stable 
isotope equivalents. Ten microliters of deuterated BAs (d8-TCA, d4-GCA, d4-TCDCA, 
d4-GCDCA) solutions in methanol were added to 300 µl of 100% methanol 
containing 25 nM internal standard within a Millipore 96-well filter plate. The final 
concentration range for rat culture medium analysis was 0.5 - 50 pmol/100 µl for 
each deuterated BA and for human culture analysis was 0.5 – 50 pmol/100 µl for 
d8TCA, d4-TCDCA, and d4-GCDCA and 100 – 5000 pmol/100 µl for d4-GCA. This 
was followed by the addition of 90 µl cell culture medium and then mixing on the 
plate shaker for 15 min. Further processing of medium standard was completed as 
described for medium study samples described above. 
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 LC-MS/MS Analysis. Chromatographic separation of a 10 µl sample injection 
volume was accomplished using a Shimadzu binary high-performance liquid 
chromatography system (Columbia, MD) incorporating LC-10ADvp pumps, a CTO-
10Avp oven, a Shimadzu HTc 96-well autosampler, and a Thermo Scientific Hypersil 
GOLD C18 column (100 x 1.0 mm, 3 µm) with matching guard and pre-column filter. 
The mobile phase was initially 70% [60% 0.5 mM ammonium acetate (native 
pH):40% methanol]:30% [20% 0.5 mM ammonium acetate (native pH):80% 
methanol]. From 2-15 min, the gradient was ramped to 100% [20% 0.5 mM 
ammonium acetate (native pH):80% methanol], then stepped back to initial 
conditions [60% 0.5 mM ammonium acetate (native pH):40% methanol] over 1 min. 
The flow rate through the column was 50 µl/min, and the column was maintained at 
35°C. The autosampler was maintained at 4°C and rins ed with 1500 µl of 50:50 (v/v) 
methanol:water after aspiration. Methanol (10 µl/min; 100%) was added as a post-
column solvent to the MS. A Thermo Electron TSQ Quantum Discovery MAX 
(Thermo Fisher Scientific) with an Ion Max ESI source in negative ion electrospray 
ionization mode was used for tandem mass spectrometry. The scan type was 
selected reaction monitoring (SRM). The transitions monitored at unit resolution are 
listed in Table 3.2.  
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Results 
 
 Determination of BAs in Cells + Bile, Cells, and Medium of Untreated Rat 
SCH over Days in Culture. Total BAs (sum of TCA, GCA, TCDCA, and GCDCA) 
were measured in cells + bile, cells, and medium in rat SCH over days 1 to 4 of 
culture (Figure 3.1). BAs in cells + bile and in cells tended to decrease over days 1 
to 4 in culture, while the mass of total BAs in the bile (cells + bile minus cells) 
remained relatively constant. These data confirm that BAs do not accumulate in the 
cells over days in culture. Unlike cells + bile and cells, total BAs in the culture 
medium remained relatively equal over days 1 and 2, but increased 2.6-fold from 
day 2 to day 3, and increased 3.1-fold from day 2 to day 4.  
 Accumulation of BAs in Cells + Bile, Cells, and Medium of Rat and 
Human SCH. Experiments were designed to compare the BA pools between rat and 
human SCH. Figures 3.2 – 3.5 show the accumulation of TCA, GCA, TCDCA, and 
GCDCA, respectively, in cells + bile, cells, and medium of rat and human SCH 
following 24-h treatment with vehicle or 10 µM TRO. In controls, accumulation of 
TCA in cells + bile, cells, and medium in rat SCH was about 3-fold, 2-fold, and 20-
fold higher, respectively, than in human SCH (Figure 3.2). Treatment with TRO 
appeared to decrease TCA accumulation in cells + bile and cells in human, but not 
rat SCH; however, because of variability, the differences were not statistically 
significant. In rat SCH, TRO treatment decreased the BEI of TCA by 3% compared 
to control (Table 3.3) whereas in human SCH, TRO decreased the BEI of TCA by 
43% compared to control (Table 3.4). In contrast, accumulation of GCA in cells + 
bile, cells, and medium in human SCH was over 1000-fold, 1300-fold, and 80-fold 
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higher, respectively, than in rat SCH (Figure 3.3). Treatment with TRO appeared to 
decrease GCA accumulation in cells + bile and cells in human SCH, but the effect 
was not statistically significant. GCA was the only BA to accumulate within cells 
following TRO treatment; the effect was only observed in rat SCH. Overall 
accumulation of GCA was quantitatively far less than the other BAs. TRO treatment 
decreased the BEI of GCA by 12% compared to control in rat SCH (Table 3.3), but 
had no inhibitory effect on the BEI of GCA in human SCH (Table 3.4). The relative 
abundance of TCA versus GCA in rat versus human SCH was consistent with 
published reports: taurine conjugation of BAs is greater in the rat, and conjugation of 
BAs to glycine is greater in humans.  
 The trends observed with TCA and GCA also were observed with TCDCA 
and GCDCA. In controls, accumulation of TCDCA in cells + bile, cells, and medium 
in rat SCH was about 2.5-fold, 2.4-fold, and 12-fold higher, respectively, than in 
human SCH (Figure 3.4). Treatment with TRO also appeared to decrease TCDCA 
accumulation in cells + bile and cells in both human and rat; however, because of 
variability, the differences were not statistically significant. TRO treatment decreased 
the BEI of TCDCA by 15% compared to control in rat SCH (Table 3.3), and by 67% 
compared to control in human SCH (Table 3.4). Accumulation of GCDCA in cells + 
bile, cells, and medium in human SCH was over 400-fold, 450-fold, and 30-fold 
higher, respectively, than in rat SCH (Figure 3.5). Treatment with TRO appeared to 
decrease GCDCA accumulation in cells + bile and cells in human, but the effect was 
not statistically significant. In rat SCH, TRO treatment decreased the BEI of GCDCA 
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by 27% compared to control (Table 3.3), while in human, TRO decreased the BEI of 
GCDCA by 48% compared to control (Table 3.4).  
 Accumulation of total BAs (the sum of all BAs measured) in rat and human 
SCH are shown in Figure 3.6. The medium accumulation of total BAs was about 9-
fold higher in human than in rat SCH; likewise, cells + bile and cell accumulation of 
total BAs were about 57-fold and 70-fold higher, respectively, in human than rat 
SCH. Total BAs in cells + bile plus medium of human SCH treated with TRO were 
decreased by 19% of control, suggesting that TRO might affect BA synthesis 
pathways. Figure 3.7 shows the contribution of each individual BA species as a 
percentage of the total in cells + bile, cells, bile, and medium of rat and human SCH. 
Overall, about 90% of BAs in rat SCH were conjugated to taurine, and 10% to 
glycine. In human SCH, about 99% of BAs were conjugated to glycine and 1% to 
taurine. In rat SCH, TCDCA was the predominant BA in cells, while TCA was the 
most abundant BA in the bile and medium. GCA and GCDCA together comprised 
16% or less of the total BAs in all compartments in both control and TRO-treated rat 
SCH. TRO appeared to have little effect on the relative percentages of the individual 
BAs in each compartment of rat SCH. In human SCH, GCDCA was the most 
abundant BA in cells, while GCA was predominant in bile and medium. TCA and 
TCDCA comprised less than 1% of the total BAs in all compartments in both control 
and TRO-treated human SCH. TRO appeared to increase GCDCA in cells, at the 
same time decreasing GCDCA in the bile, although due to variability, these 
differences were not statistically significant.  
 93 
 Estimates for individual and total BA concentrations in cells + bile and cells 
were calculated based on estimates of hepatocyte intracellular volume and the 
number of cells/well (6.83 µl cells/well for rat SCH, 6.79 µl cells/well for human) (Lee 
et al., 2010), (Tables 3.3 and 3.4); concentrations for total cholic acid (CA) species 
(TCA + GCA) and total chenodeoxycholic acid species (TCDCA + GCDCA) are 
presented in Table 3.5. Concentrations of BAs in the medium were calculated using 
a volume of 1.5 ml/well. Based on these estimates, intracellular concentrations of the 
total BAs measured were about 70-fold higher in human than in rat SCH, while 
concentrations in the medium were only about 8-fold higher in human than in rat 
SCH. BA concentrations in the bile compartment were not estimated because the 
volume of the bile canalicular spaces is not known.  
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Discussion 
 BAs Decreased in Cells + Bile and Cells, but Increased in Medium, of 
Untreated Rat SCH over Days in Culture. Initial experiments were carried out in 
order to characterize the disposition of BAs over time in culture in the intracellular, 
biliary, and medium compartments of rat SCH. The mass of total BAs in cells + bile 
and cells decreased over time while total BAs in bile remained relatively constant; 
thus it appears that the increase in BAs in the culture medium over time may be due 
to increased BA synthesis starting on day 3 of culture. Whether the increase is a 
recovery of normal synthesis capability following the isolation process, or a response 
to culture conditions, is unclear. However, it has been reported that cholesterol 7α-
hydroxylase (the rate-limiting enzyme for BA synthesis) mRNA levels increased 
several-fold from day 2 to day 4 and then declined in human SCH (Ellis et al. 1998). 
While our studies only measured BAs up to day 4 in rat, Sauter et al. (1996) reported 
that total BA efflux into the culture medium by human SCH remained relatively 
constant from days 4-12 of culture (Sauter et al. 1996).  
 Importantly, these data also demonstrate that in this in vitro model, BAs do 
not accumulate in hepatocytes over time in culture, indicating that efflux 
mechanisms are functional and that the model is not inherently cholestatic. 
However, it is not clear whether increasing BAs in the medium over time are 
preferentially effluxed into the medium from the basolateral membrane (i.e., by 
Mrp4), or whether BAs are effluxed into the medium from contractions of the bile 
canaliculi. In rat liver in vivo, contractions of the bile canaliculi mediated by actin 
filaments facilitate bile flow (Watanabe et al. 1991). Similar regular, ordered 
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contractions have been reported in the bile canaliculi of isolated hepatocyte couplets 
in vitro (Oshio and Phillips 1981; Phillips et al. 1982). Contractions of the bile 
canaliculi in the SCH model may release accumulated BAs into the culture medium 
over time.  
 Alternatively, while MRP4/Mrp4 normally is expressed at low levels in 
hepatocytes, it is induced in cholestasis, presumably as an adaptive response 
mechanism to compensate for increased intracellular concentrations of BAs; such 
induction in vivo may explain the increased excretion of BAs in the urine of patients 
with cholestasis (Assem et al. 2004; Schuetz et al. 2001; Zollner et al. 2003). If 
intracellular BAs increase over time, MRP4/Mrp4 protein expression and/or 
membrane localization may increase in order to compensate. The canalicular 
transport proteins P-gp, BSEP, and MRP2 reside inside intracellular compartments 
and are capable of trafficking, within minutes, to the canalicular membrane under 
increased demand for BA and organic anion efflux (reviewed in Kipp and Arias 
2002). This rapid insertion of transport proteins into the membrane allows for more 
rapid upregulation of transport capability than would be possible through increased 
protein synthesis. Therefore, while basal MRP4 expression is considered low in liver, 
it is possible that increased membrane trafficking of the protein from cytosolic 
vesicular compartments may increase MRP4-mediated BA efflux.  
 Clear Species Differences are Evident in BA profiles of Rat versus 
Human SCH. BA profiles between rat and human SCH differed in two prominent 
ways. First, the total mass of BAs was about 12-fold greater in human SCH than in 
rat SCH. Second, taurine-conjugated BAs predominated in rat SCH, while glycine-
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conjugated BAs predominated in human SCH. It has been reported that cultured 
human hepatocytes have a greater capacity to produce BAs than cultured rat 
hepatocytes, even though the synthesis of BAs in rat liver in vivo is 3- to 5-fold 
higher than that in human liver (Ellis et al. 1998). Although variability was high in 
human SCH in this study, the results were consistent with this observation. 
Variability was not entirely unexpected; in historic controls for human plasma BA 
concentrations, variability in CA and CDCA concentrations were 103-115% and 62-
84% (Ahlberg et al. 1977; Tagliacozzi et al. 2003). In rodents, but not humans, 
CDCA can be hydroxylated and conjugated to form glyco- and tauromuricholic acids 
(GMCA and TMCA). Because humans do not synthesize these BAs, they were not 
included in this study; however, limited analysis of GMCA and TMCA in rat SCH 
suggested that the mass of BAs in rat including TMCA and GMCA would still have 
been several-fold lower than in human (data not shown).  
 Overall, taurine-conjugated BAs comprised 90% of BAs in the rat SCH, 
consistent with previous reports that ~94-98% of BAs in rats are conjugated to 
taurine (Alvaro et al. 1986; Mizuta et al. 1999; Pellicoro et al. 2007). In human SCH, 
99% of BAs were conjugated to glycine and 1% to taurine; these values are 
considerably greater than the value of ~75% glycine conjugates and ~25% taurine 
conjugates in human plasma and bile reported in the literature (Alvaro et al. 1986; 
Byrne et al. 2002; Tagliacozzi et al. 2003). An explanation for the decreased taurine 
conjugation of BAs in human SCH is unclear. One reason could be depletion of 
available taurine; hepatic taurine concentrations are a major determinant of the 
proportion of BAs conjugated with taurine versus glycine (Hardison and Proffitt 
 97 
1977). When homogenates of both human and rat liver were exposed to equimolar 
concentrations of taurine and glycine, conjugation of CA to taurine predominated, 
but when human liver homogenates were exposed to high concentrations of glycine, 
conjugation of CA to glycine predominated. Therefore, because glycine is easily 
synthesized and not readily depleted in vivo, the concentration of available taurine 
determines the amount of BAs conjugated to taurine (Gottfries et al. 1966). While 
both rat and human SCH were exposed to the exact same culture conditions, rat 
hepatocytes were treated on day 3 and collected on day 4, while human hepatocytes 
were treated on day 6 and collected on day 7 because bile canaliculi formation in 
human SCH is slower than in rat SCH. Alternatively, preferential glycine-conjugation 
of BAs in human SCH may be the result of altered function of bile acid–coenzyme 
A:amino acid N-acyltransferase (BAAT), the single enzyme responsible for the 
conjugation of BAs to both glycine and taurine in humans.  
 Intracellular and Medium Concentrations of BAs Were Estimated Using 
the B-CLEAR® System. Concentrations of BAs were estimated in cells + bile and 
cells using estimates for cell volume described in Materials and Methods, while BA 
concentrations in the medium were based on a volume of 1.5 ml/well. Direct 
comparisons of intracellular concentrations of BAs between this study and other 
published values are difficult; efflux of total BAs into the culture medium is most 
commonly reported for in vitro studies, and studies wherein BAs are measured in rat 
or human liver tissue are likely to also contain residual BAs from bile canaliculi within 
the tissue. Furthermore, the same BAs are not always measured in each study. 
However, our estimate for the concentration of total BAs (TCA + GCA + TCDCA + 
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GCDCA) in the medium of rat SCH (0.36 ± 0.19 µM) is comparable to the published 
concentration of 0.13 ± 0.02 µM in rat conventionally-cultured hepatocytes (Ellis et 
al. 1998). In contrast, Dunn et al. (1991) reported a BA secretion rate for total BAs in 
rat SCH of ~1.2 nmol/hr in 4 ml medium; this translates to a much higher maximum 
concentration of ~7 µM over a 24-h period (Dunn et al. 1991). The concentration of 
BAs in the medium of human SCH (3.25 ± 1.99 µM), also is in good agreement with 
the published value of 3.68 ± 1.47 µM (Ellis et al. 1998), and for human plasma BA 
concentrations of ~3-10 µM (Ahlberg et al. 1977; Tagliacozzi et al. 2003). The 
intracellular concentration of total BAs in humans in vivo is thought to be maintained 
at < 3 µM through efficiently coupled uptake and efflux, as well as intracellular 
binding of BAs to cytosolic BA binding proteins (Hofmann 1999), although 
intracellular BA concentrations can be as high as 200 µM (Blitzer and Boyer 1982). 
The intracellular concentration of total BAs in rat SCH (2.6 ± 1.3 µM) was 
comparable to this value, whereas intracellular concentrations of total BAs in human 
SCH were much higher than in rat (183.5 ± 155.2 µM), but variability was also quite 
high. It is possible that hepatocytes from individual human subjects have differing 
capacities for BA synthesis based on underlying genetic factors, disease states of 
donor tissue, or liver exposure to drugs/xenobiotics prior to tissue collection.  
 TRO Displayed Minimal Effects on BA Profiles of Rat versus Human 
SCH. TRO trended to decrease BA accumulation in cells of both rat and human 
SCH; only the intracellular accumulation of GCA was increased in rat SCH. Effects 
on BEI were more pronounced. In particular, in rat SCH, TRO decreased the BEI of 
TCDCA, which was the most abundant BA in cells, by 15%; in human SCH, TRO 
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decreased the BEI of GCDCA, which was the most abundant BA, by 48%. TRO-
mediated inhibition of the BEI of TCDCA and GCDCA, did not increase 
concentrations of these BA species in cells. TRO inhibits both the NTCP/Ntcp-
mediated uptake and BSEP/Bsep-mediated canalicular excretion of exogenously 
administered [3H]TCA in both rat and human hepatocytes (Kemp et al. 2005; Marion 
et al. 2007). Thus, even though the BEI of [3H]TCA is decreased, inhibition of 
[3H]TCA uptake may prevent increased intracellular accumulation of TCA. The same 
may be true for TCDCA and GCDCA; TRO-mediated inhibition of BA reuptake from 
the culture medium might also account for the decreased cellular accumulation. TRO 
also decreased the mass of total BAs by 19% compared to control, suggesting that 
overall BA synthesis was compromised. TRO has been shown to reduce cholesterol 
synthesis in HepG2 cells and Caco2 cells (Klopotek et al. 2006), which may in turn 
decrease BA synthesis.  
 Data concerning the intracellular concentrations of xenobiotics (drugs, toxins, 
etc.) at the target organ or tissue often are limited, especially in human studies. 
However, intracellular concentrations may be a critical determinant of efficacy and/or 
toxicity. Rat and human SCH models are useful for determining the cellular and 
biliary disposition of xenobiotics, as well as the targets of these xenobiotics (i.e., 
BAs), since it is possible to measure BAs in the cells + bile, cells, and medium 
compartments directly, and the bile compartment indirectly. In this study, BA profiles 
in rat and human hepatocytes were similar to those reported in the literature. 
Treatment with TRO decreased the intracellular accumulation of BAs, and also 
decreased biliary excretion, consistent with previously published acute studies of 
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[3H]TCA hepatobiliary disposition in the presence of TRO. Overall, the impact of 
TRO on BA transport, whether endogenous or exogenous, appears to be directed 
towards decreased hepatic exposure to potentially cytotoxic BAs.  
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Donor HU0803 HU1067 HU1184 HU1191
Age 42 61 73 19
Sex male male female male
Race Caucasian Caucasian Caucasian Caucasian
Height (in) 72 76 66 74
Weight (lb) 240 215 150 152
BMI (%) 32.6 26.2 24.2 19.5
Smoker no no no no
Alcohol Use rare no rare no
Serology not known not tested Hep B and Hep C: non-reactive Hep B and Hep C: non-reactive
HIV: not tested HIV: not tested
Medications not known Zantac  300 mg QD Hydrochlorithiazide 12.5 mg QDnone
Prilosec 20 mg BID Flagyl
Allegra 180 mg QD
Diltiazem CD 180 mg QD
Iron
Multivitamin
Vitamin D
 
 
Table 3.1: Demographic data for human liver donors.  
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TCA 515.7 none 5.7 514 124
d8-TCA 545.73 Na+ 5.7 522 128
d4-TCA (IS) 519.73 none 5.7 518 124
TCDCA 499.7 none 8.1 498 80
d4-TCDCA  503.73 none 8.1 502 80
GCA 465.62 none 5.8 464 74
d4-GCA 469.65 none 5.8 468 74
GCDCA 449.62 none 8.1 448 74
d4-GCDCA 453.65 none 8.1 452 74
Analyte
Molecular 
Weight Salt
Retention 
Time (min) Precursor m/z Product m/z
 
 
Table 3.2: Transitions monitored at unit resolution for LC-MS/MS analysis.  
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Rat cells + bile (µM) cells (µM) medium (µM) BEI (%)
CTL 2.15 ± 0.67 0.73 ± 0.14 0.252 ± 0.112 66.2
TRO 2.17 ± 0.43 0.77 ± 0.11 0.265 ± 0.142 64.4
CTL 0.12 ± 0.04 0.06 ± 0.01 0.029 ± 0.022 50.0
TRO 0.13 ± 0.07 0.07 ± 0.01 0.031 ± 0.025 44.1
CTL 2.23 ± 1.04 1.62 ± 1.01 0.054 ± 0.049 27.3
TRO 1.64 ± 0.65 1.26 ± 0.67 0.050 ± 0.044 23.1
CTL 0.37 ± 0.07 0.23 ± 0.10 0.030 ± 0.010 37.3
TRO 0.29 ± 0.03 0.21 ± 0.05 0.024 ± 0.004 27.2
TCA
GCA
TCDCA
GCDCA
 
 
Table 3.3: BEI (%) and concentrations (µM) of BAs in cells + bile, cells, and medium 
in rat SCH. Calculations assume a hepatocyte volume of 6.83 µl cells/well of a 6-well 
plate for rat SCH (Lee et al., 2010). 
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Human cells + bile (µM) cells (µM) medium (µM) BEI (%)
CTL 0.7 ± 0.41 0.39 ± 0.19 0.013 ± 0.006 44.3
TRO 0.33 ± 0.18 0.25 ± 0.08 0.011 ± 0.005 25.4
CTL 136.6 ± 111.5 78.78 ± 64.01 2.341 ± 1.359 42.3
TRO 59.0 ± 46.0 32.46 ± 26.89 2.336 ± 1.498 45.0
CTL 0.88 ± 0.25 0.67 ± 0.15 0.005 ± 0.002 24.0
TRO 0.47 ± 0.03 0.43 ± 0.06 0.004 ± 0.001 8.0
CTL 142.57 ± 130.02 103.63 ± 90.89 0.891 ± 0.614 27.3
TRO 73.82 ± 70.05 63.44 ± 62.35 0.706 ± 0.392 14.1
TCA
GCA
TCDCA
GCDCA
 
Table 3.4: BEI (%) and concentrations (µM) of BAs in cells + bile, cells, and medium 
in human SCH. Calculations assume a hepatocyte volume of 6.79 µl cells/well of a 
6-well plate for human SCH (Lee et al., 2010).  
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cells + bile (µM)* cells (µM)* medium (µM)
CA 2.3 ± 0.7 0.8 ± 0.2 0.3 ± 0.1
CDCA 2.6 ± 1.1 1.9 ± 1.1 0.1 ± 0.1
total 4.9 ± 1.8 2.6 ± 1.3 0.4 ± 0.2
cells + bile (µM)** cells (µM)** medium (µM)
CA 137.3 ± 111.9 79.2 ± 64.2 2.4 ± 1.4
CDCA 143.5 ± 130.3 104.3 ± 91.0 0.9 ± 0.6
total 280.8 ± 242.2 183.5 ± 155.2 3.3 ± 2.0
CTL Rat
CTL 
Human
 
 
Table 3.5: Concentration (µM) of total CA species (TCA + GCA) and total CDCA 
species (TCDCA + GCDCA) in cells + bile, cells, and medium of CTL rat and human 
SCH. * Assumes a hepatocyte volume of 6.83 µl cells/well of a 6-well plate for rat 
SCH; ** assumes a hepatocyte volume of 6.79 µl cells/well of a 6-well plate for 
human SCH (Lee et al., 2010).  
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Figure 3.1: Total accumulation (pmol/mg protein) of total BAs in cells + bile (solid 
bars), cells (open bars), and medium (hatched bars) in rat SCH over days 1 through 
4 of culture. Values represent mean ± range of duplicate measurements in n = 2 
experiments (cells + bile and cells) or mean ± SD of 6 individual measurements in n 
= 1 experiment.  
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Figure 3.2: Accumulation (pmol/mg protein) of TCA in cells + bile (solid bars), cells 
(open bars), and medium (hatched bars) in rat and human SCH following 24-h 
treatment with vehicle (0.1% DMSO) or 10 µM TRO. In rat SCH, values represent 
the mean ± SEM of triplicate measurements (cells + bile and cells) in n = 3 
experiments, and mean ± range (medium) of 3-6 measurements in n = 2 
experiments. In human SCH, values represent mean ± SD of duplicate 
measurements (cells + bile and cells) in n = 4 experiments and mean ± SD of 2-6 
measurements (medium) in n = 4 experiments. 
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Figure 3.3: Accumulation (pmol/mg protein) of GCA in cells + bile (solid bars), cells 
(open bars), and medium (hatched bars) in rat and human SCH following 24-h 
treatment with vehicle (0.1% DMSO) or 10 µM TRO. In rat SCH, values represent 
the mean ± SEM of triplicate measurements (cells + bile and cells) in n = 3 
experiments, and mean ± range (medium) of 3-6 measurements in n = 2 
experiments. In human SCH, values represent mean ± SD of duplicate 
measurements (cells + bile and cells) in n = 4 experiments and mean ± SD of 2-6 
measurements (medium) in n = 4 experiments. Inset shows accumulation of GCA in 
cells + bile, cells, and medium in rat SCH with the y-axis scaled for easier 
visualization.  
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Figure 3.4: Accumulation (pmol/mg protein) of TCDCA in cells + bile (solid bars), 
cells (open bars), and medium (hatched bars) in rat and human SCH following 24-h 
treatment with vehicle (0.1% DMSO) or 10 µM TRO. In rat SCH, values represent 
the mean ± SEM of triplicate measurements (cells + bile and cells) in n = 3 
experiments, and mean ± range (medium) of 3-6 measurements in n = 2 
experiments. In human SCH, values represent mean ± SD of duplicate 
measurements (cells + bile and cells) in n = 4 experiments and mean ± SD of 2-6 
measurements (medium) in n = 4 experiments.  
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Figure 3.5: Accumulation (pmol/mg protein) of GCDCA in cells + bile (solid bars), 
cells (open bars), and medium (hatched bars) in rat and human SCH following 24-h 
treatment with vehicle (0.1% DMSO) or 10 µM TRO. In rat SCH, values represent 
the mean ± SEM of triplicate measurements (cells + bile and cells) in n = 3 
experiments, and mean ± range (medium) of 3-6 measurements in n = 2 
experiments. In human SCH, values represent mean ± SD of duplicate 
measurements (cells + bile and cells) in n = 4 experiments and mean ± SD of 2-6 
measurements (medium) in n = 4 experiments. Inset shows accumulation of GCDCA 
in cells + bile, cells, and medium in rat SCH with the y-axis scaled for easier 
visualization.  
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Figure 3.6: Accumulation (pmol/mg protein) of total BAs measured in cells + bile 
(solid bars), cells (open bars), and medium (hatched bars) in rat and human SCH 
following 24-h treatment with vehicle (0.1% DMSO) or 10 µM TRO. In rat SCH, 
values represent the mean ± SEM of triplicate measurements (cells + bile and cells) 
in n = 3 experiments, and mean ± range (medium) of 3-6 measurements in n = 2 
experiments. In human SCH, values represent mean ± SD of duplicate 
measurements (cells + bile and cells) in n = 4 experiments and mean ± SD of 2-6 
measurements (medium) in n = 4 experiments. Inset shows accumulation of BAs in 
cells + bile, cells, and medium in rat SCH with the y-axis scaled for easier 
visualization.  
 112 
 
0%
20%
40%
60%
80%
100%
c
e
lls
 
+
 
bi
le
c
e
lls bi
le
m
e
di
u
m
c
e
lls
 
+
 
bi
le
c
e
lls bi
le
m
e
di
u
m
c
e
lls
 
+
 
bi
le
c
e
lls bi
le
m
e
di
u
m
c
e
lls
 
+
 
bi
le
c
e
lls bi
le
m
e
di
u
m
Rat CTL RAT TRO Human CTL Human TRO
%
 
To
ta
l B
ile
 
A
c
id
s
GCDCA
TCDCA
GCA
TCA
 
 
Figure 3.7: Accumulation of individual BA species as percent of total in cells + bile, 
cells, bile, and medium in rat and human SCH following 24-h treatment with vehicle 
(0.1% DMSO) or 10 µM TRO.  
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CHAPTER 4 
 
Inhibition of MRP4-Mediated Taurocholic Acid Transport by Troglitazone 
Sulfate 
 120 
Abstract 
 Multidrug resistance-associated protein 4 (MRP4) is an efflux transport 
protein expressed on the basolateral (sinusoidal) membrane of hepatocytes. 
Because MRP4 mRNA and protein are upregulated in humans during cholestasis, 
MRP4 may play a role in the compensatory efflux of excess intracellular bile acids 
(BAs). If this compensatory efflux route is compromised, for example by xenobiotics, 
or a disease state, or polymorphism, cytotoxicity may ensue. Inhibition of BA 
transport has been hypothesized as one mechanism by which the drug troglitazone 
(TRO) causes hepatotoxicity. TRO inhibits basolateral uptake of BAs via Na+-
taurocholate cotransporting polypeptide (NTCP/Ntcp), and inhibits canalicular BA 
efflux via the bile salt export pump (BSEP/Bsep); TRO also inhibits organic anion 
transport polypeptide (Oatp) isoforms in rat. The major metabolite of TRO, TRO-
sulfate (TS), is an even more potent inhibitor of BSEP/Bsep than TRO. Whether TS 
inhibits MRP4-mediated BA efflux is not known. This study was designed to assess 
the potential for TS-mediated inhibition of compensatory BA transport by MRP4 by 
measuring uptake of [3H]TCA in the presence of TS in membrane vesicles from 
HEK293 cells overexpressing MRP4 protein. Initial pilot studies showed that TS is a 
substrate of MRP4, and inhibits uptake of the known MRP4 substrates methotrexate 
(MTX) and dehydroepiandrosterone sulfate (DHEAS). Uptake of [3H]TCA by MRP4 
was linear for up to 5 min; TS inhibited [3H]TCA uptake in a concentration-dependent 
manner. These results suggest that, in addition to inhibition of BSEP/Bsep-mediated 
biliary efflux of BAs, TRO (via TS) may mediate its toxic effect through inhibition of 
compensatory basolateral BA efflux. Impaired MRP4 function in susceptible 
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individuals may cause intracellular accumulation of BAs, TS, or both. 
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Introduction 
 Multidrug resistance-associated protein 4 (MRP4) is a member of the ATP-
binding cassette (ABC) transport protein superfamily that uses the energy from the 
hydrolysis of ATP to transport substrates. MRP4 protein is expressed in a number of 
different tissues, including the liver (Rius et al. 2003) and kidneys (van Aubel et al. 
2002). In the liver, MRP4 is localized to the basolateral (sinusoidal) hepatocyte 
membrane, and excretes substrates such as conjugated steroids, prostanoids, cyclic 
nucleotides, bile acids (BAs), and sulfated conjugates of xenobiotics (reviewed in 
Borst et al. 2007) from hepatocytes into the sinusoidal blood. MRP4 protein normally 
is expressed at low levels in hepatocytes, but is induced during cholestasis in 
humans (Gradhand et al. 2008), and also in mice (Mennone et al. 2006) and rats 
(Denk et al. 2004), presumably as an adaptive response mechanism to compensate 
for increased intracellular concentrations of BAs. Interestingly, increased MRP4 
protein expression on the basolateral membrane of hepatocytes can occur without 
concurrent increased MRP4 mRNA (Denk et al. 2004), suggesting that post-
translational mechanisms participate in increased protein mobilization to the 
membrane.  
 Troglitazone (TRO), a peroxisome proliferator-activated receptor γ (PPARγ) 
agonist marketed for the treatment of noninsulin-dependent type II diabetes, was 
removed from the U.S. market three years after its release following numerous 
reports of idiosyncratic hepatotoxicity. Inhibition of BA transport leading to 
cholestatic liver injury is one proposed mechanism for TRO’s hepatotoxicity. TRO is 
metabolized primarily to a sulfate conjugate (TS) in humans (Honma et al. 2002; 
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Kawai et al. 1997), and to a quinone (TQ) (Yamazaki et al. 1999); a glucuronide 
conjugate (TG) also is formed to a lesser extent (Watanabe et al. 2002; Yoshigae et 
al. 2000). Of the metabolites detected in human plasma at steady-state after multiple 
oral dosing for 7 days, the sulfate and quinone metabolites of TRO predominated, 
making up 70% and 10%, respectively (Loi et al. 1999a; Loi et al. 1997), while the 
glucuronide conjugate was a minor metabolite in plasma (Loi et al. 1999b; Parke-
Davis 1998). TRO inhibits both basolateral BA uptake in human and rat hepatocytes 
via NTCP/Ntcp and canalicular BA efflux via BSEP/Bsep (Kemp et al. 2005; Marion 
et al. 2007); however, TS, the major metabolite of TRO, is an even more potent 
inhibitor of BSEP/Bsep than TRO (Funk et al. 2001a; Funk et al. 2001b).  
 Studies examining the disposition of TRO in rats showed that there was a 
high degree of TS accumulation in liver; accumulation was greater in males, and 
was attributed to an increased rate of sulfation in male rats as compared to females 
(Funk et al. 2001a). In in vitro studies using rat sandwich-cultured hepatocytes 
(SCH), TS also accumulated within hepatocytes to a greater extent than TRO or its 
glucuronide or quinone metabolites (Lee et al. 2009). Under cholestatic conditions, 
BAs, especially sulfated BAs, increase in the plasma and urine (Assem et al. 2004; 
Schuetz et al. 2001; Zollner et al. 2003). Induction of MRP4 may account for these 
changes in BA disposition, since MRP4 effluxes sulfated steroids (Zelcer et al. 
2003), and both unsulfated and sulfated BAs into the blood (Geier et al. 2007). 
Sulfated BAs in particular are not substrates of BSEP, so removal from the liver by 
MRP4 presents a potential mechanism for protecting the liver from further damage 
(Assem et al. 2004). Therefore, TS and BAs may compete for transporter-mediated 
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efflux from the hepatocyte. If basolateral efflux is compromised (i.e., due to impaired 
MRP4 function), then toxicity may be exacerbated if TS and/or BAs accumulate.  
 In this study, a role for MRP4 in the efflux of TS and BAs was explored. 
Membrane vesicles were prepared from untransfected (CTL) or transfected HEK293 
cells overexpressing MRP4 protein. Pilots studies determined that TS was both a 
substrate of MRP4 and inhibited uptake of known MRP4 substrates. MRP4-
mediated uptake of [3H]TCA was measured in the presence of increasing 
concentrations of TS to assess inhibition of BA transport; data revealed that TS 
inhibited [3H]TCA transport in a concentration-dependent manner. This interaction 
between TS, BAs, and MRP4 provides another potential mechanism by which TRO 
can cause the intrahepatic accumulation of BAs.  
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Materials and Methods 
 Chemicals. [3H]TCA (5 Ci/mmol; purity > 97%) and [3H]dehydroepiandro-
sterone sulfate (DHEAS) (63 Ci/mmol; purity > 97%) were purchased from Perkin 
Elmer (Waltham, MA). [3H]Methotrexate (MTX) (24 Ci/mmol; purity > 97%) was 
acquired from Moravek (Brea, CA). TS was a gift from Daiichi Sankyo Co., LTD., 
Tokyo, Japan. Dulbecco’s modified Eagle’s medium (DMEM) with phenol red, and 
MAX Efficiency® DH5α™ Competent Cells were purchased from Invitrogen 
(Carlsbad, CA). Cellgro® fetal bovine serum (FBS) was acquired from Mediatech, 
Inc. (Manassas, VA). Dimethyl sulfoxide (DMSO) was purchased from Fisher 
Scientific (Fairlawn, NJ). Type A/E glass fiber filters were acquired from Pall 
Corporation (Ann Arbor, MI). Creatine kinase, FuGENE® 6 transfection reagent, and 
Complete Mini EDTA-free protease inhibitor cocktail tablets were purchased from 
Roche Applied Science (Mannheim, Germany). All other chemicals and reagents 
were of analytical grade and were readily available from commercial sources.  
 MRP4 Expression Vector and Transfection in HEK293 Cells. The 
pcDNA3.1/Hygro-ABCC4 cDNA vector was a kind gift from Dr. Deitrich Keppler. 
Construction of the expression vector pcDNA3.1/Hygro-ABCC4 cDNA encoding 
MRP4 (ABCC4) has been described previously (Rius et al. 2003). Amplification of 
the cDNA was perfomed as follows: 10 µl of E. coli competent cells were heat-
transformed using 100 ng of plasmid DNA stock and cultured overnight on Luria 
Bertani (LB) agar plates containing 50 µg/ml ampicillin. Colonies were selected 12 h 
later and incubated in 2 ml sterile LB broth containing ampicillin for 8 h at 37°C with 
vigorous shaking. The entire volume of the starter culture was added to 60 ml of LB 
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broth containing ampicillin and grown at 37°C for a n additional 8–10 h with vigorous 
shaking. Cell cultures were centrifuged at 1200 × g for 10-min. Plasmid DNA was 
purified from the transformed E. coli cell pellets using the QIAGEN Plasmid Maxi Kit 
(QIAGEN, Valencia, CA), and purity and concentration were measured 
spectrophotometrically using a NanoDrop spectrophotometer (Thermo Scientific, 
Wilmington, DE).  
 Human HEK293 cells were cultured in BD Falcon 175 cm2 tissue culture 
treated flasks (Fisher Scientific, Pittsburgh, PA) in DMEM with phenol red 
supplemented with 10% (v/v) FBS and incubated at 37°C and 5% CO2 in a 
humidified incubator. The HEK293 cells were transfected with the pcDNA3.1/Hygro-
ABCC4 cDNA construct using FuGENE® 6 transfection reagent. Untransfected 
HEK293 cells served as controls, and were otherwise treated identically, 
concurrently with transfected cells. After 72 h, the culture medium was aspirated, 
cells were rinsed 1x with 10 ml ice-cold phosphate-buffered saline (PBS), and 
scraped into 5 ml/flask of ice-cold PBS on ice. Cells from 8 flasks were consolidated 
into a single 50 ml conical tube and centrifuged at 800 × g for 5 min at 4°C, and the 
supernatant was removed. Cell pellets were washed 2x by resuspending in 10 ml 
buffer containing 250 mM sucrose, 50 mM tris(hydroxymethyl)aminomethane (Tris), 
and 0.25 mM CaCl2, pH 7.4, and centrifuging at 800 × g for 5 min. Following the final 
centrifugation step, the wash buffer was aspirated and cell pellets were resuspended 
in buffer containing 250 mM sucrose, 50 mM Tris, 0.25 mM CaCl2, 10 µl of 200 
mg/ml benzamidine, and one Complete mini EDTA-free protease inhibitor cocktail 
 127 
tablet per tube, pH 7.4. Pellets were snap-frozen using liquid nitrogen and stored at -
80°C until preparation of membrane vesicles.  
 Membrane Vesicle Preparation and Immunoblotting. Plasma membrane 
vesicles were prepared as described with modifications (Loe et al. 1996). Briefly, 
transfected and untransfected (control) HEK293 cell pellets were thawed on ice, 
resuspended, and membranes disrupted by N2 cavitation. The exploded cell 
suspension was centrifuged for 10 min at 800 × g at 4°C and the supernatant was 
layered over a cushion of 35% (w/v) sucrose, 1 mM EDTA, and 50 mM Tris, pH 7.4, 
and centrifuged at 100,000 × g at 4°C for 1 h. Foll owing centrifugation, the interface 
was removed and placed in a buffer solution containing 25 mM sucrose and 50 mM 
Tris, pH 7.4 and centrifuged at 100,000 × g for 30 min. The pelleted membranes 
were washed with buffer containing 250 mM sucrose, 50 mM Tris, pH 7.4, and 
resuspended and vesicularized by passing through a 27-gauge needle and syringe 
20 times. Aliquots of vesicles were stored at -80°C until  use. Relative expression of 
MRP4 protein in the membrane fractions was determined by immunoblot. Protein (2-
10 µg total protein/well) was resolved by electrophoresis on NuPAGE® Novex® 4% 
to 20% Bis-Tris gels (Invitrogen, Carlsbad, CA), and following transfer to 
nitrocellulose membranes, blots were blocked overnight with 5% (w/v) skim milk 
powder in Tris-buffered saline with 0.1% Tween 20 (TBS-T) buffer, pH 7.4, rinsed 3 
x, and incubated with the M4I-10 rat monoclonal antibody (Alexis Biochemicals, San 
Diego, CA) at a dilution of 1:1000 for 2 h. After washing, blots were incubated with 
horseradish peroxidase-conjugated goat anti-rat antibody (Sigma-Aldrich, St. Louis, 
MO) followed by application of SuperSignal West Dura (Thermo Scientific, 
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Wilmington, DE) enhanced duration chemiluminescent substrate. Bands were 
visualized using a VersaDoc 1000 imaging system(Bio-Rad Laboratories, Hercules, 
CA), and relative band density was determined using Quantity One 1-D Analysis 
Software v4.4.0 (Bio-Rad Laboratories, Hercules, CA).  
 Transport Studies. All transport assays were performed using a rapid 
filtration method as described (Loe et al. 1996). Membrane vesicles (10 µg protein) 
were incubated at 37°C in a 50 µl total reaction volu me containing 4 mM ATP or 
AMP, 10 mM MgCl2, 10 mM dithiothreitol (DTT), 10 mM creatine phosphate, 100 
mg/ml creatine kinase, 3 mM GSH, 5 µM TCA, and substrate (10 µM TS, 10 µM 
MTX plus 60 nCi/reaction [3H]MTX, trace [3H]DHEAS, or 5 µM TCA plus 100 
nCi/reaction [3H]TCA). MK571 (18 or 50 µM) was included as a positive control for 
MRP4 inhibition. At selected timepoints, the uptake reaction was stopped by adding 
800 µl ice-cold buffer containing 250 mM sucrose, 50 mM Tris, pH 7.4. The entire 
850 µl aliquot was filtered through glass fiber type A/E filters and washed 2x with the 
same ice-cold buffer. Filters were allowed to dry 1 h, and radioactivity trapped within 
the filters was quantitated by liquid scintillation counting in the case of [3H]MTX, 
[3H]DHEAS, and [3H]TCA, while TS was measured by LC-MS/MS. Transport in the 
presence of AMP was subtracted from transport in the presence of ATP and 
reported as ATP-dependent uptake. Transport also was measured in membrane 
vesicles prepared from untransfected HEK293 cells. The inhibitory effect of TS on 
MRP4-mediated TCA uptake was determined using the same method as described 
above; the initial rate of [3H]TCA uptake was measured at a single timepoint (2 min) 
in the presence of increasing concentrations of TS (0-100 µM).  
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 Data Analysis. Statistical analysis (one-way analysis of variance [ANOVA] 
and Dunnett’s multiple comparison test, or two-way ANOVA with Bonferroni’s 
multiple comparison test) was performed using GraphPad Prism 5.03. In all cases, a 
p value < 0.05 was considered statistically significant.   
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Results 
 Pilot studies were undertaken to determine whether TS is a substrate for 
MRP4, and whether TS inhibits uptake of the known MRP4 substrates MTX and 
DHEAS. Figure 4.1 shows uptake (nM) at 1 and 5 min of TS into MRP4-expressing 
membrane vesicles incubated with 10 µM TS. Uptake at 5 min was almost 2.5-fold 
higher than at 1 min, showing that uptake of TS increased over time. Figure 4.2 
shows uptake of [3H]MTX (pmol/mg protein/90 s) into MRP4-expressing membrane 
vesicles in the presence of vehicle (0.1% DMSO; CTL), 1 or 10 µM TS, or 18 µM 
MK571. MK571 inhibited [3H]MTX uptake; TS also inhibited [3H]MTX uptake in a 
concentration-dependent manner. Uptake of the MRP4 substrate [3H]DHEAS 
(µl/min/mg protein) was measured in the presence of vehicle (0.1% DMSO; CTL), 50 
µM TS, or 50 µM MK571 (Figure 4.3). As with [3H]MTX, both TS and MK571 
inhibited MRP4-mediated [3H]DHEAS uptake. These pilot studies established that 
TS is a substrate for MRP4, and that TS inhibits the transport of known MRP4 
substrates.  
 ATP-dependent uptake of [3H]TCA in CTL and MRP4-expressing membrane 
vesicles over time is shown in Figure 4.4. Uptake was linear up to ~5 min; the 2 min 
timepoint was chosen for subsequent experiments. At 2 min, the uptake rate of 
[3H]TCA in MRP4-expressing membrane vesicles was ~56 pmol/mg protein/min, 
while the uptake rate in CTL vesicles was ~29 pmol/mg protein/min. The ATP-
dependent uptake rate (pmol/mg protein/min) of [3H]TCA in CTL membrane vesicles 
(solid circles) and MRP4-expressing membrane vesicles (open squares) in the 
presence of increasing concentrations of TS (0-100 µM) is plotted in Figure 4.5. The 
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uptake rate of [3H]TCA in the MRP4-expressing membrane vesicles without TS (~50 
pmol/mg protein/min) was consistent with results from the uptake time course 
(Figure 4.4), while uptake in CTL vesicles was higher (~38 pmol/mg protein/min vs 
~29 pmol/mg protein/min). At the maximum TS concentration used (100 µM), uptake 
in MRP4 vesicles was reduced by 72% to ~14 pmol/mg protein/min. In CTL vesicles, 
uptake in the presence of 100 µM TS was reduced by 71% to ~11 pmol/mg 
protein/min.  
 Immunoblot analysis of MRP4 protein expression in membrane vesicles from 
CTL (untransfected) HEK293 cells and in membrane vesicles from MRP4-
transfected HEK293 cells was performed; a representative blot is shown in Figure 
4.7. While overexpression of MRP4 protein was detected in the membrane vesicles 
from transfected HEK293 cells, endogenous MRP4 expression in the untransfected 
HEK293 cells was high.  
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Discussion 
 A number of studies have examined the role of impaired BA transport in the 
idiosyncratic hepatotoxicity observed with TRO. While TRO-mediated inhibition of 
BSEP/Bsep- and NTCP/Ntcp-mediated BA transport has been reported using 
multiple model systems, we believe this is the first study to specifically explore the 
potential role of the basolateral efflux transport protein MRP4 in the toxicity of TRO. 
Jemnitz et al. reported that in rat SCH, 100 µM TRO had no effect on basolateral 
efflux of preloaded [3H]TCA, but decreased [3H]TCA canalicular efflux and increased 
[3H]TCA intracellular accumulation; in human SCH, 100 µM TRO decreased 
basolateral [3H]TCA efflux slightly, markedly decreased canalicular [3H]TCA efflux, 
and almost doubled [3H]TCA intracellular accumulation (Jemnitz et al. 2010). The 
authors concluded that TRO had no effect on basolateral efflux of [3H]TCA in rats. 
Because canalicular and basolateral efflux of TCA were the same magnitude in 
human hepatocytes, the authors concluded that greater inhibition of canalicular 
efflux caused the increased intracellular accumulation of [3H]TCA, and not impaired 
basolateral efflux. However, the present data challenge this observation, and instead 
indicate that the major metabolite of TRO, TS, is capable of inhibiting MRP4-
mediated BA transport, as well as the transport of other known MRP4 substrates 
including MTX and DHEAS.  
 TS has been shown to accumulate in the livers of rats to levels 20-fold higher 
than parent TRO (Funk et al. 2001b). TS also accumulated within rat and human 
hepatocytes in vitro; following a 2-h incubation with 10 µM TRO, the intracellular 
concentration of TS ranged from 132 to 222 µM in rat SCH and from 136 to 160 µM 
 133 
in human SCH (Lee et al. 2009). Our results indicate that MRP4-mediated TCA 
transport is inhibited by TS at concentrations well below those measured within cells. 
Sulfation of xenobiotics in general renders compounds more hydrophilic and less 
toxic, but whether or not TS is in itself inherently hepatotoxic is unclear; in HEPG2 
cells, only parent TRO and its quinone derivative were cytotoxic (Yamamoto et al. 
2001). Inhibition of TRO sulfation resulted in increased cytotoxicity in human and 
porcine hepatocyte cultures (Kostrubsky et al. 2000). However, in immortalized 
human hepatocyte-derived THLE-2 cells, TS caused greater oxidative stress than 
parent TRO (Saha et al. 2010). BAs, on the other hand, are known to be cytotoxic, 
and can induce apoptosis or necrosis if they accumulate within hepatocytes. 
Therefore, competition between BAs and TS for transport out of the cell may 
exacerbate toxicity if normal compensatory efflux routes are impaired.  
 Research indicates that MRP4 compensates for impaired canalicular BA 
excretion. Gradhand et al. (2008) found that although MRP4 protein expression 
varied 45-fold in humans, expression was increased in patients with cholestasis 
(Gradhand et al. 2008). While MRP3 is also upregulated under cholestatic 
conditions, MRP4 probably plays a more significant role in basolateral BA efflux. 
Human MRP3 protein expressed in Sf9 vesicles did not transport TCA to a 
significant extent (Akita et al. 2002). In Mrp3 knockout mice, Mrp4 expression 
between knockout mice and WT mice was similar, and enterohepatic circulation of 
BAs was unaffected by the loss of Mrp3 (Belinsky et al. 2005). Similarly, Mrp3 
knockout mice exhibited normal BA transport, but altered hepatic transport of hepatic 
glucuronides (Zelcer et al. 2006). Mrp4, but not Mrp3, protein was upregulated in 
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common bile duct-ligated (CBDL) WT mice; CBDL Mrp4 knockout mice had more 
severe liver injury caused by the intracellular accumulation of BAs than WT CBDL 
mice, suggesting that increased Mrp4 protein in cholestasis protects against damage 
caused by BA accumulation (Mennone et al. 2006).  
 In addition to cholestasis, MRP4 appears to be involved in hepatoprotection 
from multiple types of toxic insult. In rats treated with carbon tetrachloride (CCl4), 
decreased Bsep and Mrp2 mRNA expression and increased Mrp3 and Mrp4 mRNA 
expression were observed (Okumura et al. 2007). When mice were treated with toxic 
doses of CCl4 or acetaminophen (APAP), CCl4 induced Mrp4 mRNA 26-fold but 
reduced Mrp3 mRNA to 20% of control, whereas APAP increased Mrp3 mRNA by 
3.5-fold, and Mrp4 mRNA by 16-fold (Aleksunes et al. 2006). In humans, APAP-
induced liver failure was associated with increased mRNA and protein expression of 
MRP4, but not MRP3 (Barnes et al. 2007). Campion et al. (2008) reported that 
induction of Mrp4 protein in mouse following APAP treatment was dependent on 
Kuppfer cell derived/released mediators, potentially TNF-α and IL-1β (Campion et al. 
2008).  
 In humans, increased MRP4 protein expression may overcome TS-mediated 
BA transport inhibition, and may decrease intracellular accumulation of TS. 
However, if individuals are unable to increase the amount of functional MRP4 protein 
on the membrane, perhaps because of a disease state alteration or a genetic 
polymorphism, then hepatotoxicity may ensue due to increased intracellular BAs or 
TS. Gradhand et al. found two single-nucleotide polymorphisms (SNPs) in the MRP4 
gene in humans that resulted in significantly lower or significantly higher protein 
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expression, although the authors could not associate these mutations with 
decreased or increased MRP4 function (Gradhand et al. 2008). However, during a 
screen of SNPs in MRP4 in an ethnically diverse human population, Abla et al. 
identified two variants that resulted in a significant reduction in function and caused 
increased cellular accumulation of the antiviral agents azidothymidine (AZT) and 
adefovir in HEK293T cells transiently transfected with MRP4 (Abla et al. 2008). The 
effect of TRO on MRP4 mRNA or protein in humans has not been examined. Lee et 
al. reported that treatment of rat SCH with BSO, an inhibitor of glutathione synthesis, 
induced Mrp4 protein expression and decreased trabectedin toxicity (Lee et al. 
2008). In the present rat SCH studies, treatment with 100 µM TRO increased Mrp4 
protein expression 63% over control in one experiment, but no change in Mrp4 
protein was observed in a second experiment, although BSO increased Mrp4 protein 
in both experiments (data not shown).  
 One clear limitation of the studies presented here is the high level of substrate 
transport by the untransfected control membrane vesicles from HEK293 cells. While 
untransfected HEK293 cells do not express endogenous MRP3 (data not shown), it 
cannot be ruled out that another BA transport protein is expressed in these parent 
cells. However, the high expression of MRP4 protein in membrane vesicles from 
untransfected cells implicates MRP4 as the protein responsible for transport. 
Interestingly, an unidentified protein that reacted with the MRP4 antibody 
consistently appeared on immunoblots of CTL and MRP4-transfected vesicles that 
increased in intensity with increased MRP4 protein expression. Clearly, a parent cell 
line that expressed no, or very little, MRP4 would be more desirable, but is beyond 
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the scope of this dissertation project. These are the first studies to suggest that TS 
inhibits MRP4-mediated BA transport. Future goals of this research include the 
development and characterization of a more specific MRP4 protein-expressing cell 
line.  
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Figure 4.1: ATP-dependent uptake (nM) at 1 and 5 min of TS into MRP4-expressing 
membrane vesicles incubated with 10 µM TS. Bars represent mean ± SD of triplicate 
determinations in n = 1 experiment.  
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Figure 4.2: Uptake of [3H]MTX (pmol/mg protein/90 s) into MRP4-expressing 
membrane vesicles in the presence of vehicle (0.1% DMSO; CTL), 1 or 10 µM TS, 
or 18 µM MK571. Bars represent mean ± SD of triplicate determinations in n = 1 
experiment. * p < 0.05 vs CTL. 
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Figure 4.3: Uptake clearance (µl/min/mg protein) of DHEAS into MRP4-expressing 
membrane vesicles in the presence of vehicle (0.1% DMSO; CTL), 50 µM TS, or 50 
µM MK571. Bars represent mean ± SD of triplicate determinations in n = 1 
experiment. * p < 0.05 vs CTL.   
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Figure 4.4: Time-dependent uptake (pmol/mg protein) of [3H]TCA in CTL (solid 
circles) and MRP4-expressing (open squares) membrane vesicles. Symbols 
represent mean ± range of duplicate determinations in n = 1 experiment.  
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Figure 4.5: ATP-dependent uptake rate (pmol/mg protein/min) of [3H]TCA in CTL 
membrane vesicles (solid circles) and MRP4-expressing membrane vesicles (open 
squares) in the presence of increasing concentrations of TS (0-100 µM). Symbols 
represent mean ± SEM of triplicate determinations in n = 3 experiments; p > 0.05 vs 
CTL at all concentrations of TS.  
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Figure 4.6: MRP4 protein expression (~180 kDa) in membrane vesicles from CTL 
(untransfected) HEK293 cells (lanes 1 and 2, 2 µg protein/lane; lanes 5 and 6, 10 µg 
protein/lane) and in membrane vesicles from MRP4-transfected HEK293 cells (lanes 
3 and 4, 2 µg protein/lane; lanes 7 and 8, 10 µg protein/lane). Unidentified protein 
bands consistently appeared at ~52 kDa in vesicles from both untransfected CTL 
and MRP4-transfected HEK293 cells.  
 
 
 143 
REFERENCES 
 
Abla, N., Chinn, L. W., Nakamura, T., Liu, L., Huang, C. C., Johns, S. J., Kawamoto, 
M., Stryke, D., Taylor, T. R., Ferrin, T. E., Giacomini, K. M., and Kroetz, D. L. (2008). 
The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a 
highly polymorphic gene. J Pharmacol Exp Ther 325, 859-68. 
Akita, H., Suzuki, H., Hirohashi, T., Takikawa, H., and Sugiyama, Y. (2002). 
Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with 
rat MRP3. Pharm Res 19, 34-41. 
Aleksunes, L. M., Scheffer, G. L., Jakowski, A. B., Pruimboom-Brees, I. M., and 
Manautou, J. E. (2006). Coordinated expression of multidrug resistance-associated 
proteins (Mrps) in mouse liver during toxicant-induced injury. Toxicol Sci 89, 370-9. 
Assem, M., Schuetz, E. G., Leggas, M., Sun, D., Yasuda, K., Reid, G., Zelcer, N., 
Adachi, M., Strom, S., Evans, R. M., Moore, D. D., Borst, P., and Schuetz, J. D. 
(2004). Interactions between hepatic Mrp4 and Sult2a as revealed by the 
constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279, 22250-
7. 
Barnes, S. N., Aleksunes, L. M., Augustine, L., Scheffer, G. L., Goedken, M. J., 
Jakowski, A. B., Pruimboom-Brees, I. M., Cherrington, N. J., and Manautou, J. E. 
(2007). Induction of hepatobiliary efflux transporters in acetaminophen-induced 
acute liver failure cases. Drug Metab Dispos 35, 1963-9. 
Belinsky, M. G., Dawson, P. A., Shchaveleva, I., Bain, L. J., Wang, R., Ling, V., 
Chen, Z. S., Grinberg, A., Westphal, H., Klein-Szanto, A., Lerro, A., and Kruh, G. D. 
(2005). Analysis of the in vivo functions of Mrp3. Mol Pharmacol 68, 160-8. 
Borst, P., de Wolf, C., and van de Wetering, K. (2007). Multidrug resistance-
associated proteins 3, 4, and 5. Pflugers Arch 453, 661-73. 
Campion, S. N., Johnson, R., Aleksunes, L. M., Goedken, M. J., van Rooijen, N., 
Scheffer, G. L., Cherrington, N. J., and Manautou, J. E. (2008). Hepatic Mrp4 
induction following acetaminophen exposure is dependent on Kupffer cell function. 
Am J Physiol Gastrointest Liver Physiol 295, G294-304. 
Denk, G. U., Soroka, C. J., Takeyama, Y., Chen, W. S., Schuetz, J. D., and Boyer, J. 
L. (2004). Multidrug resistance-associated protein 4 is up-regulated in liver but 
down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 40, 585-91. 
 144 
Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M., and 
Gasser, R. (2001a). Troglitazone-induced intrahepatic cholestasis by an interference 
with the hepatobiliary export of bile acids in male and female rats. Correlation with 
the gender difference in troglitazone sulfate formation and the inhibition of the 
canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. 
Toxicology 167, 83-98. 
Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. (2001b). Cholestatic 
potential of troglitazone as a possible factor contributing to troglitazone-induced 
hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump 
(Bsep) in the rat. Mol Pharmacol 59, 627-35. 
Geier, A., Wagner, M., Dietrich, C. G., and Trauner, M. (2007). Principles of hepatic 
organic anion transporter regulation during cholestasis, inflammation and liver 
regeneration. Biochim Biophys Acta 1773, 283-308. 
Gradhand, U., Lang, T., Schaeffeler, E., Glaeser, H., Tegude, H., Klein, K., Fritz, P., 
Jedlitschky, G., Kroemer, H. K., Bachmakov, I., Anwald, B., Kerb, R., Zanger, U. M., 
Eichelbaum, M., Schwab, M., and Fromm, M. F. (2008). Variability in human hepatic 
MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 8, 
42-52. 
Honma, W., Shimada, M., Sasano, H., Ozawa, S., Miyata, M., Nagata, K., Ikeda, T., 
and Yamazoe, Y. (2002). Phenol sulfotransferase, ST1A3, as the main enzyme 
catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30, 944-9. 
Jemnitz, K., Veres, Z., and Vereczkey, L. (2010). Contribution of high basolateral 
bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing 
cholestasis in human. Toxicol Sci 115, 80-8. 
Kawai, K., Kawasaki-Tokui, Y., Odaka, T., Tsuruta, F., Kazui, M., Iwabuchi, H., 
Nakamura, T., Kinoshita, T., Ikeda, T., Yoshioka, T., Komai, T., and Nakamura, K. 
(1997). Disposition and metabolism of the new oral antidiabetic drug troglitazone in 
rats, mice and dogs. Arzneimittelforschung 47, 356-68. 
Kemp, D. C., Zamek-Gliszczynski, M. J., and Brouwer, K. L. (2005). Xenobiotics 
inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol 
Sci 83, 207-14. 
Kostrubsky, V. E., Sinclair, J. F., Ramachandran, V., Venkataramanan, R., Wen, Y. 
H., Kindt, E., Galchev, V., Rose, K., Sinz, M., and Strom, S. C. (2000). The role of 
 145 
conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte 
cultures. Drug Metab Dispos 28, 1192-7. 
Lee, J. K., Leslie, E. M., Zamek-Gliszczynski, M. J., and Brouwer, K. L. (2008). 
Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-
associated proteins (Mrps) may prevent hepatotoxicity. Toxicol Appl Pharmacol 228, 
17-23. 
Lee, J. K., Marion, T., Abe, K., Lim, C., Pollack, G. M., and Brouwer, K. L. (2009). 
Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-
cultured hepatocytes: use of Monte Carlo simulations to assess the impact of 
changes in biliary excretion on troglitazone sulfate accumulation. J Pharmacol Exp 
Ther 332, 26-34.  
Loe, D. W., Almquist, K. C., Deeley, R. G., and Cole, S. P. (1996). Multidrug 
resistance protein (MRP)-mediated transport of leukotriene C4 and 
chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-
dependent vincristine transport. J Biol Chem 271, 9675-82. 
Loi, C. M., Alvey, C. W., Vassos, A. B., Randinitis, E. J., Sedman, A. J., and Koup, J. 
R. (1999a). Steady-state pharmacokinetics and dose proportionality of troglitazone 
and its metabolites. J Clin Pharmacol 39, 920-6. 
Loi, C. M., Randinitis, E. J., Vassos, A. B., Kazierad, D. J., Koup, J. R., and Sedman, 
A. J. (1997). Lack of effect of type II diabetes on the pharmacokinetics of 
troglitazone in a multiple-dose study. J Clin Pharmacol 37, 1114-20. 
Loi, C. M., Young, M., Randinitis, E., Vassos, A., and Koup, J. R. (1999b). Clinical 
pharmacokinetics of troglitazone. Clin Pharmacokinet 37, 91-104. 
Marion, T. L., Leslie, E. M., and Brouwer, K. L. (2007). Use of sandwich-cultured 
hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-
induced hepatotoxicity. Mol Pharm 4, 911-8. 
Mennone, A., Soroka, C. J., Cai, S. Y., Harry, K., Adachi, M., Hagey, L., Schuetz, J. 
D., and Boyer, J. L. (2006). Mrp4-/- mice have an impaired cytoprotective response 
in obstructive cholestasis. Hepatology 43, 1013-21. 
 146 
Okumura, H., Katoh, M., Minami, K., Nakajima, M., and Yokoi, T. (2007). Change of 
drug excretory pathway by CCl4-induced liver dysfunction in rat. Biochem 
Pharmacol 74, 488-95. 
Parke-Davis. (1998). Rezulin (troglitazone) package insert, Morris Plains, NJ. 
Rius, M., Nies, A. T., Hummel-Eisenbeiss, J., Jedlitschky, G., and Keppler, D. 
(2003). Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) 
localized to the basolateral hepatocyte membrane. Hepatology 38, 374-84. 
Saha, S., New, L. S., Ho, H. K., Chui, W. K., and Chan, E. C. (2010). Direct toxicity 
effects of sulfo-conjugated troglitazone on human hepatocytes. Toxicol Lett 195, 
135-41. 
Schuetz, E. G., Strom, S., Yasuda, K., Lecureur, V., Assem, M., Brimer, C., Lamba, 
J., Kim, R. B., Ramachandran, V., Komoroski, B. J., Venkataramanan, R., Cai, H., 
Sinal, C. J., Gonzalez, F. J., and Schuetz, J. D. (2001). Disrupted bile acid 
homeostasis reveals an unexpected interaction among nuclear hormone receptors, 
transporters, and cytochrome P450. J Biol Chem 276, 39411-8. 
van Aubel, R. A., Smeets, P. H., Peters, J. G., Bindels, R. J., and Russel, F. G. 
(2002). The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in 
human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J 
Am Soc Nephrol 13, 595-603. 
Watanabe, Y., Nakajima, M., and Yokoi, T. (2002). Troglitazone glucuronidation in 
human liver and intestine microsomes: high catalytic activity of UGT1A8 and 
UGT1A10. Drug Metab Dispos 30, 1462-9. 
Wielinga, P. R., Reid, G., Challa, E. E., van der Heijden, I., van Deemter, L., de 
Haas, M., Mol, C., Kuil, A. J., Groeneveld, E., Schuetz, J. D., Brouwer, C., De Abreu, 
R. A., Wijnholds, J., Beijnen, J. H., and Borst, P. (2002). Thiopurine metabolism and 
identification of the thiopurine metabolites transported by MRP4 and MRP5 
overexpressed in human embryonic kidney cells. Mol Pharmacol 62, 1321-31. 
Yamamoto, Y., Nakajima, M., Yamazaki, H., and Yokoi, T. (2001). Cytotoxicity and 
apoptosis produced by troglitazone in human hepatoma cells. Life Sci 70, 471-82. 
Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. 
P., and Yokoi, T. (1999). Oxidation of troglitazone to a quinone-type metabolite 
 147 
catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. 
Drug Metab Dispos 27, 1260-6. 
Yoshigae, Y., Konno, K., Takasaki, W., and Ikeda, T. (2000). Characterization of 
UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in 
rats and humans. J Toxicol Sci 25, 433-41. 
Zelcer, N., Reid, G., Wielinga, P., Kuil, A., van der Heijden, I., Schuetz, J. D., and 
Borst, P. (2003). Steroid and bile acid conjugates are substrates of human 
multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 371, 
361-7. 
Zelcer, N., van de Wetering, K., de Waart, R., Scheffer, G. L., Marschall, H. U., 
Wielinga, P. R., Kuil, A., Kunne, C., Smith, A., van der Valk, M., Wijnholds, J., 
Elferink, R. O., and Borst, P. (2006). Mice lacking Mrp3 (Abcc3) have normal bile 
salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 
44, 768-75. 
Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Marschall, H. U., Zatloukal, K., 
Denk, H., and Trauner, M. (2003). Adaptive changes in hepatobiliary transporter 
expression in primary biliary cirrhosis. J Hepatol 38, 717-27. 
 
 
  
 
CHAPTER 5 
 
Conclusions and Future Directions 
 149 
Conclusions 
 Despite over a decade’s worth of research following the removal of TRO from 
the market in 2000, the precise cause of TRO-mediated hepatotoxicity remains 
unclear. Numerous mechanisms have been proposed, including (i) induction of 
mitochondrial permeability transition, (ii) induction of apoptosis, (iii) biotransformation 
to reactive intermediates leading to depletion of GSH, covalent binding to cellular 
macromolecules, or oxidative stress, and (iv) inhibition of BA transport (reviewed in 
Yokoi 2010). While there are many potential mechanisms of toxicity, it is not clear 
why some patients suffered severe hepatotoxicity, while the majority of patients 
taking TRO did not exhibit impaired liver function. Because numerous drugs and 
compounds in development inhibit BA transport, the lack of a clear understanding 
about the relationship between impaired BA transport and drug-induced liver injury, 
coupled with the lack of predictive models, present a major challenge in the 
development of drugs with minimal potential for idiosyncratic hepatotoxicity.  
 Preclinical models were unsuccessful in predicting the hepatotoxic potential of 
TRO. A key strategy to avoid this pitfall is to develop robust, in vitro, preferably high-
throughput methods to identify compounds like TRO early in the development 
process, and even predict, based on structure-activity relationships, molecular 
structures that may be transport protein inhibitors before further development. The 
potential for this type of structure-activity relationship screening to predict inhibitors 
of BSEP already has been demonstrated (Saito et al. 2009). This approach is 
necessary to prevent development of potentially hepatotoxic compounds until the 
molecular mechanisms of BA transport inhibition and compensatory BA transport 
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mechanisms are clarified, and an understanding of individual susceptibility is 
elucidated. Until it is clear how impaired BA transport by xenobiotics differentially 
affects individuals based on genotype or phenotype, disease state, concomitant drug 
use, or other factors, the most conservative approach is to identify and remove these 
compounds from the development pipeline before they advance into clinical trials.  
 The goals of this dissertation work were to examine the effect of TRO on the 
hepatobiliary disposition of individual BAs, to determine the effect of TRO on 
intracellular BA composition and accumulation, and to elucidate the contribution of 
the basolateral efflux protein MRP4/Mrp4 to the intracellular accumulation of BAs. A 
number of model systems were employed to carry out this work, including primary 
rat and human SCH, suspended rat and human hepatocytes, and inside-out plasma 
membrane vesicles from MRP4-overexpressing HEK293 cells. In addition, 
discussion of preliminary experiments utilizing siRNA-mediated knockdown of Mrp4 
protein in rat SCH is included in Future Directions.  
 It was initially hypothesized that species differences in hepatic transport 
protein inhibition following TRO exposure could account for the hepatotoxicity 
observed in humans but not in rats, such that more potent inhibition of BA transport 
proteins in human hepatocytes cause intracellular accumulation of BAs that is not 
observed in rat hepatocytes. While experiments in human SCH and suspended 
hepatocytes demonstrated that 10 µM TRO inhibited both the uptake and biliary 
efflux of [3H]TCA, intracellular accumulation of [3H]TCA was not observed in either 
species (see Appendix A). An additional species difference between rats and 
humans is the composition of the respective BA pools. In rats, TCA is the 
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predominant BA, comprising nearly 50% of the BA pool; TCA is also the least 
cytotoxic of the primary BAs. In contrast, TCA makes up <10% of the BA pool in 
humans, whereas CDCA and its glycine and taurine conjugates are the most 
abundant BAs, and are also the most cytotoxic of the primary BAs. This led to the 
hypothesis that more cytotoxic BAs may accumulate within hepatocytes following 
acute TRO exposure because of differences in the affinity of individual BAs for 
transport proteins.  
 Differential Inhibition of BA Transport by TRO. The goal of Specific Aim 1 
(Chapter 2) was to demonstrate that TRO differentially affects the intracellular 
accumulation of BAs, leading to the accumulation of more cytotoxic BAs, such as 
CDCA, compared to TCA. In contrast to [3H]TCA, TRO significantly increased 
intracellular accumulation of [14C]CDCA species in rat SCH. TRO inhibited the 
accumulation of [14C]CDCA less than [3H]TCA because [14C]CDCA uptake is 
primarily Na+-independent, while TRO had a greater inhibitory effect on Na+-
dependent Ntcp function. Studies in suspended rat hepatocytes confirmed that 
uptake of [14C]CDCA was primarily Na+-independent, whereas uptake of [3H]TCA 
was primarily Na+-dependent, and determined that TRO exhibited a greater 
inhibitory effect on [3H]TCA uptake than [14C]CDCA uptake. Therefore, it appears 
that greater inhibition of [3H]TCA uptake precludes its intracellular accumulation.  
 These results are significant for a number of reasons. First, TCA is the most 
commonly used BA for transport studies, yet these results clearly indicated that TRO 
affects individual BAs differently. If screens for inhibitors of BA transport only include 
one BA substrate (i.e., TCA), then the potential to miss important interactions, such 
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as the accumulation of CDCA, is obvious. In a comparison of GCA and TCA as 
model substrates for BA uptake and accumulation in rat and human SCH, Diebert et 
al. reported marked species differences in the accumulation and Clbile of GCA and 
TCA, while the BEIs were very similar; these authors concluded that GCA was the 
preferable substrate in human whereas TCA was more appropriate for rat SCH 
(Deibert et al. 2010). Second, these results suggest that CDCA and its glycine and 
taurine conjugates may accumulate in human liver following treatment with TRO. 
This is supported by the observations that, following extrahepatic biliary obstruction, 
concentrations of CDCA in human liver increase 20-fold (Greim et al. 1973), and that 
GCDCA is missing from the bile of primary sclerosing cholangitis patients with 
chronic cholestasis (Ijare et al. 2008). Intrahepatic accumulation of CDCA species in 
humans following TRO treatment would explain the cholestatic-type liver injury in 
some patients, but since not all patients exhibited cholestasis, then some other 
mechanism may have been involved, such as impaired compensatory basolateral 
BA efflux. The concentration of TRO at which significant intracellular accumulation of 
CDCA was observed (100 µM) is higher than the maximum plasma concentrations 
observed in humans of 3.6-6.3 µM (Loi et al. 1999); however, the concentration of 
TRO in the liver has not been determined. Based on estimates by Lee et al., the 
intracellular concentration in human SCH of TRO and TS following incubation with 
10 µM TRO reached 49.4-84.7µM and 136-160 µM, respectively (Lee et al. 2009). 
  Effect of TRO on Bile Acid Profiles in Rat and Human SCH. The 
experiments in Specific Aim 1 were acute in nature and investigated the disposition 
of an externally added BA. Hepatocytes continue to synthesize BAs in culture (Dunn 
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et al. 1991), so the goal of Specific Aim 2 (Chapter 3) was to characterize the 
composition and size of the endogenous BA pool in medium, cells, and bile of rat 
and human SCH following a 24-h exposure to TRO. As detailed in Chapter 2, TRO 
caused the acute accumulation of CDCA and its metabolites, but not of TCA in rat 
hepatocytes. Based on this finding, it was hypothesized that 24-h exposure to TRO 
would cause the accumulation of BAs within the hepatocyte, and that CDCA species 
would accumulate to a greater extent than CA species. Results indicated that in 
human SCH, TRO had no effect on GCA biliary excretion but decreased the biliary 
excretion of TCA 43%, TCDCA 67%, and GCDCA 48%; this supported the 
hypothesis that inhibition of BA transport proteins can differentially affect individual 
BA species. However, contrary to expectations, there was a trend toward decreased 
accumulation of all the BAs in the cells and bile of human SCH treated with TRO, 
and the total mass of BAs measured in TRO-treated human SCH was ~19% lower 
than in control cells. One potential explanation for this finding is that TRO treatment 
may have decreased BA synthesis in the human hepatocytes, perhaps as an 
adaptive mechanism, leading to less BA accumulation. Another possible explanation 
is that BAs and metabolites of TRO [predominantly TS according to (Lee et al. 
2009)] are excreted back into the culture medium by basolateral efflux transport 
proteins such as MRP4/Mrp4, and TRO- or TS-mediated inhibition of NTCP/Ntcp 
and OATPs/Oatps prevented the reuptake of these compounds into the hepatocytes. 
 Data from Chapter 2 indicated that unconjugated CDCA, as well as CDCA 
conjugated to glycine and taurine, accumulated within cells following acute 
incubation with TRO. Unconjugated CDCA was not added to SCH in experiments 
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that examined the effect of 24-h TRO exposure on BA disposition, and no 
endogenous unconjugated CDCA was detected. This finding was expected, because 
>98% of BAs are conjugated within hepatocytes, and unconjugated BAs returning to 
hepatocytes from the portal circulation originate from bacteria-mediated 
deconjugation of BAs in the intestines. It is important to note that in the SCH model, 
there is no supply of secondary or unconjugated BAs (e.g., DCA, LCA, CDCA) 
returning to the hepatocytes from the intestines like there is in the in vivo situation, 
so unless they are added exogenously, the BAs present in the SCH system are 
primary BAs synthesized from within the hepatocytes. Results from the BA profiling 
studies suggested that, despite the acute accumulation of CDCA species observed 
following TRO exposure, all the endogenous, synthesized CDCA is conjugated to 
glycine or taurine (predominantly glycine, in these studies) during longer TRO 
incubation periods, and can be effluxed back across the basolateral membrane or 
excreted into bile.  
 Even though TRO did not cause the intracellular accumulation of BAs over a 
24-h incubation, the BA composition in control rat SCH was similar to in vivo reports, 
while BA composition in human SCH contained a higher proportion of glycine-
conjugated BAs. Based on the literature, BAs in rat plasma and bile are ~94-98% 
conjugated to taurine and the remainder to glycine, while in humans, ~75% of BAs in 
plasma and bile are conjugated to glycine and ~25% to taurine (Alvaro et al. 1986; 
Byrne et al. 2002; Mizuta et al. 1999; Tagliacozzi et al. 2003). In the present studies, 
~90% of BAs in rat SCH were taurine-conjugated, which is consistent with the 
literature. In human SCH, 99% of BAs were glycine-conjugated, ~24% higher than 
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what has been reported. One explanation could be depletion of available taurine 
over time in culture; hepatic taurine concentrations are a major determinant of the 
proportion of BAs conjugated with taurine versus glycine (Gottfries et al. 1966; 
Hardison and Proffitt 1977). While both rat and human SCH were exposed to the 
same culture conditions, rat hepatocytes were treated on day 3 and collected on day 
4, while human SCH were treated on day 6 and collected on day 7 to allow time for 
bile canaliculi formation.  
 The concentrations of total BAs in the medium of rat SCH were comparable to 
published concentrations in conventionally-cultured hepatocytes (Ellis et al. 1998) 
and SCH (Dunn et al. 1991). BA concentrations in the medium of human SCH also 
were in good agreement with published values for conventionally-cultured human 
hepatocytes (Ellis et al. 1998) and for human plasma (Ahlberg et al. 1977; 
Tagliacozzi et al. 2003). The intracellular concentration of total BAs in rat and human 
SCH were also in agreement with published estimates of hepatocyte concentrations 
in vivo (Blitzer and Boyer 1982; Hofmann 1999). The variability in BA concentrations 
in hepatocytes from individual human subjects may be due to differing capacities for 
BA synthesis based on underlying genetic factors, disease states of donor tissue, or 
liver exposure to drugs/xenobiotics prior to tissue collection.  
 TS-Mediated Inhibition of MRP4. The goal of Specific Aim 3 (Chapter 4) 
was to determine whether TS inhibits BA transport mediated by MRP4, in order to 
test the hypothesis that TS interferes with compensatory basolateral BA excretion. 
MRP4 protein is normally expressed at low levels in hepatocytes, but is induced 
during cholestasis in humans (Gradhand et al. 2008), and also in mice (Mennone et 
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al. 2006) and rats (Denk et al. 2004), presumably as an adaptive response 
mechanism to compensate for increased intracellular concentrations of BAs. BAs 
may accumulate within hepatocytes if basolateral and biliary excretion are impaired 
by TS. Membrane vesicles were prepared from untransfected (CTL) or transfected 
HEK293 cells overexpressing MRP4 protein. MRP4-mediated uptake of [3H]TCA 
was measured in the presence of increasing concentrations of TS to determine 
whether they inhibit BA transport. Results suggested that TS inhibited MRP4-
mediated [3H]TCA transport in a concentration-dependent manner. However, one 
caveat with these experiments was that the high level of substrate transport by the 
untransfected control membrane vesicles from HEK293 cells confounded 
interpretation of the data. An endogenous protein present in HEK293 cells may be 
capable of transporting TCA. MRP3 protein was not expressed in these parent cells, 
and past studies have demonstrated that OATP1B1 (Kameyama et al. 2005) and 
OATP2B1 (Sai et al. 2006) mRNA were not detected by RT-PCR in HEK293 cells. 
Transport proteins normally expressed in human kidney (from which the HEK293 
cell line is derived), such as MATEs (multidrug and toxic compound extrusion 
proteins) and OATs (organic anion transporters) may be involved, but the high 
expression of MRP4 protein in these membrane vesicles implicates MRP4 as the 
likely protein responsible. As of this writing, further efforts in our laboratory have 
resulted in the generation of stably-transfected, MRP4-overexpressing HEK293T 
cells along with mock-transfected control cells that exhibit low background MRP4 
transport. Preliminary data (not shown) show robust uptake of the MRP4 substrate 
E2-17βG in membrane vesicles from the stably MRP4-overexpressing cells, while 
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uptake is minimal in membrane vesicles from the mock-transfected control cells. Use 
of this more specific model system to confirm that TS inhibits MRP4-mediated 
transport is the focus of ongoing studies, but is beyond the scope of this dissertation 
project.  
 Consequences of Impaired MRP4 Function. Data from Specific Aim 3 
indicated that TS is a substrate for MRP4; therefore, interindividual differences in 
MRP4 function may cause intracellular accumulation of TS, which is a potent BSEP 
inhibitor, and further exacerbate BA accumulation and hepatotoxicity. Furthermore, if 
TS potently inhibits MRP4-mediated BA efflux, then the intracellular accumulation of 
BAs may be even greater than anticipated due to BSEP inhibition alone. Most 
patients who were administered TRO did not experience idiosycratic hepatotoxicity, 
which suggests that even if TS inhibits MRP4-mediated BA transport, there must be 
a compensatory mechanism by which TS-mediated MRP4 inhibition is overcome, 
perhaps upregulation of MRP4 mRNA and protein, increased MRP4 protein 
trafficking to the basolateral membrane, or upregulation of other transport proteins, 
i.e., MRP3, or OSTα/β, or increased biliary efflux of TS by BCRP. In the event that 
an individual could not compensate for impaired MRP4 function, however, 
accumulation of BAs may occur and contribute to cytotoxicity.  
 Key Conclusions. Overall, this dissertation research has made a number of 
novel contributions to the field. TRO caused significant intracellular accumulation of 
[14C]CDCA species in rat SCH. Studies in suspended rat hepatocytes revealed that 
TRO exhibited a greater inhibitory effect on [3H]TCA uptake than [14C]CDCA uptake. 
This differential effect of TRO on the uptake and accumulation of individual BAs 
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supports the hypothesis that TRO shifts the intracellular BA pool toward more toxic 
species. The SCH model reflected reasonably well the composition of the in vivo BA 
pool in rats and humans. Data from plasma membrane vesicles overexpressing 
MRP4 suggested that TS, the major metabolite of TRO, is an MRP4 substrate and 
inhibits TCA transport more potently than TRO. Impaired MRP4 function may 
predispose patients to increased intracellular concentrations of TS, a potent BSEP 
inhibitor. Furthermore, in humans, accumulation of TS may inhibit compensatory 
basolateral BA efflux and increase the intrahepatic accumulation of cytotoxic BAs in 
susceptible patients. On the other hand, inhibition of BSEP and subsequent 
intracellular accumulation of BAs may not be cytotoxic if cells can upregulate MRP4 
to compensate. This may explain, in part, the idiosyncratic nature of TRO 
hepatotoxicity. This research also has important implications for early drug 
development, because it suggests that preclinical in vitro screens for drug-induced 
transport inhibition should include multiple BA substrates, not just TCA, in order to 
fully characterize the effects of a compound on BA homeostasis.  
 
 Future Directions. Several issues and intriguing questions were raised 
during this dissertation research that should be explored further:  
 Effects of Transport Protein Inhibitors on Disposition of Primary and 
Secondary BAs in Rat and Human SCH. Numerous drugs have been shown to 
inhibit BA transport proteins, including cyclosporin A, bosentan, glyburide, 
erythromycin estolate, troleandomycin, glibenclamide, rifampin, ritonavir, saquinavir, 
and efavirenz (Fattinger et al. 2001; Funk et al. 2001a; Funk et al. 2001b; 
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Kostrubsky et al. 2003; McRae et al. 2006; Stieger et al. 2000). It is not currently 
known whether differential inhibition of BA transport is unique to TRO, or if it is 
characteristic of multiple inhibitors; likewise, the effects of TRO or TS on the 
disposition of other BA substrates are not known. Therefore, the differential inhibition 
of TCA versus CDCA uptake and accumulation observed in these studies could be 
extended to include other inhibitors and the primary BAs GCA, TCDCA, and 
GCDCA. Furthermore, the secondary BAs lithocholic acid (LCA) and deoxycholic 
acid (DCA) are even more cytotoxic than CDCA or GCDCA. Even though they make 
up only a small proportion of total BAs (0.5% and 6.8%, respectively) (Tagliacozzi et 
al. 2003), the effecs of TRO and TS on these BAs should be investigated as well. 
Because the BA pool differs between rats and humans, the use of human SCH could 
reveal species differences regarding the effects of transport protein inhibitors on 
individual BAs. In addition, the novel finding from this dissertation work that MK571 
inhibits BSEP/Bsep-mediated BA transport warrants further characterization using 
BSEP/Bsep-expressing membrane vesicles.  
 BA Profiling and Optimization of Culture Conditions. Studies from 
Specific Aim 2 (Chapter 3) suggested that further optimization of the SCH model for 
the purposes of BA profiling may be necessary. First, because enterohepatic cycling 
is not present in vitro but represents a major source of BAs presented to the 
hepatocyte for vectorial transport in vivo, one option is to add BAs to the culture 
medium to more closely replicate the in vivo situation. In humans, ~95-98% of BAs 
that are excreted into the bile are taken back up in the intestine and are returned to 
the liver during enterohepatic cycling; only ~2-5% of BAs per day are newly 
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synthesized. However, in the SCH model, the culture medium is replaced daily; this 
removes a substantial mass of BAs from the system that are replaced with newly 
synthesized BAs. It is not known whether this change in concentration gradient 
affects the vectorial driving force for BA efflux, increasing efflux from the cells, or 
how this daily flux in BAs affects expression of enzymes related to BA synthesis 
such as CYP7A1 or CYP8B1. Additionally, nuclear-receptor mediated feedback 
regulation of BA synthesis, or factors such as available cholesterol may be 
impacted. It did appear, based on the BA profiling in human SCH, that depletion of 
taurine may occur over time in culture, thus shifting the conjugation of newly-
synthesized BAs to glycine conjugates moreso than taurine conjugates. Optimal 
addition of taurine may restore the balance between glycine and taurine conjugation 
to ~75%:25%, similar to that reported in the literature (Alvaro et al. 1986; Tagliacozzi 
et al. 2003).  
 Co-cultures of Hepatocytes with Other Cell Types in Sandwich Culture. 
Another possibility is the exploration of sandwich co-cultures of hepatocytes along 
with Kupffer cells and stellate cells in order to more accurately recreate the in vivo 
hepatic environment. This is relevant because Campion et al. reported that induction 
of hepatic Mrp4 in mice in vivo following APAP exposure was dependent on Kupffer 
cell-derived mediators (Campion et al. 2008). Therefore, it is possible that, with 
appropriate culture conditions, the expression and function of MRP4 may be more 
inducible by potential hepatotoxins such as TRO, yielding new insights as to the role 
of MRP4 in compensatory BA transport. Also, cytotoxicity of TRO was increased in 
the human hepatomoma cell line Huh-7 when these cells were co-cultured with the 
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monocytic cell line THP-1, suggesting that inflammatory mediators released by the 
THP-1 cells may potentiate toxicity (Edling et al. 2009). Thus, even though these two 
cell lines are immortalized, these data suggest that TRO cytotoxicity in primary 
hepatocytes also may be modulated by co-culture with other hepatic cell types. In a 
number of studies by Roth et al., bacteria-derived lipopolysaccharides were added to 
co-cultures of Kupffer cells and hepatocytes along with toxicants in order to create a 
model of inflammatory stress-mediated idiosyncratic hepatotoxicity (reviewed in 
Deng et al. 2009). The adaptation of this type of model system to SCH may prove to 
be a useful in vitro system for identifying idiosyncratic hepatotoxins that also affect 
the disposition of substrates, including BAs.  
 MRP4-Overexpressing Membrane Vesicles from Stably Transfected 
HEK293T Cells. As discussed previously, the membrane vesicles studies 
undertaken in this dissertation research (Chapter 4) displayed high background 
expression of MRP4 protein in the untransfected control HEK293 cells. Recently, a 
stably-transfected HEK293T cell line was developed in our laboratory with high 
MRP4 substrate transport capabilities in MRP4-overexpressing cells and very low 
background transport in mock-transfected cells. Experiments in Specific Aim 3 
(Chapter 4) may be repeated with membrane vesicles from this stably-transfected 
MRP4-overexpressing cell line to determine whether (a) TS is an MRP4 substrate, 
(b) CDCA is an MRP4 substrate, and (c) TS inhibits MRP4-mediated BA transport. 
Additionally, the effect of BAs on MRP4-mediated TS transport should be explored 
to determine whether BAs inhibit MRP4-mediated TS efflux. Based on the results of 
BA profiling experiments performed as part of this dissertation (Chapter 3), and data 
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from Lee et al., BAs and TS may reach similar hepatocellular concentrations [a 
maximum intracellular concentration of nearly 200 µM was estimated for TS in rat 
SCH (Lee et al. 2009), and the same for total intracellular BAs in human SCH in the 
BA profiling experiments]. 
 siRNA-Mediated Transport Protein Knockdown. RNAi remains a 
potentially powerful tool to elucidate the role of individual transport proteins in 
substrate transport or toxic effect. The use of synthetic siRNAs to knock down Mrp2 
and Mrp3 protein (Tian et al. 2004), and adenoviral-vector mediated RNAi to knock 
down Bcrp (Yue, et al., 2009) in rat SCH has been performed by our laboratory in 
order to elucidate the function of these transport proteins. Van Aubel et al. used 
siRNA to knock down MRP4 protein in MRP4-overexpressing HEK293/4.63 cells; 
using this model, it was then demonstrated that the efflux of the endogenous MRP4 
substrate urate decreased, and that the increase in intracellular urate inhibited 
transport of methotrexate, an exogenous MRP4 substrate (Van Aubel et al., 2005). 
Pilot experiments (not shown) were designed and conducted to test the hypothesis 
that impaired Mrp4 function increases hepatocellular accumulation of BAs and 
increases TRO cytotoxicity. An adenoviral vector expressing an siRNA designed to 
knock down Mrp4 protein in rat SCH was generated. Accumulation of exogenous 
[3H]TCA and [14C]CDCA was measured in rat SCH treated with an adenoviral vector 
expressing a non-targeting control siRNA or an siRNA targeting Mrp4, with or 
without exposure to TRO or MK571. Mrp4 protein was successfully knocked down 
using this approach, and BA transport clearly was affected by siRNA treatment. 
However, interpretation of the data was confounded by off-target effects, which may 
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have been caused by adenoviral vector infection of SCH at too high an MOI. To that 
end, optimization of siRNA-mediated Mrp4 knockdown for more specific knockdown 
without off-target effects is another logical direction of this research.  
 These future directions share a common goal of optimizing the available in 
vitro models to most accurately reflect the in vivo hepatic environment. In this way, 
continued exploration of the role of endogenous BAs in drug-induced hepatotoxicity, 
as well as the function of compensatory efflux proteins in the response to 
hepatotoxicants, may reveal important interactions that could lead to improved 
screening techniques for new drug candidates.  
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Abstract 
 
 Drug-induced liver toxicity is a significant problem in drug development and 
clinical practice, and growing evidence suggests that inhibition of bile acid (BA) 
transport protein function may be one mechanism of hepatotoxicity. Troglitazone 
(TRO) is one such drug that caused idiosyncratic hepatotoxicity in humans, but 
toxicity was not evident in preclinical animal testing. One possible explanation for 
this is that in humans, but not experimental animal species, TRO causes the 
intracellular accumulation of BAs in hepatocytes. In vivo and in vitro studies in rats 
have demonstrated that TRO inhibits BA transport proteins. The goal of this 
research was to determine how TRO affects in vitro BA transport in human 
hepatocytes in comparison to rat, in order to test the hypothesis that TRO causes 
BA accumulation in human, but not rat, hepatocytes. Using sandwich-cultured 
hepatocytes (SCH) from both species, acute (10-min) intracellular accumulation and 
biliary excretion of taurocholic acid (TCA) were measured in the presence and 
absence of TRO. The effects of increasing concentrations of TRO on the basolateral 
uptake of TCA was examined in suspended human and rat hepatocytes. Results 
indicated that TRO inhibited both basolateral uptake and canalicular excretion of 
TCA in a concentration-dependent manner in both human and rat SCH. Uptake of 
TCA in suspended human hepatocytes was predominantly Na+-dependent, whereas 
uptake in suspended rat hepatocytes involved both Na+-dependent and independent 
mechanisms. Interestingly, TRO inhibited TCA uptake in suspended human 
hepatocytes more potently (IC50 = 0.33 µM) than in rat hepatocytes (IC50 = 1.9 µM). 
These data suggest that TRO inhibits both BA uptake and excretion in human and 
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rat hepatocytes. Other factors, such as compensatory basolateral efflux transport 
protein function or individual BA species, may contribute to TRO-mediated 
hepatotoxicity in humans.  
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Introduction 
 Drug-induced hepatotoxicity can lead to acute liver failure and even death, 
and is the most common adverse event leading to the removal of pharmaceuticals 
from clinical use (Kaplowitz 2001). Idiosyncratic toxicity, or rare hepatotoxic 
reactions of unknown etiology occurring in a small subset of patients, is a frequent 
reason for attrition of drug candidates in the development pipeline. Unfortunately, the 
mechanisms of drug-induced hepatotoxicity are varied and poorly understood, and 
current models used for safety assessment in drug development do not accurately 
predict hepatotoxicity in humans. While research into mechanisms of drug-induced 
hepatotoxicity has focused primarily on the formation of reactive metabolites and 
cellular damage from stable adduct formation, more recent evidence has led to the 
hypothesis that inhibition of normal BA transport is another important mechanism of 
hepatotoxicity (Byrne et al. 2002; Fattinger et al. 2001; Stieger et al. 2000).  
 Compounds that inhibit one or more of the proteins responsible for BA 
excretion may cause the intracellular accumulation of BAs in hepatocytes and 
subsequent toxicity due to detergent effects on cellular membranes, mitochondrial 
dysfunction, and cellular necrosis (Delzenne et al. 1992; Desmet 1995; Gores et al. 
1998; Pauli-Magnus et al. 2005). A number of drugs, including cyclosporin, 
glibenclamide, rifampin, and troglitazone (TRO), have been shown to inhibit rat 
Bsep-mediated taurocholic acid (TCA) biliary excretion in vitro (Fattinger et al. 2001; 
Funk et al. 2001a; Pauli-Magnus and Meier 2006; Stieger et al. 2000). TRO is a 
peroxisome proliferator-activated receptor gamma (PPARγ) agonist that was first in 
a new class of thiazolidinedione antidiabetic agents. TRO was approved by the FDA 
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in 1997 for the treatment of type II diabetes, but was subsequently withdrawn from 
the market in 2000 after numerous reports of liver failure. Preclinical toxicological 
testing of TRO in animals failed to predict this hepatotoxicity, and subsequent 
research efforts have focused on elucidating the mechanism(s) of TRO-associated 
hepatotoxicity. While the precise mechanism(s) remain(s) unclear, several 
hypotheses have been suggested, including metabolism of TRO to electrophilic 
reactive intermediates, mitochondrial injury and induction of mitochondrial 
permeability transition, induction of apoptosis, PPARγ-mediated steatosis, and 
inhibition of BSEP (Masubuchi 2006; Smith 2003).  
 Recent studies have generated a wealth of data supporting a potential role for 
altered hepatic transport processes in TRO’s hepatotoxicity. TRO decreased bile 
secretion rates in isolated perfused rat livers (Preininger et al. 1999), while both TRO 
and TRO sulfate (TS), a major metabolite excreted into bile, competitively inhibited 
rat Bsep in isolated canalicular rat liver plasma membrane vesicles (Funk et al. 
2001a; Funk et al. 2001b). Kostrubsky et al. demonstrated that inhibition of TRO 
sulfation resulted in increased cytotoxicity in human and porcine hepatocyte 
cultures, presumably due to accumulation of unmetabolized parent compound 
(Kostrubsky et al. 2000). In addition, Kostrubsky et al. demonstrated that the biliary 
excretion of TS and TRO glucuronide (TG) in TR- rats was impaired, presumably 
due to loss of Mrp2 in the case of TG (Kostrubsky et al. 2001), and deficient Bcrp in 
the case of TS (Yue, in press). Kemp et al. examined the effect of TRO on BA 
transport mechanisms in rat SCH (Kemp et al. 2005). TRO (10 µM) decreased the 
total accumulation of TCA in cells plus canalicular networks approximately 3-fold; 
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TRO also significantly decreased the BEI of TCA with an IC50 of 0.91 ± 0.12 µM. 
Further investigations in suspensions of freshly isolated rat hepatocytes revealed 
that 10 µM TRO decreased the initial rate of TCA uptake by ~3-fold.  
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Methods 
 Chemicals. TRO was purchased from Biomol (Plymouth Meeting, PA). 
Taurocholate, dexamethasone, Hanks’ balanced salt solution (HBSS), HBSS without 
calcium chloride, magnesium sulfate, phenol red and sodium bicarbonate, and 
collagenase (type IV) were purchased from Sigma-Aldrich (St. Louis, MO). 
Collagenase (type I, class I) was obtained from Worthington Biochemical (Freehold, 
NJ). [3H]TCA (5 ci/mmol; purity > 97%) was purchased from Perkin Elmer (Boston, 
MA). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Fairlawn, 
NJ). Fetal bovine serum (FBS), insulin, and Dulbecco’s modified Eagle’s medium 
(DMEM) were purchased from GIBCO (Grand Island, NY). ITS+ Premix (insulin, 
transferrin, selenium) and BD Matrigel™ Basement Membrane Matrix were 
purchased from BD Biosciences (Palo Alto, CA). All other chemicals and reagents 
were of analytical grade and were readily available from commercial sources.  
 Hepatocyte Isolation and Culture. Hepatocytes were isolated from male 
Wistar rats (220-300 g; Charles River Laboratories, Inc., Raleigh, NC) by a two-step 
collagenase perfusion method as described previously (Annaert et al. 2001; Liu et al. 
1998). Rats were maintained on a 12-h light/dark cycle with free access to water and 
rodent chow. Rats were allowed to acclimate for at least 5 days before 
experimentation. The Institutional Animal Care and Use Committee of the University 
of North Carolina at Chapel Hill approved all procedures. Human hepatocytes for 
SCH experiments were isolated by a modification of the above method (Hamilton et 
al. 2001) from freshly resected human liver tissue procured through the Department 
of Surgery, University of North Carolina at Chapel Hill School of Medicine by 
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qualified medical staff, with donor consent and with the approval of the UNC 
Hospitals Ethics Committee. Human hepatocytes used in suspended experiments 
[Hu274 (48 year-old-female, Caucasian) and Hu299 (43-year-old female, 
Caucasian)], were obtained from CellzDirect (Pittsboro, NC).  
 Rat and human hepatocytes were seeded at a density of 1.5 × 106 cells per 
well on 6-well BioCoat™ plates (BD Biosciences, Bedford, MA) in 1.5 ml Dulbecco’s 
modified Eagle’s medium containing 5% fetal bovine serum, 10 µM insulin, and 1 µM 
dexamethasone. Cells were incubated at 37°C in a humi dified incubator and allowed 
to attach for 2 h (rat) or 3 h (human), at which time the medium was aspirated to 
remove unattached cells, and medium was replaced. Twenty-four hours later, cells 
were overlaid with BD MatrigelTM basement membrane matrix at a concentration of 
0.25mg/ml in 2 ml ice-cold media containing 1% ITS and 0.1µM dexamethasone. 
Rat and human hepatocytes were cultured for 3 and 9 more days, respectively, 
before experimentation to allow maximum formation of canalicular networks between 
cells; medium was changed daily.  
 Transport Studies Using Sandwich-Cultured Primary Rat and Human 
Hepatocytes. On day 4 of culture (rat) or day 10 (human), hepatocytes were rinsed 
3 times for 20 sec during each rinse with 2 ml per well of warmed Hank’s balanced 
salt solution with or without Ca2+. Following the washes, 2 ml of HBSS with or 
without Ca2+ was added and cells were incubated at 37°C for 10 min.  After 
incubation, medium was double-aspirated from each well and 1 ml of dosing solution 
containing HBSS with Ca2+, 1 µM [3H]TCA (5 µCi/100 ml), and vehicle (0.1% DMSO) 
or specified concentrations of TRO was added. Cells were incubated at 37°C for 10 
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min. After incubation, the dosing solution was aspirated from the cells and uptake 
was stopped by rinsing cells 3 x with 2 ml ice-cold HBSS with Ca2+. After washing, 
HBSS was aspirated and 1 ml of lysis buffer (Triton X-100 0.5% in phosphate-
buffered saline) was added to each well, and plates were shaken for 20 min on a 
rotary shaker. Aliquots (500 µl) of sample and 100 µl of dosing solution were 
collected for quantification of radioactivity, and 500 µl aliquots were reserved for 
protein quantification. TCA accumulation in collagen-precoated dishes without cells 
was subtracted to correct for nonspecific binding to the collagen substrate.  
 Transport Studies Using Suspended Primary Rat and Human 
Hepatocytes. Isolated hepatocytes were washed twice with ice-cold HBSS modified 
with 10 mM Tris and 5 mM glucose (+ Na+ condition) or Na+-free choline buffer (10 
mM Tris, 5 mM glucose, 5.4 mM KCl, 1.8 mM CaCl2, 0.9 mM MgSO4, 10 mM 
HEPES, 137 mM choline). Cells were suspended at 1x106 cells/ml in the same 
buffer, placed on ice and used immediately in experiments. Hepatocyte suspensions 
(4 ml rat; 1 ml human) were pre-incubated at 37°C fo r 5 min in bottom-inverted 
Erlenmyer flasks (rat) or for 3 min in 16 x 100 mm test tubes (human); vehicle or 
TRO (0.1-20 µM) was added followed by [3H]TCA (1 µM; 60 nCi/ml). At indicated 
time points, 200 µl samples were removed, placed in a 0.4 ml polyethylene tube 
containing a top layer of silicone oil:mineral oil (82:18 v/v) (100 µl) and a bottom 
layer of 3 M KOH (50 µl) and centrifuged. Radioactivity in the cell pellet and 
supernatant was quantified by liquid scintillation counting. The adherent fluid volume 
was determined by incubation of cells with [14C]inulin (60 nCi/ml). Protein 
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concentrations in the incubation mixtures were quantified at the end of each 
experiment.  
 Sample Analysis. [3H]TCA was quantified by liquid scintillation counting 
using a Packard Minaxi TriCarb scintillation counter (Meriden, CT). Protein 
concentrations were determined with the BCA (bicinchoninic acid) protein assay kit 
(Pierce, Rockford, IL) and bovine serum albumin (0.2-2 mg/ml) as a standard using 
a Bio-Tek FL600 Microplate Fluorescence Reader and KC4 Kineticalc for Windows 
2.7 (BioTek Instruments, Inc., Winooski, VT).  
 Data Analysis. The biliary excretion index (BEI), or the fraction of 
accumulated compound that resides in the bile canaliculi, was calculated using B-
CLEAR™ technology (Qualyst, Inc., Research Triangle Park, NC) based on the 
following equation: 
 
BEI = [(Accumulationcells+bile canaliculi – Accumulationcells)/Accumulationcells+bile canaliculi] × 
100 
 
The in vitro biliary clearance (Clbile) in ml/min/mg protein was calculated using the 
equation: 
 
Clbile = [(Accumulationcells+bile canaliculi – Accumulationcells)/(Concentrationincubation medium × 
Incubation time)] × 100 
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Clbile was scaled up to ml/min/kg using 200 mg of protein/g of liver and 40 g of 
liver/kg of rat body weight (Seglen 1976).  
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Results 
 Results indicated that TRO inhibited TCA uptake and excretion in human 
SCH, in addition to rat SCH. In agreement with the findings of Kemp et al. (2005), in 
rat SCH, 0.1-10 µM TRO decreased TCA cellular accumulation, and cell + bile 
accumulation, in a concentration-dependent manner (Figure A.1). The BEI of TCA 
also was reduced from 85.8% to 71.0% at the highest concentration of TRO studied 
(10 µM), a reduction of 17.2% compared with the control value, consistent with 
inhibition of Bsep-mediated TCA excretion into the canalicular lumen. The Clbile of 
TCA was reduced in a concentration-dependent manner by TRO, from 38.5 to 33 
ml/min/kg at 0.1 µM TRO and to 7.8 ml/min/kg at 10 µM TRO (Table A.1). Similar 
results were observed in human SCH; 1 µM and 10 µM TRO decreased TCA 
accumulation in cells and cells + bile, as well as the BEI (Figure A.1). Clbile of TCA in 
human hepatocytes was decreased from 16.8 to 12.6 and 1.9 ml/min/kg, 
respectively, by 1 and 10 µM TRO (Table A.1).  
 While the SCH model is useful for measuring overall alterations in the 
hepatobiliary disposition of BAs, and especially for examining alterations in BA 
excretion, suspended hepatocytes may be preferred for analysis of impaired BA 
uptake due to the technical ease of determining initial uptake rates. Thus, 
suspended hepatocytes are a useful tool to further characterize xenobiotic-induced 
alterations in BA uptake observed in SCH. The effect of TRO on TCA uptake has 
been assessed previously in rat hepatocytes at a single TRO concentration; TRO 
significantly inhibited initial TCA uptake (Kemp et al. 2005). In the present studies, 
increasing concentrations of TRO were used to determine concentration-dependent 
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inhibition of TCA uptake in both rat and human suspended hepatocytes. Figure A.2 
shows the decrease in TCA uptake as a function of TRO concentration in rat and 
human suspended hepatocytes. The effect of TRO on TCA uptake by rat 
hepatocytes was assessed in the presence and absence of Na+ (Figure A.2A). 
Transport in the presence of Na+ was inhibited more potently (IC50 = 2.3 µM) than in 
the absence of Na+ (IC50 = 13.3 µM), suggesting that Na+-dependent Ntcp is more 
sensitive to TRO inhibition than the Na+-independent Oatps. The overall Na+-
dependent uptake (i.e., uptake in the presence of Na+ minus uptake in the absence 
of Na+) of TCA by rat hepatocytes was inhibited potently by TRO (IC50 = 1.9 µM). 
Interestingly, TRO was an even more potent inhibitor of Na+-dependent TCA uptake 
in human hepatocytes (IC50 = 0.33 µM) (Figure A.2B). This difference in Ntcp/NTCP 
inhibition could have implications for species differences in susceptibility to TRO-
induced hepatotoxicity (Figure A.3).  
 
 181 
Discussion 
 Inhibition of BA transport protein function, leading to the intracellular 
accumulation of cytotoxic BAs, has been hypothesized as one mechanism of drug-
induced hepatotoxicity (Byrne et al. 2002; Fattinger et al. 2001; Stieger et al. 2000). 
Inhibition of BA excretion via BSEP may result in BA accumulation within the cell, 
whereas inhibition of BA uptake would be expected to disrupt BA homeostasis and 
lead to elevated plasma BA concentrations (Figure A.3).  
 Similar to previous reports in rat SCH (Kemp et al. 2005), our results 
indicated that TRO inhibits both biliary excretion of TCA, as evidenced by 
decreasing BEI, and basolateral uptake of TCA, as shown by decreased cell 
accumulation in human SCH; Clbile also was impaired. Overall, the inhibition of both 
TCA uptake and biliary excretion resulted in a net decrease in intracellular TCA 
accumulation in both human and rat SCH. This observation is contrary to the original 
hypothesis that TRO causes the intracellular accumulation of BAs in human 
hepatocytes but not in rat hepatocytes. However, altered BA homeostasis may play 
an important role in TRO-mediated hepatotoxicity. 
 Alterations in bile composition due to decreased intracellular BA content could 
change the BA:phospholipid ratio of the bile, resulting in supersaturation of bile with 
cholesterol, the formation of intrahepatic sludge and cholesterol gallstones (Persley 
and Jain 2000). This may cause a cascade of events that predisposes the liver to 
cellular injury. In addition, decreased return of BAs from the portal circulation to the 
hepatocyte leads to increased BA biosynthesis, which is thought to occur because of 
decreased intracellular BA concentrations; BA synthesis can increase up to 15-fold 
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under these conditions (Hofmann 1999). TRO-mediated inhibition of NTCP may 
exacerbate altered BA homeostasis by inducing BA synthesis.  
 In addition, differences in the BA pool between humans and other animal 
species may contribute to TRO toxicity. The BA pool in humans is more 
hydrophobic, with the cytotoxic BA glycochenodeoxycholic acid (GCDCA) 
comprising 31% of all BAs; in contrast, in rats, more hydrophilic and less cytotoxic 
TCA constitutes the majority of BAs (Alvaro et al. 1986; Tagliacozzi et al. 2003). 
TRO may have a different influence on the hepatic disposition of TCA compared to 
other BAs such as GCDCA. TRO had a greater effect on Ntcp-mediated TCA uptake 
in rat SCH; thus, it is possible that BAs that have a high affinity for uptake by the 
organic anion transporting polypeptides may be less affected by TRO-mediated 
inhibition of uptake, and may differentially accumulate within cells.  
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Conclusions 
 Drug-induced hepatotoxicity is well recognized as a significant but poorly 
understood issue in drug development. Model systems that can be employed to 
elucidate factors predisposing patients to drug-induced liver injury, or to determine 
the hepatotoxic potential of drug candidates, are particularly relevant in current drug 
development. SCH represent a useful model for examining mechanisms of drug-
induced hepatotoxicity. A number of drugs have been shown to impair BA transport 
using this system. Research from our laboratory demonstrates that TRO, a known 
hepatotoxin, inhibits BA transport in both human and rat SCH in a concentration-
dependent manner. Thus, the SCH model confirms and supplements data from 
other commonly employed experimental systems such as suspended hepatocytes 
and membrane vesicles. This model may be an efficient screening tool to identify 
compounds that alter BA uptake and/or excretion early in drug development. The 
cellular consequences of such transport modulation may be explored over days in 
culture in an effort to identify new mechanisms of drug-induced hepatotoxicity.  
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TRO 0 µM 0.1µM 1µM 5µM 10µM
Rat 38.5 33.0 28.1 10.1 7.8
Human 16.8 12.6 1.9
TCA Clbile (mL/min/kg)
 
 
Table A.1: Clbile (ml/min/kg) of TCA in sandwich-cultured rat and human hepatocytes 
with increasing concentrations of TRO.  
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Figure A.1: TCA uptake and excretion by sandwich-cultured rat (A) and human (B) 
hepatocytes in the presence and absence of TRO. On day 4 (rat) or day 10 (human) 
of culture, hepatocytes were preincubated for 10 min in the presence of Ca2+ (cells 
plus bile, solid bars) or absence of Ca2+ (cells only, white bars), followed by 
incubation with [3H]TCA (1 µM; 60 nCi/ml) in standard buffer at 37°C. [3H]TCA 
accumulation by rat hepatocytes and human hepatocytes was measured at 10 min, 
in the presence of increasing concentrations of TRO. The biliary excretion index 
(BEI) is defined as the percentage of accumulated substrate residing within the bile 
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canaliculi. Results in (A) are presented as the mean ± SEM of triplicate 
determinations obtained in 3 independent experiments. Results in (B) are presented 
as the mean ± SD of triplicate determinations in one of two experiments; similar 
results were observed in the second experiment.  
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Figure A.2: TCA uptake by rat and human primary suspended hepatocytes in the 
presence and absence of TRO. Freshly isolated hepatocytes were suspended in 
Na+-containing or Na+-free/choline-containing HBSS at 1 × 106 cells/ml and 
incubated with [3H]TCA (1 µM; 60 nCi/ml) at 37°C. (A) [ 3H]TCA uptake by rat 
hepatocytes in the presence (●) and absence (○) of Na+ was measured at 30 s, in 
the presence of increasing concentrations of TRO. Na+-dependent uptake (broken 
line) was determined by subtracting [3H]TCA uptake in the absence of Na+ from 
uptake in the presence of Na+. Symbols represent mean ± SD obtained in 4 
independent experiments, with triplicate determinations in each experiment. (B) 
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[3H]TCA uptake by human hepatocytes was measured at 45 s, in the presence of 
increasing concentrations of TRO. Na+-independent uptake was negligible for these 
human hepatocyte preparations. Symbols represent mean ± SD of triplicate 
determinations obtained in one of two experiments (IC50 for the second experiment 
was 0.69 µM). 
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Figure A.3: Potential implications of NTCP and BSEP inhibition in plasma, 
hepatocyte, and bile compartments. (A) NTCP and BSEP-mediated transport of BAs 
under homeostatic conditions. (B) Disruption of BSEP/Bsep function can result in BA 
accumulation in the hepatocyte and the plasma. (C) Inhibition of BA basolateral 
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uptake (NTCP/Ntcp) and canalicular excretion (BSEP/Bsep) may result in less intra-
hepatocyte accumulation of BAs. Plasma BA concentrations would increase 
regardless of whether hepatic BA uptake or excretion is impaired. 
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APPENDIX B 
 
Data Summary 
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pmol/mg protein cells+bile cells SEM cells+bile SEM cells BEI (%) Clbile (ml/min/kg)
CTL 325.0 129.8 8.1 12.4 60.0 ± 9.5 151 ± 26
1 µM TRO 304.7 139.8 23.0 28.0 54.3 ± 12.6 132 ± 33
10 µM TRO 294.7 148.4 12.2 11.5 49.7 ± 6.2 117 ± 16
100 µM TRO 255.7 247.8 25.2 24.2 3.1 ± 0.5 6 ± 2
50 µM MK571 344.9 362.3 17.8 12.7 0.3 ± 0.7 1 ± 2
 
Figure 2.1: Accumulation (mean and SEM; pmol/mg protein), BEI (%), and Clbile 
(ml/min/kg) of [14C]CDCA species in cells + bile and cells in WT rat SCH following a 
10-min incubation with 1 µM [14C]CDCA and vehicle control (0.1% DMSO; CTL), 1, 
10, or 100 µM TRO, or 50 µM MK571. 
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A pmol/mg protein cells+bile cells SEM cells+bile SEM cells BEI (%) Clbile (ml/min/kg)
CTL 325.3 146.0 44.1 24.8 55.7 ± 7.4 140 ± 43
1 µM TRO 277.6 132.9 27.9 24.9 53.4 ± 8.6 112 ± 5
10 µM TRO 219.6 118.3 11.9 13.3 46.5 ± 8.8 79 ± 17
100 µM TRO 230.7 222.2 11.0 13.4 5.9 ± 5.5 11 ± 10
50 µM MK571 264.0 239.1 16.4 16.0 9.5 ± 1.0 19 ± 0
B pmol/mg protein cells+bile cells SEM cells+bile SEM cells BEI (%) Clbile (ml/min/kg)
CTL 38.2 8.1 7.8 2.2 78.8 ± 9.7 24 ± 11
1 µM TRO 27.8 5.7 5.6 1.7 80.7 ± 4.8 18 ± 6
10 µM TRO 7.0 2.6 1.8 0.9 65.0 ± 8.4 4 ± 1
100 µM TRO 5.4 4.1 2.1 1.7 26.1 ± 6.1 1 ± 0
50 µM MK571 7.5 4.6 2.9 1.6 37.4 ± 6.7 2 ± 2
 
Figure 2.2: Accumulation (mean and SEM; pmol/mg protein), BEI (%), and Clbile 
(ml/min/kg) of (A) [14C]CDCA species and (B) [3H]TCA in cells + bile and cells in TR- 
rat SCH following a 10-min incubation with 1.2 µM [14C]CDCA or 1 µM [3H]TCA and 
vehicle control (0.1% DMSO; CTL), 1, 10, or 100 µM TRO, or 50 µM MK571.  
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pmol/mg protein cells+bile cells SEM cells+bile SEM cells BEI (%) Clbile (ml/min/kg)
CTL 56.5 6.9 10.8 2.1 88.3 ± 2.7 39.6 ± 12.0
10 µM MK571 34.2 11.4 9.1 3.0 66.7 ± 1.7 18.2 ± 8.5
20 µM MK571 23.4 13.3 6.5 3.6 43.1 ± 4.0 8.1 ± 4.1
50 µM MK571 13.4 17.3 3.4 2.0 0.0 0.0
 
Figure 2.3: Accumulation (mean and SEM; pmol/mg protein), BEI (%), and Clbile 
(ml/min/kg) of [3H]TCA in cells + bile and cells in WT rat SCH following a 10-min 
incubation with 1 µM [3H]TCA and vehicle control (0.1% DMSO; CTL), or 10, 20, or 
50 µM MK571. 
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BA Species Treatment cells + bile cells cells + bile SD cells SD
CDCA CTL 0 0 0 0
Treated 85.6 73.1 7.2 12.8
TCDCA CTL 34.48 4.40 6.23 1.3
Treated 185.19 66.77 16.97 6.4
GCDCA CTL 4.08 1.09 1.43 0.4
Treated 37.19 15.04 7.13 3.9
TMCA CTL 310.5 68.9 62.6 22.6
Treated 353.4 162.3 12.7 47.2
GMCA CTL 6.1 2.2 1.1 1.0
Treated 15.1 7.6 3.6 2.5
Total CTL 355.19 76.65 71.30 25.39
Treated 676.51 324.77 47.59 72.70
 
Figure 2.4: Parent CDCA and formed CDCA species (taurine- and glycine-
conjugated CDCA); TMCA, and GMCA (mean and SD; pmol/mg protein) in cells + 
bile and cells in WT rat SCH following a 10-min incubation with vehicle CTL (0.1% 
DMSO; CTL) or 1 µM unlabeled CDCA. 
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CDCA CTL CTL + Na+ CTL + Na+ CTL + Choline CTL + Choline CTL Na+-dep
time Mean SEM Mean SEM Mean
15 47.3 1.7 27.7 1.7 19.6
30 81.7 2.1 48.7 3.3 33.0
45 100.0 9.5 64.9 5.2 35.1
CDCA TRO TRO + Na+ TRO + Na+ TRO + Choline TRO + Choline TRO Na+-dep
time Mean SEM Mean SEM Mean
15 19.6 5.9 12.1 3.3 7.4
30 32.4 9.7 19.7 5.5 12.8
45 36.9 11.3 23.7 7.5 13.2
CDCA MK571 MK571 + Na+ MK571 + Na+ MK571 + Choline MK571 + Choline MK571 Na+-dep
time Mean SEM Mean SEM Mean
15 18.9 6.5 13.2 5.0 5.7
30 29.5 10.5 22.3 8.7 7.2
45 37.2 13.3 28.4 11.3 8.9
TCA CTL CTL + Na+ CTL + Na+ CTL + Choline CTL + Choline CTL Na+-dep
time Mean SEM Mean SEM Mean
15 41.5 1.8 18.2 6.9 23.4
30 77.2 1.5 26.8 10.4 50.5
45 100.0 9.5 33.6 11.7 66.4
TCA TRO TRO + Na+ TRO + Na+ TRO + Choline TRO + Choline TRO Na+-dep
time Mean SEM Mean SEM Mean
15 13.7 6.0 7.5 2.9 6.1
30 16.0 6.0 9.0 3.6 7.1
45 18.3 7.1 9.6 3.5 8.7
TCA MK571 MK571 + Na+ MK571 + Na+ MK571 + Choline MK571 + Choline MK571 Na+-dep
time Mean SEM Mean SEM Mean
15 10.2 4.6 5.3 2.6 4.9
30 12.9 5.6 7.5 4.2 5.4
45 14.8 6.3 7.7 4.1 7.1
 
 
Figure 2.5: Accumulation (mean and SEM; % control) of CDCA or TCA at 15, 30, 
and 45 s in suspended rat hepatocytes in the presence of 1 µM [14C]CDCA or 1 µM 
[3H]TCA, and vehicle (0.3% DMSO; CTL), 10 µM TRO, or 50 µM MK571. Total 
accumulation (Na+-dependent and independent) was measured in Na+-containing 
buffer (+Na+). Na+-independent uptake was measured in choline-containing buffer (+ 
Choline). Na+-dependent uptake (Na+-dep) was calculated by subtracting Na+-
independent accumulation from total accumulation.   
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pmol/mg protein cells + bile cells medium cells + bile range cells range medium SD
SUM day 1 106.8 85.0 468.6 1.4 11.3 66.1
day 2 27.9 25.7 478.4 0.6 3.1 88.4
day 3 43.4 20.5 1222.2 24.9 9.7 128.6
day 4 37.7 16.7 1466.6 21.3 8.2 187.8
 
Figure 3.1: Total accumulation (mean and range or SD; pmol/mg protein) of the sum 
of all BAs measured in cells + bile, cells, and medium in rat SCH over days 1 
through 4 of culture.  
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TCA cells + bile cells medium cells + bile SEM cells SEM medium range or SD
Rat CTL 16.3 5.5 419.4 5.1 1.0 185.8
Rat 10 µM TRO 16.5 5.9 442.1 3.3 0.9 236.2
Human CTL 5.3 3.0 21.6 3.1 1.4 9.6
Human 10 µM TRO 2.5 1.4 18.1 1.3 1.1 7.7
 
 
Figure 3.2: Accumulation (mean and SEM, range, or SD; pmol/mg protein) of TCA 
in cells + bile, cells, and medium in rat and human SCH following 24-h treatment 
with vehicle (0.1% DMSO; CTL) or 10 µM TRO. 
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GCA cells + bile cells medium cells + bile SEM cells SEM medium range or SD
Rat CTL 0.6 0.2 48.7 0.3 0.1 36.3
Rat 10 µM TRO 0.7 0.4 51.2 0.5 0.1 41.6
Human CTL 1030.2 594.4 3901.0 840.9 482.9 2265.0
Human 10 µM TRO 445.1 244.9 3892.5 346.7 202.9 2495.9
 
Figure 3.3: Accumulation (mean and SEM, range, or SD; pmol/mg protein) of GCA 
in cells + bile, cells, and medium in rat and human SCH following 24-h treatment 
with vehicle (0.1% DMSO; CTL) or 10 µM TRO.  
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TCDCA cells + bile cells medium cells + bile SEM cells SEM medium range or SD
Rat CTL 17.0 12.3 90.1 7.9 7.6 81.4
Rat 10 µM TRO 12.5 9.6 83.9 5.0 5.1 73.4
Human CTL 6.6 5.0 5.1 1.9 1.2 2.9
Human 10 µM TRO 3.5 3.3 6.6 0.2 0.5 1.1
 
Figure 3.4: Accumulation (mean and SEM, range, or SD; pmol/mg protein) of 
TCDCA in cells + bile, cells, and medium in rat and human SCH following 24-h 
treatment with vehicle (0.1% DMSO; CTL) or 10 µM TRO.  
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GCDCA cells + bile cells medium cells + bile SEM cells SEM medium range or SD
Rat CTL 2.8 1.7 50.2 0.5 0.8 16.8
Rat 10 µM TRO 2.2 1.6 40.2 0.3 0.4 7.0
Human CTL 1075.6 781.8 1485.8 980.9 685.7 1022.8
Human 10 µM TRO 556.9 478.6 1177.0 528.5 470.4 653.1
 
 
Figure 3.5: Accumulation (mean and SEM, range, or SD; pmol/mg protein) of 
GCDCA in cells + bile, cells, and medium in rat and human SCH following 24-h 
treatment with vehicle (0.1% DMSO; CTL) or 10 µM TRO.   
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SUM OF ALL cells + bile cells medium cells + bile SEM cells SEM medium range or SD
Rat CTL 33.3 18.0 547.5 12.5 8.6 288.2
Rat 10 µM TRO 29.0 15.9 555.6 8.1 5.8 322.4
Human CTL 1906.0 1245.7 4874.4 1644.1 1054.1 2970.1
Human 10 µM TRO 907.3 655.8 4584.8 789.0 606.9 2842.1
 
 
Figure 3.6: Accumulation (mean and SEM, range, or SD; pmol/mg protein) of total 
BAs measured in cells + bile, cells, and medium in rat and human SCH following 24-
h treatment with vehicle (0.1% DMSO; CTL) or 10 µM TRO.   
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TCA GCA TCDCA GCDCA
Rat CTL cells + bile 44.1 2.5 45.9 7.5
cells 27.5 2.3 61.5 8.7
bile 63.8 2.7 27.4 6.1
medium 68.9 8.0 14.8 8.3
RAT TRO cells + bile 51.3 3.0 38.7 7.0
cells 33.3 3.1 54.4 9.2
bile 73.1 3.0 19.8 4.2
medium 71.6 8.3 13.6 6.5
Human CTL cells + bile 0.3 48.6 0.3 50.8
cells 0.2 42.9 0.4 56.5
bile 0.3 59.4 0.2 40.1
medium 0.4 72.0 0.1 27.4
Human TRO cells + bile 0.3 44.2 0.4 55.2
cells 0.3 33.6 0.4 65.7
bile 0.2 71.6 0.1 28.0
medium 0.4 76.4 0.1 23.1
 
 
Figure 3.7: Accumulation of individual BA species (% total) in cells + bile, cells, bile, 
and medium in rat and human SCH following 24-h treatment with vehicle (0.1% 
DMSO; CTL) or 10 µM TRO.   
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time (min) TS uptake (nM) SD
1 9.4 0.9
5 22.4 5.6
 
Figure 4.1: ATP-dependent uptake (mean and SD; nM) at 1 and 5 min of TS into 
MRP4-expressing membrane vesicles incubated with 10 µM TS. 
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uptake rate
treatment (pmol/mg protein/90 s) SD
CTL 114.4 7.5
1 µM TS 91.1 1.7
10 µM TS 45.2 8.3
18 µM MK571 10.9 11.3
 
Figure 4.2: Uptake of [3H]MTX (mean and SD; pmol/mg protein/90 s) into MRP4-
expressing membrane vesicles in the presence of vehicle (0.1% DMSO; CTL), 1 or 
10 µM TS, or 18 µM MK571. 
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uptake clearance 
treatment (µl/min/mg protein) SD
CTL 57.5 1.0
50 µM TS 3.0 0.6
50 µM MK571 4.0 0.5
 
Figure 4.3: Uptake clearance (mean and SD; µl/min/mg protein) of [3H]DHEAS into 
MRP4-expressing membrane vesicles in the presence of vehicle (0.1% DMSO; 
CTL), 50 µM TS, or 50 µM MK571. 
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ATP-dependent uptake
time (min) (pmol/mg protein) range
MRP4 1 48.8 8.7
MRP4 2 111.8 0.5
MRP4 5 179.8 15.4
MRP4 10 210.9 13.6
MRP4 20 237.6 6.9
CTL 1 10.6 0.1
CTL 2 57.6 5.0
CTL 5 85.2 8.7
CTL 10 80.7 10.1
CTL 20 72.1 3.0
 
Figure 4.4: ATP-dependent uptake (mean and range; pmol/mg protein) at 1, 2, 5, 
and 10 min of [3H]TCA in CTL and MRP4-expressing membrane vesicles. 
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TS ATP-dependent uptake rate
(µM) pmol/mg protein/min SEM
MRP4 0 49.4 6.8
MRP4 0.1 49.1 6.0
MRP4 0.3 42.4 3.7
MRP4 1 40.9 2.2
MRP4 3 29.0 2.0
MRP4 10 27.3 3.7
MRP4 30 20.1 2.4
MRP4 100 14.2 1.4
CTL 0 37.7 1.3
CTL 0.1 37.6 2.2
CTL 0.3 34.2 0.8
CTL 1 33.3 5.9
CTL 3 20.6 1.5
CTL 10 16.1 1.0
CTL 30 16.8 4.8
CTL 100 11.4 0.8
 
Figure 4.5: ATP-dependent uptake rate (mean and SEM; pmol/mg protein/min) of 
[3H]TCA in CTL membrane vesicles and MRP4-expressing membrane vesicles in 
the presence of increasing concentrations of TS (0-100 µM).  
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rat cells + bile cells cells + bile SEM cells SEM
CTL 100.00 14.20 0.00 2.77
0.1 µM TRO 87.74 12.19 7.20 3.00
1 µM TRO 75.64 11.72 6.49 3.22
5 µM TRO 30.54 7.11 11.23 4.18
10 µM TRO 24.26 6.43 14.02 3.37
human cells + bile cells cells + bile SD cells SD
CTL 100.00 26.83 15.64 3.77
1 µM TRO 75.84 20.93 11.32 1.05
10 µM TRO 15.58 7.12 0.90 0.50
 
Figure A.1: Accumulation (mean and SEM or SD; % control) of TCA in cells + bile 
and cells in rat and human SCH following a 10-min incubation with 1 µM [3H]TCA 
and vehicle (0.1% DMSO; CTL), 1, or 10 µM TRO.  
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[TRO] (µM) + Na+ + Na+ SEM - Na+ - Na+ SEM Na+-dependent
0 100.00 6.78 100.00 11.20 100.00
0.1 93.19 8.27 89.42 3.69 92.35
0.3 68.90 7.48 86.41 10.81 83.40
1 76.01 7.70 101.56 7.11 53.74
3 51.26 9.67 80.61 4.80 51.70
5 50.23 4.72 77.61 15.15 25.99
10 33.49 1.44 57.58 2.88 18.22
20 27.60 5.95 52.81 9.91 6.04
 
Figure A.2.A: TCA uptake (% control; mean and SEM) by rat primary suspended 
hepatocytes in the presence of increasing concentrations of TRO (0-20 µM). 
[3H]TCA uptake in the presence and absence of Na+ was measured at 30 s, in the 
presence of increasing concentrations of TRO. Na+-dependent uptake was 
determined by subtracting [3H]TCA uptake in the absence of Na+ from uptake in the 
presence of Na+.  
